[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 133
1. Tonks ID, Mould AW, Schroder WA, Cotterill A, Hayward NK, Walker GJ, Kay GF: Dual loss of rb1 and Trp53 in the adrenal medulla leads to spontaneous pheochromocytoma. Neoplasia; 2010 Mar;12(3):235-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual loss of rb1 and Trp53 in the adrenal medulla leads to spontaneous pheochromocytoma.
  • Using a Cre/loxP system, we have determined the phenotypic consequences attributable to in vivo deletion of both Rb1 and Trp53 in the mouse adrenal medulla.
  • The coablation of these two tumor suppressor genes during embryogenesis did not disrupt adrenal gland development but resulted in the neoplastic transformation of the neural crest-derived adrenal medulla, yielding pheochromocytomas (PCCs) that developed with complete penetrance and were inevitably bilateral.
  • The structural remodeling of the heart in mice harboring Rb1(-/-):Trp53(-/-) PCCs suggests that the mortality of these mice may be attributable to the inappropriate release of catecholamines from the mutated adrenal chromaffin cells.
  • On the basis of the collective data from Rb1 and Trp53 knockout mouse models, it seems that the conversion of Rb1 loss-driven adrenal medulla hyperplasia to PCC can be greatly enhanced by the compound loss of Trp53, whereas the loss of Trp53 alone is generally ineffectual on adrenal chromaffin cell homeostasis.
  • Consequently, the Trp53 tumor suppressor gene is an efficient genetic modifier of Rb1 loss in the development of PCC, and their compound loss in the adrenal medulla has a profound impact on both cellular homeostasis and animal vitality.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Genes, p53 / physiology. Pheochromocytoma / pathology. Retinoblastoma Protein / physiology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2001 Jun;54(6):443-8 [11376017.001]
  • [Cites] J Neurosci. 2001 Feb 15;21(4):1110-6 [11160381.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1455-60 [11818530.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3803-11 [12097293.001]
  • [Cites] Mol Cell Biol. 2003 Feb;23(3):1044-53 [12529408.001]
  • [Cites] J Pathol. 2003 Jul;200(3):375-82 [12845634.001]
  • [Cites] Genesis. 2003 Nov;37(3):131-8 [14595836.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1235-43 [15026807.001]
  • [Cites] Cancer. 1977 Nov;40(5):1987-2004 [922654.001]
  • [Cites] J Neurosci Methods. 1980 Oct;3(1):1-5 [6164878.001]
  • [Cites] Scanning Microsc. 1988 Mar;2(1):503-12 [3368774.001]
  • [Cites] Hypertension. 1991 Nov;18(5 Suppl):III35-9 [1657774.001]
  • [Cites] Cell. 1992 Apr 17;69(2):265-73 [1568246.001]
  • [Cites] Nature. 1992 Apr 23;356(6371):713-5 [1570015.001]
  • [Cites] J Endocrinol Invest. 1992 Oct;15(9):651-63 [1479148.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] EMBO J. 1994 Sep 15;13(18):4251-9 [7925270.001]
  • [Cites] EMBO J. 1994 Sep 15;13(18):4260-8 [7925271.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):480-4 [7951317.001]
  • [Cites] Oncogene. 1995 Jul 20;11(2):325-35 [7624147.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):144-8 [8563751.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6933-8 [9192669.001]
  • [Cites] Genes Dev. 1998 Jun 1;12(11):1599-609 [9620848.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5284-90 [9710613.001]
  • [Cites] EMBO J. 1999 Mar 15;18(6):1571-83 [10075928.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3916-21 [10097138.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2577-80 [10363976.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Genes Dev. 2004 Dec 1;18(23):2952-62 [15574596.001]
  • [Cites] Fam Cancer. 2005;4(1):17-23 [15883706.001]
  • [Cites] Pigment Cell Res. 2005 Aug;18(4):252-64 [16029419.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4564-76 [16738322.001]
  • [Cites] Science. 2006 Jun 16;312(5780):1650-3 [16728594.001]
  • [Cites] Pigment Cell Res. 2006 Aug;19(4):260-83 [16827746.001]
  • [Cites] Cell. 2006 Jul 14;126(1):107-20 [16839880.001]
  • [Cites] Cell Cycle. 2006 Sep;5(18):2054-6 [16969113.001]
  • [Cites] Oncogene. 2007 Jan 25;26(4):554-70 [16953232.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):160-5 [17427103.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):407-13 [18223555.001]
  • [Cites] Endocr Relat Cancer. 2008 Jun;15(2):609-21 [18509008.001]
  • [Cites] Neoplasia. 2008 Nov;10(11):1213-21 [18953430.001]
  • [Cites] J Invest Dermatol. 2009 Jan;129(1):184-93 [18633434.001]
  • [Cites] Biochim Biophys Acta. 2009 May;1787(5):328-34 [19413947.001]
  • [Cites] Science. 2009 May 22;324(5930):1029-33 [19460998.001]
  • [Cites] Pigment Cell Melanoma Res. 2009 Jun;22(3):328-30 [19243574.001]
  • [Cites] PLoS One. 2009;4(9):e7094 [19763184.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):372-82 [10667590.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):383-9 [10667591.001]
  • [Cites] Curr Biol. 2000 May 4;10(9):543-6 [10801445.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):6147-58 [10913196.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10826-31 [10995476.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):222-4 [11175795.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):418-25 [11694875.001]
  • (PMID = 20234817.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Catecholamines; 0 / Retinoblastoma Protein; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  • [Other-IDs] NLM/ PMC2838441
  •  go-up   go-down


2. Ohno N, Terada N, Komada M, Saitoh S, Costantini F, Pace V, Germann PG, Weber K, Yamakawa H, Ohara O, Ohno S: Dispensable role of protein 4.1B/DAL-1 in rodent adrenal medulla regarding generation of pheochromocytoma and plasmalemmal localization of TSLC1. Biochim Biophys Acta; 2009 Mar;1793(3):506-15
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dispensable role of protein 4.1B/DAL-1 in rodent adrenal medulla regarding generation of pheochromocytoma and plasmalemmal localization of TSLC1.
  • Protein 4.1B is a membrane skeletal protein expressed in various organs, and is associated with tumor suppressor in lung cancer-1 (TSLC1) in vitro.
  • Although involvement of 4.1B in the intercellular junctions and tumor-suppression was suggested, some controversial results posed questions to the general tumor-suppressive function of 4.1B and its relation to TSLC1 in vivo.
  • In this study, the expression of 4.1B and its interaction with TSLC1 were examined in rodent adrenal gland, and the involvement of 4.1B in tumorigenesis and the effect of 4.1B deficiency on TSLC1 distribution were also investigated using rodent pheochromocytoma and 4.1B-knockout mice.
  • Although plasmalemmal immunolocalization of 4.1B was shown in chromaffin cells of rodent adrenal medulla, expression of 4.1B was maintained in developed pheochromocytoma, and morphological abnormality or pheochromocytoma generation could not be found in 4.1B-deficient mice.
  • Furthermore, molecular interaction and colocalization of 4.1B and TSLC1 were observed in mouse adrenal gland, but the immunolocalization of TSLC1 along chromaffin cell membranes was not affected in the 4.1B-deficient mice.
  • These results suggest that the function of 4.1B as tumor suppressor might significantly differ among organs and species, and that plasmalemmal retention of TSLC1 would be maintained by molecules other than 4.1B interacting in rodent chromaffin cells.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Adrenal Medulla / metabolism. Immunoglobulins / metabolism. Membrane Proteins / metabolism. Pheochromocytoma / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - B6.129S1(FVB)-Ret<tm2.1Cos>/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19321127.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5P01CA023767
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Epb4.1l3 protein, mouse; 0 / Immunoglobulins; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Tumor Suppressor Proteins; 0 / cell adhesion molecule 1, mouse
  •  go-up   go-down


3. Ait-Ali D, Stroth N, Sen JM, Eiden LE: PACAP-cytokine interactions govern adrenal neuropeptide biosynthesis after systemic administration of LPS. Neuropharmacology; 2010 Jan;58(1):208-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PACAP-cytokine interactions govern adrenal neuropeptide biosynthesis after systemic administration of LPS.
  • We have examined induction of neuropeptide expression in adrenal medulla after treatment of mice with lipopolysaccharide (LPS), a model for septic shock, which activates both immune and stress responses in vivo.
  • Messenger RNAs encoding vasoactive intestinal polypeptide (VIP) and galanin, both modulators of steroidogenesis in neighboring adrenal cortex, are up-regulated at 24 h (eight-fold for VIP and two-fold for galanin) after LPS injection, and remain elevated for the following 24 h.
  • Up-regulation of VIP and galanin by LPS is abrogated in pituitary adenylate cyclase-activating polypeptide (PACAP)-deficient mice, suggesting an interaction between LPS, or LPS-induced cytokines, and PACAP released in adrenal medulla from the splanchnic nerve.
  • Treatment of cultured chromaffin cells with 100 nM PACAP and 10 nM tumor necrosis factor-alpha (TNF-alpha), a cytokine whose production is elevated by LPS, results in long-term synergistic up-regulation of VIP and galanin mRNA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Neurosci. 1997 Oct;9(2):127-40 [9407393.001]
  • [Cites] Endocr Res. 1996 Nov;22(4):819-29 [8969945.001]
  • [Cites] J Mol Neurosci. 2005;27(1):91-105 [16055949.001]
  • [Cites] Curr Protein Pept Sci. 2005 Aug;6(4):373-85 [16101435.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6392-7 [16606831.001]
  • [Cites] Ann N Y Acad Sci. 2006 Jul;1070:500-6 [16888216.001]
  • [Cites] Int J Mol Med. 2007 Mar;19(3):511-5 [17273801.001]
  • [Cites] J Neurochem. 2007 May;101(4):1108-18 [17394532.001]
  • [Cites] Mol Immunol. 2008 May;45(10):2970-80 [18336909.001]
  • [Cites] Curr Protoc Immunol. 2007 May;Chapter 14:Unit 14.12 [18432983.001]
  • [Cites] Endocrinology. 2008 Jun;149(6):2840-52 [18292192.001]
  • [Cites] Ann N Y Acad Sci. 2008 Nov;1144:56-60 [19076364.001]
  • [Cites] Ann N Y Acad Sci. 2008 Nov;1144:83-9 [19076367.001]
  • [Cites] J Neurochem. 2009 Feb;108(4):1083-96 [19141072.001]
  • [Cites] Trends Mol Med. 2005 Feb;11(2):56-63 [15694867.001]
  • [Cites] Science. 2000 Sep 29;289(5488):2350-4 [11009421.001]
  • [Cites] Gastroenterology. 2000 Oct;119(4):1148-57 [11040201.001]
  • [Cites] Adv Exp Med Biol. 2000;482:263-77 [11192587.001]
  • [Cites] Ann N Y Acad Sci. 2000;917:94-105 [11268424.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):461-6 [11756684.001]
  • [Cites] Clin Diagn Lab Immunol. 2002 Nov;9(6):1307-12 [12414765.001]
  • [Cites] Stress. 2007 Jun;10(2):121-30 [17514580.001]
  • [Cites] Peptides. 2007 Sep;28(9):1720-6 [17513014.001]
  • [Cites] Annu Rev Immunol. 2003;21:335-76 [12524386.001]
  • [Cites] J Neuroimmunol. 2003 Jan;134(1-2):52-60 [12507772.001]
  • [Cites] Clin Sci (Lond). 2008 Mar;114(5):347-60 [18230059.001]
  • [Cites] J Leukoc Biol. 2004 Jan;75(1):18-26 [12960276.001]
  • [Cites] J Theor Biol. 2004 May 21;228(2):195-215 [15094015.001]
  • [Cites] Mol Endocrinol. 2004 Jul;18(7):1721-39 [15087472.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Dec;83(23):9245-9 [3538020.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Auton Nerv Syst. 1990 Sep;31(1):31-9 [1702130.001]
  • [Cites] Am J Physiol. 1991 Dec;261(6 Pt 2):R1431-7 [1750568.001]
  • [Cites] Neuroendocrinology. 1991 Dec;54(6):623-8 [1664501.001]
  • [Cites] Endocrinology. 1992 Apr;130(4):2252-8 [1372239.001]
  • [Cites] J Neurochem. 1992 Aug;59(2):780-3 [1378491.001]
  • [Cites] Science. 1993 Mar 26;259(5103):1912-5 [8096091.001]
  • [Cites] J Biol Chem. 1994 Mar 4;269(9):6823-31 [7509811.001]
  • [Cites] Nucleic Acids Res. 1994 Sep 11;22(18):3787-92 [7937093.001]
  • [ErratumIn] Neuropharmacology. 2010 Jun;58(7):1187
  • (PMID = 19647754.001).
  • [ISSN] 1873-7064
  • [Journal-full-title] Neuropharmacology
  • [ISO-abbreviation] Neuropharmacology
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 AG000768-04; United States / Intramural NIH HHS / / Z01 AG000772-01; United States / NIMH NIH HHS / MH / Z01 MH002386; United States / Intramural NIH HHS / / Z01 MH002386-21
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Lipopolysaccharides; 0 / Neuropeptides; 0 / Pituitary Adenylate Cyclase-Activating Polypeptide; 0 / Tumor Necrosis Factor-alpha; 37221-79-7 / Vasoactive Intestinal Peptide; 88813-36-9 / Galanin
  • [Other-IDs] NLM/ NIHMS141772; NLM/ PMC2783598
  •  go-up   go-down


Advertisement
4. Onoda N, Ishikawa T, Toyokawa T, Takashima T, Wakasa K, Hirakawa K: Adrenal schwannoma treated with laparoscopic surgery. JSLS; 2008 Oct-Dec;12(4):420-5
Genetic Alliance. consumer health - Schwannoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal schwannoma treated with laparoscopic surgery.
  • OBJECTIVE: We report a case of left adrenal schwannoma in a 62-year-old man, incidentally discovered on an abdominal computed tomography.
  • METHODS: On admission, no remarkable findings were recognized in the patient's blood and urine examination, including adrenal function.
  • Laparoscopic left adrenalectomy was performed with the diagnosis of a nonfunctioning adrenal tumor.
  • RESULTS: Macroscopically, the tumor (45 mm x 30 mm, 60 g) arose from the medulla of the adrenal gland with a clear border distinguishing it from surrounding tissues.
  • Histologically, the tumor consisted uniformly of spindle cells that were positive for S-100.
  • The diagnosis of adrenal schwannoma was made.
  • CONCLUSION: Although an increasing number of adrenal incidentaloma have been identified with the recent advances in imaging techniques, only a few cases of schwannoma of the adrenal gland have been reported.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 [10690869.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2000;108(4):318-21 [10961366.001]
  • [Cites] NIH Consens State Sci Statements. 2002 Feb 4-6;19(2):1-25 [14768652.001]
  • [Cites] Ultrastruct Pathol. 1986;10(6):505-13 [3547966.001]
  • [Cites] Ultrastruct Pathol. 1988 Sep-Oct;12(5):513-27 [3194994.001]
  • [Cites] JSLS. 2007 Jan-Mar;11(1):113-5 [17651570.001]
  • [Cites] Folia Neuropathol. 2004;42(3):177-9 [15535037.001]
  • [Cites] Surg Today. 2006;36(12):1108-13 [17123142.001]
  • [Cites] Med Sci Monit. 2006 Sep;12(9):CR355-62 [16940927.001]
  • [Cites] Radiat Med. 2007 Jul;25(6):299-302 [17634884.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1998 May;89(5):567-70 [9642996.001]
  • (PMID = 19275863.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3015997
  •  go-up   go-down


5. Lau SK, Romansky SG, Weiss LM: Sustentaculoma: report of a case of a distinctive neoplasm of the adrenal medulla. Am J Surg Pathol; 2006 Feb;30(2):268-73
MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustentaculoma: report of a case of a distinctive neoplasm of the adrenal medulla.
  • A case of a morphologically distinctive tumor of the adrenal medulla occurring in a 54-year-old woman is described.
  • On microscopic examination, the tumor was well circumscribed and characterized by the presence of ill-defined, irregular nests of spindle cells with oval to elongated nuclei, tiny nucleoli, and abundant eosinophilic cytoplasm.
  • The tumor was associated with a moderate infiltrate of lymphocytes and plasma cells with occasional lymphoid follicles.
  • Immunohistochemical studies demonstrated the tumor cells to be strongly reactive for vimentin, S-100 protein, and CD56, and nonreactive for glial fibrillary acidic protein, chromogranin, synaptophysin, melanoma-associated antigens, and dendritic cell markers.
  • The morphology, immunophenotype, and ultrastructure of this unique neoplasm suggest derivation from sustentacular cells of the adrenal medulla.
  • We propose the designation "sustentaculoma" for this hitherto undescribed neoplasm of the adrenal gland.
  • [MeSH-major] Adrenal Gland Diseases / metabolism. Adrenal Gland Diseases / pathology. Adrenal Medulla / metabolism. Adrenal Medulla / pathology. Biomarkers, Tumor / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434904.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


6. Cardoso CC, Bornstein SR, Hornsby PJ: Optimizing orthotopic cell transplantation in the mouse adrenal gland. Cell Transplant; 2010;19(5):565-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimizing orthotopic cell transplantation in the mouse adrenal gland.
  • Orthotopic cell transplantation models are important for a complete understanding of cell-cell interactions as well as tumor biology.
  • In published studies of orthotopic transplantation in the mouse adrenal gland, human neuroblastoma cells have been shown to invade and occupy the adrenal, but in these investigations a true orthotopic model was not established.
  • Here we show an orthotopic model in which transplanted cells are retained within the adrenal gland by formation of a fibrin clot.
  • To establish an appropriate technique, we used brightly fluorescent 10 microm polystyrene microspheres injected into the mouse adrenal gland.
  • When the microspheres were injected in a fibrinogen/thrombin mixture, fluorescence was confined to the adrenal gland.
  • When 3 x 10(5) cells were implanted orthotopically, by 16 days the cell mass had expanded and had invaded the cortex, whereas when 1 x 10(5) cells were used, tumor masses were much smaller.
  • When mice were sacrificed at different time points, we found that tumor growth resulting was progressive and that by 26 days cells there was extensive invasion into the cortex or almost complete replacement of the cortex with tumor cells.
  • In summary, the present orthotopic model for intra-adrenal cell transplantation is valuable for investigation of growth of neoplastic cells of both cortical and medullary origin and should be useful for future studies of cortex-medulla interactions.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Transplant. 1999 Nov-Dec;8(6):617-25 [10701491.001]
  • [Cites] Mol Cell Endocrinol. 2009 Mar 5;300(1-2):175-9 [19047010.001]
  • [Cites] Xenotransplantation. 2002 Jan;9(1):58-67 [12005105.001]
  • [Cites] In Vivo. 2002 Mar-Apr;16(2):77-85 [12073775.001]
  • [Cites] Cell Transplant. 2002;11(2):139-45 [12099637.001]
  • [Cites] Adv Anat Pathol. 2003 Mar;10(2):101-6 [12605092.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6144-51 [15342398.001]
  • [Cites] J Natl Cancer Inst. 1984 Jul;73(1):51-7 [6610792.001]
  • [Cites] Cancer Res. 1987 Jul 15;47(14):3824-9 [3474062.001]
  • [Cites] Cancer Metastasis Rev. 1991 Dec;10(4):311-9 [1786632.001]
  • [Cites] J Pediatr Surg. 1994 Apr;29(4):538-42 [8014811.001]
  • [Cites] Cancer Res. 1995 Feb 1;55(3):681-4 [7834640.001]
  • [Cites] Clin Exp Metastasis. 1995 Mar;13(2):123-33 [7533687.001]
  • [Cites] Clin Exp Metastasis. 1997 Mar;15(2):140-50 [9062390.001]
  • [Cites] Nat Med. 1997 Sep;3(9):978-83 [9288723.001]
  • [Cites] Endocr Rev. 1998 Apr;19(2):101-43 [9570034.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(3):279-84 [10352881.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):881-90 [15514941.001]
  • [Cites] Clin Exp Metastasis. 2004;21(6):563-70 [15679054.001]
  • [Cites] Mech Ageing Dev. 2007 Jan;128(1):25-30 [17123586.001]
  • [Cites] J Mol Med (Berl). 1999 Sep;77(9):666-76 [10569204.001]
  • [Cites] Curr Med Chem. 2007;14(27):2925-36 [18045138.001]
  • [Cites] Cell Transplant. 2008;17(1-2):19-25 [18468231.001]
  • [Cites] Cell Transplant. 2008;17(9):1005-14 [19177837.001]
  • [Cites] Rev Endocr Metab Disord. 2001 Aug;2(3):313-21 [11705135.001]
  • (PMID = 20525431.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / AG012287-14; United States / NIA NIH HHS / AG / P01 AG020752-020006; United States / NIA NIH HHS / AG / AG020752-020006; United States / NIA NIH HHS / AG / P01 AG020752; United States / NIA NIH HHS / AG / R37 AG012287-14; United States / NIA NIH HHS / AG / R37 AG012287
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9001-31-4 / Fibrin; 9001-32-5 / Fibrinogen; EC 3.4.21.5 / Thrombin
  • [Other-IDs] NLM/ NIHMS246503; NLM/ PMC3735364
  •  go-up   go-down


7. Morimoto R, Satoh F, Murakami O, Hirose T, Totsune K, Imai Y, Arai Y, Suzuki T, Sasano H, Ito S, Takahashi K: Expression of adrenomedullin 2/intermedin in human adrenal tumors and attached non-neoplastic adrenal tissues. J Endocrinol; 2008 Jul;198(1):175-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of adrenomedullin 2/intermedin in human adrenal tumors and attached non-neoplastic adrenal tissues.
  • AM is expressed in various tumors including adrenocortical tumors and modulates tumor growth.
  • The AM2/IMD expression has not been studied, however, in adrenal tumors.
  • The expression of AM2/IMD and AM was therefore studied in human adrenal tumors and attached non-neoplastic adrenal tissues by immunocytochemistry (ICC).
  • AM2/IMD and AM immunoreactivities were detected in medulla of attached non-neoplastic tissues, while the degree of immunoreactivity for AM2/IMD and AM in cortices of attached adrenals was relatively weak or undetectable.
  • RIA detected IR-AM2/IMD in adrenal tumors (0.414+/-0.12 to 0.786+/-0.27 pmol/g wet weight, mean+/-S.E.M.) and attached adrenal tissues (0.397+/-0.052 pmol/g wet weight).
  • RT-PCR showed expression of AM2/IMD, CRLR, and RAMP1, RAMP2, and RAMP3 mRNA in tissues of adrenal tumors and attached adrenal glands.
  • In conclusion, AM2/IMD is expressed in human adrenal tumors and attached non-neoplastic adrenal tissues and may play (patho-)physiological roles in normal and neoplastic adrenals as an autocrine/paracrine regulator.
  • [MeSH-major] Adrenal Gland Neoplasms / chemistry. Adrenal Glands / chemistry. Peptide Hormones / analysis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18460550.001).
  • [ISSN] 1479-6805
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ADM2 protein, human; 0 / Peptide Hormones; 0 / RNA, Messenger
  •  go-up   go-down


8. Choi EK, Kim WH, Park KY: A case of a composite adrenal medullary tumor of pheochromocytoma and ganglioneuroma masquerading as acute pancreatitis. Korean J Intern Med; 2006 Jun;21(2):141-5
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of a composite adrenal medullary tumor of pheochromocytoma and ganglioneuroma masquerading as acute pancreatitis.
  • Composite adrenal medullary tumors, composed of both pheochromocytoma and ganglioneuroma, are extremely rare, as are pheochromocytomas masquerading as acute relapsing pancreatitis.
  • An abdominal computed tomographic scan revealed an enlarged pancreas and a 3-cm left adrenal incidentaloma.
  • An adrenalectomy was performed and a composite adrenal medullary tumor of pheochromocytoma and ganglioneuroma was confirmed during a pathologic examination.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Medulla. Ganglioneuroma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pancreatitis / etiology. Pheochromocytoma / diagnosis

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] South Med J. 1995 Apr;88(4):475-8 [7716605.001]
  • [Cites] Circulation. 2000 Jul 4;102(1):E11-3 [10880429.001]
  • [Cites] Hinyokika Kiyo. 2000 Dec;46(12):887-90 [11211805.001]
  • [Cites] Int J Clin Pract. 2003 Jul-Aug;57(6):547-8 [12918898.001]
  • [Cites] Korean J Gastroenterol. 2003 Aug;42(2):172-5 [14532724.001]
  • [Cites] Adv Morphog. 1970;8:41-114 [4906187.001]
  • [Cites] Can Med Assoc J. 1977 Feb 19;116(4):357-9 [844016.001]
  • [Cites] Am J Gastroenterol. 1978 Nov;70(5):480-8 [742604.001]
  • [Cites] Anaesthesia. 1983 Sep;38(9):888-91 [6625139.001]
  • [Cites] Arch Pathol Lab Med. 1985 May;109(5):470-2 [3838664.001]
  • [Cites] Am J Surg Pathol. 1988 Jul;12(7):559-66 [3389453.001]
  • [Cites] Clin Chem. 1988 Oct;34(10):2096-102 [3048784.001]
  • [Cites] Clin Biochem. 1989 Apr;22(2):109-14 [2470532.001]
  • [Cites] J Auton Nerv Syst. 1989 Mar;26(2):97-106 [2723339.001]
  • [Cites] Mayo Clin Proc. 1994 Apr;69(4):366-70 [7513373.001]
  • [Cites] Can J Anaesth. 1994 Mar;41(3):244-7 [7514507.001]
  • [Cites] Med Clin North Am. 1995 Jan;79(1):131-53 [7808088.001]
  • (PMID = 16913447.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3890739
  •  go-up   go-down


9. Ilias I, Pacak K: Diagnosis and management of tumors of the adrenal medulla. Horm Metab Res; 2005 Dec;37(12):717-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of tumors of the adrenal medulla.
  • The adrenal medulla consists of chromaffin cells, the site of catecholamine biosynthesis.
  • Pheochromocytomas are chromaffin-cell tumors; 80-85 % arise from the adrenal medulla and 15-20 % arise from extra-adrenal chromaffin tissues (paragangliomas).
  • Pheochromocytomas account for 6.5 % of incidentally discovered adrenal tumors; they are found in 50 % of patients with multiple endocrine neoplasia 2A (MEN 2A) and 5-25 % of patients with von Hippel-Lindau (VHL) syndrome.
  • The diagnosis of pheochromocytoma should first be established biochemically by measuring plasma free metanephrines (the measurement of urinary fractionated metanephrines is the second choice).
  • Primary treatment for both types of tumor is surgical; chemotherapy is used for inoperable disease.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / therapy. Adrenal Medulla / physiopathology. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Humans. Multiple Endocrine Neoplasia Type 2a / diagnosis. Multiple Endocrine Neoplasia Type 2a / therapy. Neuroblastoma / diagnosis. Neuroblastoma / therapy. Pheochromocytoma / diagnosis. Pheochromocytoma / therapy. Prognosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16372223.001).
  • [ISSN] 0018-5043
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


10. Jakowski JD, Wakely PE Jr, Jimenez RE: An uncommon type of adrenal incidentaloma: a case report of a schwannoma of the adrenal medulla with cytological, histological, and ultrastructural correlation. Ann Diagn Pathol; 2008 Oct;12(5):356-61
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An uncommon type of adrenal incidentaloma: a case report of a schwannoma of the adrenal medulla with cytological, histological, and ultrastructural correlation.
  • Benign nerve sheath tumors of the adrenal gland are an extremely uncommon cause of an incidentaloma.
  • We report a case of a schwannoma of the adrenal medulla in an asymptomatic 51-year-old woman, which was discovered incidentally on a computed tomography scan after routine workup for her degenerative joint diseases of the lumbar spine.
  • Because of the large size and unknown biologic nature of the tumor by clinical and radiographic studies alone, an adrenalectomy was performed.
  • The gross specimen featured a well-circumscribed medullary based tumor with cystic degeneration.
  • The diagnosis of a nerve sheath tumor was based on classic histological findings, supported by S-100 positivity, and ultrastructurally by the finding of typical Schwann cells.
  • The cytological diagnosis from the fine-needle aspiration biopsy material obtained at the time of gross examination was much more challenging on retrospective review.
  • A review of the histogenesis and differential diagnosis of this common nerve sheath tumor in this unusual location is discussed.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Medulla / pathology. Neurilemmoma / pathology
  • [MeSH-minor] Adrenalectomy. Biomarkers, Tumor / analysis. Biopsy. Female. Humans. Incidental Findings. Middle Aged. S100 Proteins / analysis. Schwann Cells / ultrastructure. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18774499.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


11. Keating DJ, Rychkov GY, Giacomin P, Roberts ML: Oxygen-sensing pathway for SK channels in the ovine adrenal medulla. Clin Exp Pharmacol Physiol; 2005 Oct;32(10):882-7
Hazardous Substances Data Bank. ROTENONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxygen-sensing pathway for SK channels in the ovine adrenal medulla.
  • The aim of the present study was to identify the oxygen-sensing pathway in the oxygen-sensitive sheep adrenal medullary chromaffin cell (AMCC).
  • [MeSH-major] Adrenal Medulla / physiology. Chromaffin Cells / physiology. Potassium Channels / physiology. Signal Transduction / physiology
  • [MeSH-minor] Animals. Biphenyl Compounds / pharmacology. Cell Hypoxia / physiology. Cell Line, Tumor. Dithiothreitol / pharmacology. Humans. Hydrogen Peroxide / pharmacology. Membrane Potentials / drug effects. Membrane Potentials / physiology. Mice. Onium Compounds / pharmacology. Oxidants / pharmacology. Patch-Clamp Techniques. Plasmids / genetics. Rotenone / pharmacology. Sheep. Transfection

  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173951.001).
  • [ISSN] 0305-1870
  • [Journal-full-title] Clinical and experimental pharmacology & physiology
  • [ISO-abbreviation] Clin. Exp. Pharmacol. Physiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biphenyl Compounds; 0 / Onium Compounds; 0 / Oxidants; 0 / Potassium Channels; 03L9OT429T / Rotenone; 10182-84-0 / diphenyliodonium; BBX060AN9V / Hydrogen Peroxide; T8ID5YZU6Y / Dithiothreitol
  •  go-up   go-down


12. Trimeche Ajmi S, Chadli Chaieb M, Mokni M, Braham R, Ach K, Maaroufi A, Chaieb L: Corticomedullary mixed tumor of the adrenal gland. Ann Endocrinol (Paris); 2009 Dec;70(6):473-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corticomedullary mixed tumor of the adrenal gland.
  • Abdominal magnetic resonance imaging showed a right heterogeneous adrenal mass measuring 4 x 6 cm with mixed component of fat and adrenal tissue suggesting corticosurrenaloma.
  • In the postoperative course, the patient presented adrenal insufficiency treated with hydrocortisone hemisuccinate.
  • Histological examination showed a single tumor mass composed of an admixed population of adrenal cortical and medullary cells.
  • [MeSH-major] Adrenal Cortex / pathology. Adrenal Gland Neoplasms / diagnosis. Adrenal Medulla / pathology
  • [MeSH-minor] Adipocytes / pathology. Adrenal Insufficiency / drug therapy. Adrenal Insufficiency / etiology. Adrenalectomy / adverse effects. Adult. Amenorrhea. Androgens / blood. Chromogranin A / analysis. Cushing Syndrome. Diagnosis, Differential. Female. Hirsutism. Humans. Hydrocortisone / blood. Hypertension. Hypokalemia. Immunohistochemistry. Magnetic Resonance Imaging. Obesity. Weight Gain

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19878923.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgens; 0 / Chromogranin A; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


13. Gross MD, Gauger PG, Djekidel M, Rubello D: The role of PET in the surgical approach to adrenal disease. Eur J Surg Oncol; 2009 Nov;35(11):1137-45
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of PET in the surgical approach to adrenal disease.
  • BACKGROUND: Appropriate surgical approach to diseases of the adrenal requires a diagnosis sufficient to determine the biochemical status of adrenal dysfunction and anatomic evaluation sufficient to differentiate unilateral from bilateral disease, intra-adrenal from extra-adrenal neoplasm, adrenal tumor recurrence or adrenal metastases.
  • High resolution computed tomography (CT) and magnetic resonance have been the primary imaging modalities for the evaluation of anatomy, while scintigraphic studies have played a secondary role in diagnosis.
  • The recent availability of functional imaging provided by positron emission tomography (PET) with radiopharmaceuticals designed to depict substrate precursor uptake, cellular metabolism or receptor binding in neoplasms and CT as a single modality, hybrid PET/CT, to directly correlate function and anatomy has had a significant impact upon the diagnostic and therapeutic approach to many cancers and has been applied to adrenal disease with some early success that we describe in this review.
  • METHODS: In addition to the authors' experience, a search of Medline and PubMed databases was performed using search terms: 'adrenal scintigraphy', 'positron tomography', 'computed tomography', 'adrenal surgery', 'adrenal mass', '(18)F-fluorodeoxyglucose', 'adrenal carcinoma', 'adrenal medulla' and 'pheochromocytoma'.
  • CONCLUSIONS: Present PET radiopharmaceuticals and their use in hybrid PET/CT have demonstrated efficacy in the preoperative and follow-up evaluation of neoplasms of the adrenal cortex and medulla that hopefully will continue to improve with the development of newer tracers that continue to exploit unusual characteristics of the adrenals.
  • [MeSH-major] Adrenal Gland Neoplasms / radionuclide imaging. Adrenal Gland Neoplasms / surgery. Radiopharmaceuticals. Tomography, Emission-Computed
  • [MeSH-minor] Diagnosis, Differential. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19243910.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals
  • [Number-of-references] 75
  •  go-up   go-down


14. Hattori Y, Kanamoto N, Kawano K, Iwakura H, Sone M, Miura M, Yasoda A, Tamura N, Arai H, Akamizu T, Nakao K, Maitani Y: Molecular characterization of tumors from a transgenic mouse adrenal tumor model: comparison with human pheochromocytoma. Int J Oncol; 2010 Sep;37(3):695-705
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of tumors from a transgenic mouse adrenal tumor model: comparison with human pheochromocytoma.
  • Adrenal neuroblastoma and pheochromocytoma have the same embryonic origin from neural crest cells and mainly arise from the adrenal medulla.
  • Recently, transgenic mice exhibiting tumors in the bilateral adrenal medulla by the expression of SV40 T-antigen were developed.
  • In this study, we investigated mRNA expression in adrenal tumors of transgenic mice and compared them with human pheochromocytoma by DNA microarray analysis.
  • To compare mouse adrenal tumors and human pheochromacytoma, we found that the expressions of noradrenergic neuron-related genes, including dopa decarboxylase, phenylethanolamine-N-methyltransferase and chromogranin B, were up-regulated in humans but not in mice; however, the expression of neuroblastoma-related genes, including Mycn, paired-like homeobox 2b, gamma-aminobutyric acid A receptor beta3 subunit, islet 1 and kinesin family member 1A, was up-regulated in both species.
  • From the gene expression profiles, the characterization of mouse adrenal tumor, may be similar to that of human adrenal neuroblastoma rather than pheochromacytomas.
  • This mouse model would be a useful tool for the development of anti-cancer drugs and for understanding the etiology of adrenal neuroblastoma.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Pheochromocytoma / genetics


15. Takahashi K, Shoji I, Shibasaki A, Kato I, Hiraishi K, Yamamoto H, Kaneko K, Murakami O, Morimoto R, Satoh F, Ito S, Totsune K: Presence of kisspeptin-like immunoreactivity in human adrenal glands and adrenal tumors. J Mol Neurosci; 2010 May;41(1):138-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of kisspeptin-like immunoreactivity in human adrenal glands and adrenal tumors.
  • Kisspeptins have also been reported to stimulate the aldosterone secretion from the adrenal cortex.
  • However, the expression of kisspeptins in human adrenal glands and adrenal tumors has not been clarified yet.
  • We, therefore, studied the presence of kisspeptin-like immunoreactivity (LI) in human adrenal glands and adrenal tumors (adrenocortical adenomas, adrenocortical carcinomas, and pheochromocytomas) by radioimmunoassay and immunocytochemistry.
  • Kisspeptin-LI was detected in all the tissues examined; normal portions of adrenal glands (3.0 +/- 2.3 pmol/g wet weight, n = 21, mean +/- SD), aldosterone-producing adenomas (4.6 +/- 3.3 pmol/g wet weight, n = 10), cortisol-producing adenomas (2.7 +/- 1.4 pmol/g wet weight, n = 14), adrenocortical carcinomas (1.7 +/- 0.2 pmol/g wet weight, n = 4), and pheochromocytomas (1.8 +/- 0.8 pmol/g wet weight, n = 6).
  • Immunocytochemistry showed positive kisspeptin-immunostaining in normal adrenal glands, with stronger immunostaining found in the medulla.
  • Furthermore, positive kisspeptin-immunostaining was found in all types of adrenal tumors examined; adrenocortical adenomas, adrenocortical carcinomas, and pheochromocytomas.
  • The intensity of kisspeptin-immunostaining in these adrenal tumors was, however, not so strong as that in normal adrenal medulla.
  • The present study has shown for the first time the presence of kisspeptin-LI in adrenal glands and adrenal tumors.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Adrenal Glands / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetologia. 2009 May;52(5):855-62 [19221709.001]
  • [Cites] N Engl J Med. 2003 Oct 23;349(17):1614-27 [14573733.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1897-903 [15070962.001]
  • [Cites] Peptides. 1992 Jan-Feb;13(1):121-3 [1535705.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Aug;76(8):4079-83 [386355.001]
  • [Cites] Peptides. 2003 Feb;24(2):301-6 [12668216.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4671-8 [15914529.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34631-6 [11457843.001]
  • [Cites] J Cell Sci. 2004 Mar 15;117(Pt 8):1319-28 [15020672.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 4;88(23):1731-7 [8944003.001]
  • [Cites] Reprod Sci. 2007 Dec;14(8):836-45 [18089602.001]
  • [Cites] Peptides. 2008 May;29(5):873-80 [17686550.001]
  • [Cites] Endocr J. 2008 Mar;55(1):49-55 [18187873.001]
  • [Cites] Neurosci Lett. 1996 Jan 26;203(3):207-10 [8742029.001]
  • [Cites] Endocrinology. 2007 Jan;148(1):140-7 [17023533.001]
  • [Cites] Peptides. 2000 Feb;21(2):251-6 [10764953.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):28969-75 [11387329.001]
  • [Cites] Diabetologia. 2006 Sep;49(9):2131-5 [16826407.001]
  • [Cites] Nature. 2001 May 31;411(6837):613-7 [11385580.001]
  • [Cites] Endocrinology. 2004 Sep;145(9):4073-7 [15217982.001]
  • [Cites] Lancet. 1983 Sep 3;2(8349):540-2 [6136694.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Dec;90(12):6609-15 [16174713.001]
  • [Cites] Endocrinology. 2004 Oct;145(10):4565-74 [15242985.001]
  • [Cites] J Neuroendocrinol. 2009 Mar;21(4):299-304 [19210293.001]
  • [Cites] J Endocrinol. 2008 Jul;198(1):175-83 [18460550.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 19898965.001).
  • [ISSN] 1559-1166
  • [Journal-full-title] Journal of molecular neuroscience : MN
  • [ISO-abbreviation] J. Mol. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KISS1 protein, human; 0 / Kisspeptins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


16. Woods AM, Judd AM: Interleukin-4 increases cortisol release and decreases adrenal androgen release from bovine adrenal cells. Domest Anim Endocrinol; 2008 May;34(4):372-82
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-4 increases cortisol release and decreases adrenal androgen release from bovine adrenal cells.
  • ACTH is the primary regulator of adrenal function during acute stress.
  • However, during chronic inflammatory stress additional factors play a major role in the regulation of adrenal secretion.
  • Many cytokines circulate in the blood and are synthesized and released from adrenal tissue.
  • Furthermore, these peptides modify adrenal function.
  • Recently, interleukin-4 (IL-4) was demonstrated to be released from a human adrenal tumor cell line.
  • Therefore, we hypothesized that normal bovine adrenocortical cells could express IL-4 and that this cytokine may modify adrenal function.
  • We determined that IL-4 and IL-4 receptors (IL-4R) are expressed in the bovine adrenal cortex whereas the expression of IL-4 and IL-4R in the adrenal medulla was not apparent.
  • However, the ACTH-stimulated release of cortisol from the bovine adrenal cells was augmented by IL-4.
  • IL-4 exposure had no affect on adrenal androgen release from bovine zona reticularis cells, but IL-4 inhibited the ACTH-stimulated release of adrenal androgens from these cells.
  • The effects of IL-4 on ACTH-stimulated cortisol and adrenal androgen release were dependent upon the IL-4 incubation interval and the IL-4 concentration.
  • Because communication between the immune and endocrine systems is important in inflammatory conditions, IL-4 may play a role in coordinating the adrenal response to inflammatory stress.
  • [MeSH-major] Adrenal Glands / drug effects. Adrenal Glands / metabolism. Androgens / secretion. Cattle / metabolism. Hydrocortisone / secretion. Interleukin-4 / pharmacology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18055157.001).
  • [ISSN] 0739-7240
  • [Journal-full-title] Domestic animal endocrinology
  • [ISO-abbreviation] Domest. Anim. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Receptors, Interleukin-4; 207137-56-2 / Interleukin-4; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


17. Takahashi K, Totsune K, Saruta M, Fukuda T, Suzuki T, Hirose T, Imai Y, Sasano H, Murakami O: Expression of urocortin 3/stresscopin in human adrenal glands and adrenal tumors. Peptides; 2006 Jan;27(1):178-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of urocortin 3/stresscopin in human adrenal glands and adrenal tumors.
  • In the present study, we studied expression of Ucn3/SCP in the normal adrenal and adrenal tumors by radioimmunoassay and reverse transcriptase-polymerase chain reaction (RT-PCR).
  • High concentrations of immunoreactive (IR)-Ucn3 were present in the normal portions of adrenal glands (4.2+/-0.51 pmol/g wet weight, mean+/-S.E.M., n = 14), and the levels were higher than those in the brain.
  • IR-Ucn3 was also detected in the tumor tissues of aldosterone-secreting adenomas (6.2+/-0.6 pmol/g wet weight, n = 10), cortisol-secreting adenomas (5.0+/-1.2 pmol/g wet weight, n = 4), and pheochromocytomas (1.9+/-0.4 pmol/g wet weight, n = 7).
  • Reverse phase high performance liquid chromatography showed that IR-Ucn3 in normal portions of adrenal glands and aldosterone-secreting adenomas was eluted mainly in the positions of Ucn3 and SCP with several minor peaks eluting earlier.
  • The RT-PCR showed expression of Ucn3 mRNA in normal portions of adrenal gland (positive ratio; 4/4), aldosterone-secreting adenomas (3/4), cortisol-secreting adenomas (1/3) and pheochromocytomas (6/7).
  • These findings indicate that Ucn3 is produced in normal adrenal and adrenal tumors (both adrenocortical tumors and pheochromocytomas), and suggest that Ucn3 acts as an autocrine or paracrine regulator in normal adrenal and adrenal tumors.
  • [MeSH-major] Adenoma / metabolism. Adrenal Cortex / metabolism. Adrenal Gland Neoplasms / metabolism. Adrenal Medulla / metabolism. Corticotropin-Releasing Hormone / biosynthesis. Pheochromocytoma / metabolism. Urocortins / biosynthesis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16095756.001).
  • [ISSN] 0196-9781
  • [Journal-full-title] Peptides
  • [ISO-abbreviation] Peptides
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / UCN3 protein, human; 0 / Urocortins; 9015-71-8 / Corticotropin-Releasing Hormone
  •  go-up   go-down


18. Tischler AS, Kimura N, Mcnicol AM: Pathology of pheochromocytoma and extra-adrenal paraganglioma. Ann N Y Acad Sci; 2006 Aug;1073:557-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology of pheochromocytoma and extra-adrenal paraganglioma.
  • The 2004 WHO classification of endocrine tumors defines pheochromocytoma as a tumor arising from chromaffin cells in the adrenal medulla.
  • Closely related tumors in extra-adrenal sympathetic and parasympathetic paraganglia are classified as extra-adrenal paragangliomas.
  • A pheochromocytoma is an intra-adrenal sympathetic paraganglioma.
  • While arbitrary, this nomenclature serves to emphasize important distinctive properties of intra-adrenal tumors that must be taken into account in clinical practice and research.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Paraganglioma / pathology. Pheochromocytoma / pathology


19. Opocher G, Schiavi F, Cicala MV, Patalano A, Mariniello B, Boaretto F, Zovato S, Pignataro V, Macino B, Negro I, Mantero F: Genetics of adrenal tumors. Minerva Endocrinol; 2009 Jun;34(2):107-21
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetics of adrenal tumors.
  • Endocrinology pioneered the development of molecular medicine, but also the study of adrenal tumors had a great impact in this field.
  • Particularly important was the detection of genetics of tumors derived from the adrenal medulla, as well as that of those derived from the sympathetic and parasympathetic paraganglia.
  • Less well understood is the genetics of adrenal cortex tumors, in particular adrenocortical carcinoma, a rare and particularly aggressive disease.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Biomarkers, Tumor / genetics. Mutation. Pheochromocytoma / genetics
  • [MeSH-minor] Adrenal Cortex Neoplasms / genetics. Adrenocortical Carcinoma / genetics. Genetic Predisposition to Disease. Genomics. Humans. Neoplasm Proteins / genetics. Paraganglioma / genetics

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19471236.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Number-of-references] 81
  •  go-up   go-down


20. Morimoto R, Satoh F, Murakami O, Totsune K, Arai Y, Suzuki T, Sasano H, Ito S, Takahashi K: Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues. Peptides; 2008 May;29(5):873-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues.
  • In addition to its vascular actions, UII has been shown to have mitogenic effects on tumor growth and some regulatory effects on adrenal steroidogenesis.
  • In the present study, we examined expression of UII and UT-R in human adrenal tumors and attached non-neoplastic adrenal tissues by immunohistochemistry.
  • Both UII and UT-R were immunolocalized in tumor cells of all adrenal tumors examined: 8 cases of cortisol-producing adenomas, 8 cases of aldosterone-producing adenomas, 2 cases of non-functioning adenomas, 17 cases of adrenocortical carcinomas, and 8 cases of pheochromocytomas.
  • In attached adrenals, immunoreactivity for UII was detected in medulla, but much weaker in the cortex than in cortical tumors, suggesting that expression of UII was up-regulated in neoplastic adrenocortical tissues.
  • No significant differences were found in the degree of immunoreactivity for UT-R between the tumors and the attached adrenal tissues.
  • The present study showed that both UII and UT-R were expressed in the adrenal tumors and attached non-neoplastic adrenal tissues, and suggests possible roles of UII and UT-R in tumor growth and/or secretory activities of these tumors.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Adrenal Glands / metabolism. Receptors, G-Protein-Coupled / metabolism. Urotensins / metabolism

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17686550.001).
  • [ISSN] 0196-9781
  • [Journal-full-title] Peptides
  • [ISO-abbreviation] Peptides
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, G-Protein-Coupled; 0 / UTS2R protein, human; 0 / Urotensins; 9047-55-6 / urotensin II
  •  go-up   go-down


21. Iwase K, Nagasaka A, Kato K, Itoh A, Jimbo S, Hibi Y, Kobayashi N, Yamamoto H, Seko T, Miura K: Cu/Zn- and Mn-superoxide dismutase distribution and concentration in adrenal tumors. J Surg Res; 2006 Sep;135(1):150-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cu/Zn- and Mn-superoxide dismutase distribution and concentration in adrenal tumors.
  • The tissue distribution of Cu/Zn- and Mn-superoxide dismutases (SOD) in adrenal tumors was studied by an immunohistochemical technique, and the concentrations of both SODs were measured by a sensitive sandwich enzyme immunoassay technique.
  • In the normal adrenal gland, both Cu/Zn- and Mn-SODs were localized predominantly in the reticular zone of the cortex.
  • Cu/Zn-SOD was stained clearly in the inner fascicular zone of the cortex, but not in the medulla, whereas Mn-SOD was stained weakly in the medulla.
  • In different adrenal tumors, the localization of both stained SODs reflected the origin of the tumor cell.
  • The concentrations of both SODs in the tissues of medullary tumors were lower than those in the normal adrenal gland and adrenocortical adenomas.
  • The concentration of Cu/Zn-SOD in the tumor tissue of Cushing's syndrome adenoma was higher, and that of Mn-SOD was lower than the concentrations in the normal adrenal gland.
  • The ratio of the tissue concentrations of Mn-SOD to Cu/Zn-SOD was lower in adrenal medullary tumors and Cushing's syndrome adenomas than in the normal adrenal gland and primary aldosteronism adenomas, indicating the predominance of Cu/Zn-SOD in the former, and Mn-SOD in the latter.
  • These data suggest that the localization of Cu/Zn- and Mn-SODs in adrenal tissues reflects the specificity of the adrenal cells that produce the tissue-specific hormones.
  • An investigation of changes in these enzymes in adrenal tumors may also provide useful information on adrenal tumor cell differentiation.
  • [MeSH-major] Adrenal Cortex / enzymology. Adrenal Cortex Neoplasms / metabolism. Adrenocortical Adenoma / metabolism. Superoxide Dismutase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780879.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


22. McNicol AM: Histopathology and immunohistochemistry of adrenal medullary tumors and paragangliomas. Endocr Pathol; 2006;17(4):329-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathology and immunohistochemistry of adrenal medullary tumors and paragangliomas.
  • The term pheochromocytoma is reserved for intra-adrenal tumors.
  • This short review discusses the gross and microscopic features, the immunohistochemical profile, the problem of recognizing malignant potential, and the rare instances where a differential diagnosis has to be considered.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Medulla / pathology. Paraganglioma, Extra-Adrenal / pathology. Pheochromocytoma / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Chromaffin Cells / chemistry. Chromaffin Cells / pathology. Humans. Hyperplasia. Immunohistochemistry / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1552-7 [11075859.001]
  • [Cites] Endocr Pathol. 2002 Summer;13(2):99-110 [12165657.001]
  • [Cites] Appl Pathol. 1987;5(4):229-45 [2446641.001]
  • [Cites] Arch Pathol Lab Med. 1985 Jul;109(7):633-5 [3839362.001]
  • [Cites] J Pathol. 2000 Jun;191(2):175-80 [10861578.001]
  • [Cites] Neuropeptides. 1999 Apr;33(2):159-63 [10657486.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):57-63 [9422316.001]
  • [Cites] Endocr Pathol. 2002 Spring;13(1):17-27 [12114747.001]
  • [Cites] Semin Diagn Pathol. 2000 May;17(2):120-6 [10839612.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):423-36 [15369446.001]
  • [Cites] Cancer. 1995 Feb 1;75(3):860-4 [7828138.001]
  • [Cites] Arch Pathol Lab Med. 1990 May;114(5):506-10 [2159272.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1261-7 [11688460.001]
  • [Cites] Endocr Pathol. 2002 Summer;13(2):149-56 [12165664.001]
  • [Cites] AJR Am J Roentgenol. 1990 Dec;155(6):1247-50 [2173385.001]
  • [Cites] J Urol. 2002 Jun;167(6):2514-5 [11992070.001]
  • [Cites] J Clin Pathol. 1998 Jun;51(6):477-8 [9771451.001]
  • [Cites] Histopathology. 1991 May;18(5):453-8 [1679411.001]
  • [Cites] Hum Pathol. 1993 Apr;24(4):420-3 [8491482.001]
  • [Cites] Mod Pathol. 1998 Dec;11(12):1160-4 [9872645.001]
  • [Cites] Arch Pathol Lab Med. 1991 May;115(5):484-7 [1673596.001]
  • [Cites] Urol Clin North Am. 2000 Aug;27(3):393-402 [10985140.001]
  • [Cites] Am J Clin Pathol. 1976 Aug;66(2):279-90 [949038.001]
  • [Cites] Am J Surg Pathol. 1980 Apr;4(2):109-20 [7377461.001]
  • [Cites] Virchows Arch. 1997 Mar;430(3):239-45 [9099982.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1119-28 [15167935.001]
  • [Cites] Hum Pathol. 2000 Mar;31(3):386-93 [10746684.001]
  • [Cites] J Endocrinol. 1999 May;161(2):341-7 [10320833.001]
  • [Cites] J Intern Med. 2002 Sep;252(3):239-46 [12270004.001]
  • [Cites] Hum Pathol. 1998 May;29(5):522-6 [9596278.001]
  • [Cites] Am J Pathol. 1976 Apr;83(1):177-96 [1275056.001]
  • [Cites] Cancer. 1990 Oct 15;66(8):1833-5 [2208039.001]
  • [Cites] Am J Surg Pathol. 1987 Jun;11(6):480-6 [3592062.001]
  • [Cites] Hum Pathol. 1990 Nov;21(11):1168-80 [2172151.001]
  • [Cites] J Med Genet. 2002 Sep;39(9):617-22 [12205103.001]
  • [Cites] Surgery. 1990 Dec;108(6):1124-9; discussion 1129-30 [2174194.001]
  • [Cites] Endocr Pathol. 2005 Spring;16(1):23-32 [16000843.001]
  • [Cites] Horm Metab Res. 2005 Jun;37(6):384-90 [16001332.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):551-66 [11979086.001]
  • [Cites] Mod Pathol. 1999 Dec;12(12):1107-11 [10619262.001]
  • [Cites] Hum Pathol. 1985 Jun;16(6):580-9 [3997135.001]
  • [Cites] Hum Pathol. 1988 Jan;19(1):41-50 [2447010.001]
  • [Cites] Am J Pathol. 1986 Oct;125(1):45-54 [3777139.001]
  • (PMID = 17525481.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 46
  •  go-up   go-down


23. Kimura N, Watanabe T, Noshiro T, Shizawa S, Miura Y: Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol; 2005;16(1):23-32
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors.
  • Pheochromocytomas and extra-adrenal sympathetic paragangliomas show varied histological patterns, and it is difficult to diagnose malignancy or predict the clinical course using current histological criteria.
  • In the present study, we reviewed 146 sympathetic paragangliomas including 116 adrenal (102 unilateral, 14 bilateral) and 30 extra-adrenal tumors including 38 metastatic tumors.
  • The frequency of these tumor types were 113 WD (77%), 27 MD (19%), and 6 PD (4%).
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Medulla / pathology. Paraganglioma, Extra-Adrenal / secondary. Pheochromocytoma / secondary
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Catecholamines / metabolism. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1985 Jul;109(7):633-5 [3839362.001]
  • [Cites] J Endocrinol Invest. 1992 Oct;15(9):643-9 [1479147.001]
  • [Cites] Arch Pathol Lab Med. 1991 May;115(5):484-7 [1673596.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Endocr Pathol. 2003 Winter;14(4):329-50 [14739490.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(1):25-32 [1353277.001]
  • [Cites] Endocr Pathol. 1996 Summer;7(2):131-136 [12114640.001]
  • [Cites] Am J Hypertens. 2000 Jan;13(1 Pt 1):35-43 [10678269.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):25-36 [12746560.001]
  • [Cites] Hum Pathol. 1990 Nov;21(11):1168-80 [2172151.001]
  • [Cites] Arch Orthop Trauma Surg. 2001 Nov;121(10):598-600 [11768644.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):551-66 [11979086.001]
  • [Cites] Mod Pathol. 1999 Dec;12(12):1107-11 [10619262.001]
  • [Cites] Cancer. 1977 Nov;40(5):1987-2004 [922654.001]
  • [Cites] J Endocrinol Invest. 1992 Oct;15(9):631-42 [1479146.001]
  • [Cites] Hum Pathol. 1985 Jun;16(6):580-9 [3997135.001]
  • (PMID = 16000843.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Catecholamines; 0 / Ki-67 Antigen
  •  go-up   go-down


24. Tischler AS: Pheochromocytoma and extra-adrenal paraganglioma: updates. Arch Pathol Lab Med; 2008 Aug;132(8):1272-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pheochromocytoma and extra-adrenal paraganglioma: updates.
  • CONTEXT: Advances in genetics and gene expression profiling have led to new ways of thinking about the pathobiology of pheochromocytoma and extra-adrenal paraganglioma.
  • CONCLUSIONS: The World Health Organization reserves the term pheochromocytoma for tumors arising from chromaffin cells in the adrenal medulla.
  • Closely related tumors in extra-adrenal sympathetic and parasympathetic paraganglia are classified as extra-adrenal paragangliomas.
  • A pheochromocytoma is an intra-adrenal sympathetic paraganglioma.
  • Although arbitrary, this nomenclature emphasizes important distinctive properties of intra-adrenal tumors, including an often adrenergic phenotype, relatively low rate of malignancy, and predilection to occur in particular hereditary syndromes.
  • In addition, tumor location and risk of malignancy vary with the underlying genetic defect.
  • The "10 percent rule" for pheochromocytoma/paraganglioma--10% familial, 10% malignant, 10% extra-adrenal--is therefore no longer tenable.
  • [MeSH-major] Adrenal Gland Neoplasms. Endocrinology / trends. Paraganglioma, Extra-Adrenal. Pheochromocytoma

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18684026.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


25. Toni García M, Anda Apiñániz E, Pablo J, de Esteban M, Munárriz Alcuaz P, Goñi Iriarte MJ, Forga Llenas L: An unusual association: pheochromocytoma on an atrophied adrenal gland due to addison's disease. Endocrinol Nutr; 2008 Dec;55(10):510-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual association: pheochromocytoma on an atrophied adrenal gland due to addison's disease.
  • APS-II is defined by the development of two or more of the following entities: primary adrenal insufficiency (Addison's disease), Graves' disease, type 1A diabetes mellitus, autoimmune thyroiditis, primary hypogonadism, celiac disease, and myasthenia gravis.
  • Primary adrenal insufficiency in these patients affects the adrenal cortex, which is destroyed by autoantibodies against 21-hydroxylase.
  • Unlike other causes of adrenal insufficiency (infectious diseases, infiltrative diseases, bleeding, tumors), the adrenal medulla is not involved.
  • Pheochromocytomas are tumors arising from the chromaffin cells of the sympathetic nervous system in the adrenal medulla.
  • In this patient, the adrenal gland cortex was atrophied and the tumor was attached to the adrenal medulla.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Sociedad Española de Endocrinología y Nutrición. Published by Elsevier Espana. All rights reserved.
  • (PMID = 22980466.001).
  • [ISSN] 1575-0922
  • [Journal-full-title] Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición
  • [ISO-abbreviation] Endocrinol Nutr
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


26. Lai EW, Rodriguez OC, Aventian M, Cromelin C, Fricke ST, Martiniova L, Lubensky IA, Lisanti MP, Picard KL, Powers JF, Tischler AS, Pacak K, Albanese C: ErbB-2 induces bilateral adrenal pheochromocytoma formation in mice. Cell Cycle; 2007 Aug 01;6(15):1946-50
SciCrunch. The Antibody Registry: Reagent: Antibodies .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ErbB-2 induces bilateral adrenal pheochromocytoma formation in mice.
  • Pheochromocytoma (PCC) is a rare catecholamine-producing tumor that arises from the adrenal medulla and is often familial.
  • In the present study, ectopic expression of an activated ErbB-2 transgene resulted in bilateral adrenal PCC.
  • Analyses of tumor samples and normal adrenal tissue revealed that levels of the Pten tumor suppressor protein were greatly reduced in PCCs, while levels of the cell cycle regulatory protein cyclin D1 were usually increased.
  • In addition, levels of phospo-AKT were increased in PCCs versus normal adrenal tissue.
  • These data establish that increased ErbB-2 growth factor receptor signaling in the adrenal medulla can lead to PCC through combined influences on Pten, AKT andcyclin D1.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Adrenal Gland Neoplasms / pathology. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Pheochromocytoma / metabolism. Pheochromocytoma / pathology. Receptor, ErbB-2 / metabolism


27. Babinska A, Sworczak K, Wisniewski P, Nałecz A, Jaskiewicz K: The role of immunohistochemistry in histopathological diagnostics of clinically "silent" incidentally detected adrenal masses. Exp Clin Endocrinol Diabetes; 2008 Apr;116(4):246-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of immunohistochemistry in histopathological diagnostics of clinically "silent" incidentally detected adrenal masses.
  • BACKGROUND: The detectability of adrenal incidentalomas (incidentally found adrenal tumours) in the whole population is estimated at 0.1%; 0.42% in non-endocrine patients and at 4.3% in oncologically diagnosed ones.
  • Even up to 16% of incidentalomas of adrenal glands can be malignant lesions.
  • The issue of crucial importance is the histopathological differentiation between benign lesions and malignant tumours of the adrenal cortex and medulla.
  • OBJECTIVES: To evaluate whether the immunohistochemical analysis of the expression of p53, p21, PCNA and Ki67 in the tumour's tissue can be useful in the histopathological diagnostics of adrenal incidentalomas and whether it is important for prognosis.
  • MATERIAL AND METHODS: Our series consisted of 74 tumour samples from 164 patients operated for incidentalomas.
  • RESULTS: We found a statistically significant correlation between the expression of p53, p21, Ki67 and the differential diagnosis of adrenal cortical adenoma and adrenocortical carcinoma (for proteins: p53 p=0.010, for p21 p=0.010, for Ki67 p<0.001).
  • The statistical significant correlation between PCNA protein and diagnosis of adrenal cortical adenoma and adrenocortical carcinoma was not found.
  • The statistically significant correlation between p21, PCNA proteins and the diagnosis of benign and malignant PHEOs was not estimated.
  • [MeSH-major] Adenoma / pathology. Adrenal Gland Neoplasms / pathology. Pheochromocytoma / pathology
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Ki-67 Antigen / genetics. Proliferating Cell Nuclear Antigen / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. Tumor Suppressor Protein p53 / genetics. p21-Activated Kinases / genetics

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18393131.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; EC 2.7.11.1 / p21-Activated Kinases
  •  go-up   go-down


28. Korpershoek E, Petri BJ, van Nederveen FH, Dinjens WN, Verhofstad AA, de Herder WW, Schmid S, Perren A, Komminoth P, de Krijger RR: Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma. Endocr Relat Cancer; 2007 Jun;14(2):453-62
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma.
  • Pheochromocytomas (PCCs) are rare tumors that arise from chromaffin tissue in the adrenal medulla, but can also occur in the abdomen outside the adrenals and are then called sympathetic paragangliomas (sPGLs).
  • According to the literature, between 15 and 25% of apparently sporadic adrenal PCC and sPGL are caused by germline mutations in RET, von Hippel-Lindau disease (VHL), succinate dehydrogenase subunit B (SDHB), or subunit D SDHD.
  • However, few studies have addressed the mutationfrequency of these candidate genes in selected subgroups of PCC andsPGL, such as bilateral adrenal PCC or extra-adrenal sPGL, and none have looked at somatic mutations by analyzing tumor tissue.
  • Therefore, we have investigated the occurrence of germline and somatic mutations in RET, VHL, SDHB, and SDHD in comparatively large series of bilateral adrenal PCC (n = 33 patients) and sPGL (n = 26 patients), with the aim of determining the mutation frequency of each of these genes and to establish a genetic testing algorithm.
  • Twenty-one RET, two VHL germline, and one SDHD mutations were found in the patients with bilateral adrenal PCC.
  • We suggest that sequential mutation analysis should be directed first at RET, followed by VHL and SDHD for patients with bilateral adrenal PCC at diagnosis, and at SDHB and SDHD for patients with sPGL.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Genes, Neoplasm. Paraganglioma / genetics. Pheochromocytoma / genetics
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Animals. Cattle. DNA Mutational Analysis. Female. Germ-Line Mutation. Humans. Iron-Sulfur Proteins / genetics. Male. Mice. Middle Aged. Molecular Sequence Data. Mutation. Proto-Oncogene Proteins c-ret / genetics. Rats. Succinate Dehydrogenase / genetics. Von Hippel-Lindau Tumor Suppressor Protein / genetics

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639058.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iron-Sulfur Proteins; 0 / SDHD protein, human; EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


29. Erem C, Ucuncu O, Nuhoglu I, Cinel A, Cobanoglu U, Demirel A, Koc E, Kocak M, Guvendi GF: Adrenal ganglioneuroma: report of a new case. Endocrine; 2009 Jun;35(3):293-6
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal ganglioneuroma: report of a new case.
  • Although adrenal ganglioneuroma (GN) is a rare tumor originating from the neural crest tissue of the sympathetic nervous system, detection of this tumor has increased, as imaging procedures such as ultrasonography (US) and computed tomography (CT) have become prevalent.
  • We describe a case of adrenal GN incidentally diagnosed in a 68-year-old female patient.
  • Abdominal CT and magnetic resonance imaging showed a solid oval tumor approximately 6 x 4 cm in the left adrenal gland without remarkable signs of malignancy.
  • Histological diagnosis of the tumor was a ganglioneuroma originating from the adrenal medulla.
  • Adrenal GN occurs rarely in adults and preoperative diagnosis is difficult, especially in asymptomatic cases.
  • According to our knowledge, this is the fifth case of adrenal GN in an adult patient from Turkey in English literature.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Ganglioneuroma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Actas Urol Esp. 2003 Mar;27(3):221-5 [12812120.001]
  • [Cites] Med Pediatr Oncol. 1994;22(4):240-3 [8107654.001]
  • [Cites] Int J Urol. 1999 Sep;6(9):471-4 [10510894.001]
  • [Cites] Clin Imaging. 1993 Jan-Mar;17(1):19-21 [8439838.001]
  • [Cites] Radiographics. 2003 Jan-Feb;23(1):29-43 [12533638.001]
  • [Cites] Indian J Pathol Microbiol. 2007 Oct;50(4):782-4 [18306553.001]
  • [Cites] Clin Imaging. 1992 Jan-Mar;16(1):37-9 [1540861.001]
  • [Cites] World J Gastroenterol. 2007 Apr 14;13(14):2129-31 [17465461.001]
  • [Cites] Arch Gynecol Obstet. 2005 Jan;271(1):66-8 [14716493.001]
  • [Cites] Urology. 2000 Sep 1;56(3):508 [10962331.001]
  • [Cites] Hum Pathol. 1992 Jan;23(1):72-5 [1544674.001]
  • [Cites] Endocr Relat Cancer. 2003 Mar;10(1):99-107 [12653673.001]
  • [Cites] Radiographics. 2002 Jul-Aug;22(4):911-34 [12110723.001]
  • [Cites] Saudi Med J. 2008 Jan;29(1):122-5 [18176686.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):263 [8689183.001]
  • [Cites] Urology. 2006 Mar;67(3):622.e1-4 [16504264.001]
  • [Cites] Radiology. 1997 Mar;202(3):703-7 [9051020.001]
  • [Cites] Chang Gung Med J. 2000 Sep;23(9):550-4 [11092144.001]
  • [Cites] JSLS. 2007 Oct-Dec;11(4):487-92 [18237516.001]
  • (PMID = 19367379.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Pan Z, Repertinger S, Deng C, Sharma P: A giant cystic pheochromocytoma of the adrenal gland. Endocr Pathol; 2008;19(2):133-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A giant cystic pheochromocytoma of the adrenal gland.
  • Adrenal pheochromocytomas are rare catecholamine-secreting tumors that originate from chromaffin cells in the adrenal medulla, and giant pheochromocytomas with cystic changes are particularly rare.
  • Radiographic studies showed an 18-cm cystic mass in the left upper quadrant of the abdomen; further workups, which included light microscopy, immunohistochemical, and electron microscopic analysis, revealed a pheochromocytoma of the left adrenal gland.
  • Cytogenetic analysis and genetic mutation analyses for von-Hippel-Lindau (VHL), rearranged during transfection (RET), and succinate dehydrogenase complex subunit B (SDHB) genes were also performed but failed to reveal any abnormalities within the tumor cells.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Pheochromocytoma / pathology
  • [MeSH-minor] Adrenalectomy. DNA Mutational Analysis. Headache / diagnosis. Headache / etiology. Humans. Immunohistochemistry. Male. Microscopy, Electron. Middle Aged. Paraffin Embedding. Tissue Fixation. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1996 Sep 26;335(13):943-51 [8782503.001]
  • [Cites] Magn Reson Imaging. 1993;11(1):47-50 [8423721.001]
  • [Cites] Clin Nucl Med. 2000 Oct;25(10 ):796-800 [11043719.001]
  • [Cites] J Surg Oncol. 2005 Mar 1;89(3):193-201 [15719371.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1531-8 [8105382.001]
  • [Cites] J Urol. 1977 Nov;118(5):840-2 [916112.001]
  • [Cites] Endocr Rev. 1994 Jun;15(3):356-68 [8076587.001]
  • [Cites] Pathol Res Pract. 2002;198(2):103-6; discussion 107-8 [11928862.001]
  • [Cites] Surgery. 2000 Sep;128(3):482-4 [10965322.001]
  • [Cites] Curr Surg. 2005 Mar-Apr;62(2):193-8 [15796940.001]
  • [Cites] South Med J. 1979 Dec;72(12):1605-7 [515776.001]
  • [Cites] Hum Pathol. 2000 Mar;31(3):306-11 [10746672.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):49-54 [11404820.001]
  • [Cites] Eur J Pediatr. 1976 Jul 12;122(4):263-73 [939230.001]
  • [Cites] J Assoc Physicians India. 2002 Jun;50:842-4 [12240860.001]
  • [Cites] J Urol. 1999 Sep;162(3 Pt 1):659-64 [10458336.001]
  • [Cites] Curr Opin Oncol. 2006 Jan;18(1):1-8 [16357557.001]
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] Ir J Med Sci. 1996 Jan-Mar;165(1):57-9 [8867505.001]
  • [Cites] Curr Treat Options Oncol. 2003 Aug;4(4):329-37 [12943613.001]
  • [Cites] Hum Pathol. 1985 Jun;16(6):580-9 [3997135.001]
  • [Cites] South Med J. 2003 Sep;96(9):914-7 [14513991.001]
  • [Cites] N Engl J Med. 1984 Nov 15;311(20):1298-303 [6149463.001]
  • [Cites] Hong Kong Med J. 2000 Sep;6(3):325-8 [11025856.001]
  • (PMID = 18322657.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Palaoğlu S, Sungur A, Cila A, Ozdemir N, Ruacan S: Diethylstilbestrol-induced prolactinoma: dose-related tumor growth and effect of catecholaminergic cells on prolactin tumor cells. Surg Neurol; 2005;64 Suppl 2:S42-7
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diethylstilbestrol-induced prolactinoma: dose-related tumor growth and effect of catecholaminergic cells on prolactin tumor cells.
  • We transplanted, in rats, DES-induced prolactinoma cells into the adrenal medulla or under the renal capsule, two tissues rich and poor in catecholaminergic innervation, respectively.
  • METHODS: Prolactinoma was dose-dependently induced in ovariectomized female rats implanted with 10 and 20 mg DES, and tumor cells taken from prolactinoma induced by 20 mg DES were either transplanted under the renal capsule or into the adrenal medulla.
  • RESULTS: Although the adrenal medulla, with its high dopamine content to inhibit prolactin secretion, was devoid of any tumoral development, a significant tumoral development was evident under the renal capsule, seemingly because of no inhibitory control over prolactin secretion coexisting with the dopamine deficiency of the tissue.
  • [MeSH-major] Adrenal Medulla / pathology. Catecholamines / physiology. Kidney Cortex / pathology. Pituitary Neoplasms / pathology. Prolactinoma / pathology
  • [MeSH-minor] Animals. Carcinogens / administration & dosage. Diethylstilbestrol / administration & dosage. Dose-Response Relationship, Drug. Female. Neoplasm Transplantation. Rats

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16256840.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Catecholamines; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


32. Kura N, Igarashi K, Sekine H: Asymptomatic adrenal medullary hyperplasia detected with intraoperative hypertension: a case report. Hinyokika Kiyo; 2005 May;51(5):321-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymptomatic adrenal medullary hyperplasia detected with intraoperative hypertension: a case report.
  • We report a rare case of asymptomatic adrenal medullary hyperplasia detected by chance with intraoperative hypertension during surgery for ipsilateral renal cell carcinoma.
  • Ultrasonogram and CT scan revealed a left renal tumor but did not showed any abnormal masses in the left adrenal gland.
  • The clinical diagnosis was renal cell carcinoma and we performed left total nephrectomy.
  • Pathological examination of the extirpated kidney revealed renalcell carcinoma, while the resected adrenal gland was diagnosed as adrenal medullary hyperplasia.
  • [MeSH-major] Adrenal Medulla / pathology. Carcinoma, Renal Cell / surgery. Hypertension / etiology. Intraoperative Complications. Kidney Neoplasms / surgery
  • [MeSH-minor] Adult. Humans. Hyperplasia / diagnosis. Male. Nephrectomy

  • Genetic Alliance. consumer health - Adrenal Hypertension.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15977598.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


33. Mukai M, Takao T, Yoshida T, Inoue H, Miyagawa Y, Yoshimura K, Okuyama A, Aozasa K, Fujii T, Takatera H: [Adrenal ganglioneuroma in a 14-year-old girl: a case report]. Hinyokika Kiyo; 2006 Aug;52(8):619-21
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adrenal ganglioneuroma in a 14-year-old girl: a case report].
  • A 14-year-old girl was referred to our hospital for examination of a right adrenal tumor, incidentally found by abdominal ultrasound sonography.
  • Computed tomographic scan and magnetic resonance imaging showed a 44 x 20 mm solid tumor in the right adrenal region.
  • Laparoscopic adrenalectomy was performed and the tumor was histologically diagnosed as ganglioneuroma originated from the right adrenal medulla.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Ganglioneuroma / diagnosis
  • [MeSH-minor] Adolescent. Adrenal Medulla. Adrenalectomy. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16972624.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Okutur K, Küçükler K, Öztekın E, Borlu F, Erdem L, Demır G: A rare cause of acute abdomen: ruptured adrenal pheochromocytoma. Turk J Gastroenterol; 2010 Dec;21(4):467-9
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare cause of acute abdomen: ruptured adrenal pheochromocytoma.
  • Pheochromocytoma is a tumor of the chromaffin cells which secretes catecholamines and 90% of it originates from adrenal medulla.
  • At laparotomy, ruptured adrenal mass was seen and excised successfully.
  • The histological evaluation confirmed the diagnosis as pheochromocytoma.
  • Ruptured adrenal pheochromocytoma is a mortal situation potentially and it should be considered in patients who present with an acute abdominal syndrome and hypertension or shock.
  • It should be known that early diagnosis and surgery with proper preoperative treatment is a life saver.
  • [MeSH-major] Abdomen, Acute / etiology. Adrenal Gland Neoplasms / complications. Hypertension / etiology. Pheochromocytoma / complications

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21332008.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


35. Browning L, Bailey D, Parker A: D2-40 is a sensitive and specific marker in differentiating primary adrenal cortical tumours from both metastatic clear cell renal cell carcinoma and phaeochromocytoma. J Clin Pathol; 2008 Mar;61(3):293-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] D2-40 is a sensitive and specific marker in differentiating primary adrenal cortical tumours from both metastatic clear cell renal cell carcinoma and phaeochromocytoma.
  • BACKGROUND: The morphological similarities between the cells of clear cell renal cell carcinoma (CCRCC) and those of the adrenal cortex impose diagnostic difficulties, for example in the context of a solitary nodule in the adrenal gland in a patient with renal cell carcinoma (RCC).
  • D2-40, an antibody commonly used to highlight lymphatic endothelial cells, is consistently positive in the normal adrenal cortex.
  • AIMS: To investigate the utility of D2-40 in distinguishing neoplastic and non-neoplastic adrenal cortical cells from those of CCRCC, and from phaeochromocytoma.
  • METHODS: D2-40 antibody was applied to tissue sections from 10 normal adrenal glands, 15 renal carcinomas (13 clear cell, 2 papillary variants), 1 metastatic CCRCC in the adrenal gland, 6 adrenal cortical hyperplasias, 5 adrenal cortical adenomas, 3 adrenal cortical carcinomas, and 4 phaeochromocytomas.
  • RESULTS: D2-40 was strongly and diffusely positive in the cells of the neoplastic and non-neoplastic adrenal cortex, but negative in the cells of the CCRCC, both primary and metastatic, in 100% of the cases.
  • The cells of the adrenal medulla, and those of the phaeochromocytomas, were negative for D2-40.
  • CONCLUSIONS: D2-40 may be a useful marker for distinguishing primary adrenal cortical neoplasms from both metastatic CCRCC and phaeochromocytoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Antibodies, Monoclonal / analysis. Biomarkers, Tumor / analysis. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / secondary. Pheochromocytoma / diagnosis
  • [MeSH-minor] Adenoma / diagnosis. Adrenal Glands / immunology. Antibodies, Monoclonal, Murine-Derived. Carcinoma / diagnosis. Cytoplasm / immunology. Diagnosis, Differential. Humans. Immunohistochemistry


36. Plouin PF, Gimenez-Roqueplo AP, Bertagna X: [COMETE, a network for the study and management of hypersecreting adrenal tumors]. Bull Acad Natl Med; 2008 Jan;192(1):73-82; discussion 83-5
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [COMETE, a network for the study and management of hypersecreting adrenal tumors].
  • [Transliterated title] Le réseau national COMETE sur les tumeurs de la surrénale.
  • Patients with adrenal tumors are at risk of the consequences of tumor growth (including metastasis) and of hormone hypersecretion.
  • Pheochromocytomas and paragangliomas arise from the adrenal medulla and produce catecholamines; they may be benign or malignant, and sporadic or familial.
  • Adrenal adenomas and carcinomas arise from the adrenal cortex.
  • The overall objective of COMETE is to promote basic and clinical research into adrenal tumors.
  • This implies - in cross-sectional studies: collecting adrenal tumors, maintaining a collection of tumor and leukocyte DNA samples, keeping a computerized record of relevant biological and clinical data, and distributing biological samples and bioclinical information anonymously to collaborating research laboratories; in prospective studies: ensuring indefinite follow-up of patients with tumors at risk of malignancy or recurrence, which means establishing and maintaining a cohort of patients with large adrenocortical tumors or carcinomas anda cohort of patients with pheochromocytomas or paragangliomas.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Societies, Medical / organization & administration

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663983.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


37. Crivellato E, Belloni A, Nico B, Nussdorfer GG, Ribatti D: In vivo administered reserpine increases piecemeal degranulation in rat adrenal chromaffin cells. Anat Rec A Discov Mol Cell Evol Biol; 2006 Mar;288(3):286-91
Hazardous Substances Data Bank. RESERPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo administered reserpine increases piecemeal degranulation in rat adrenal chromaffin cells.
  • The effects of the amine-depletory agent reserpine have been evaluated by transmission electron microscopy in chromaffin cells of the rat adrenal glands.
  • The observed ultrastructural changes closely reminded of piecemeal degranulation (PMD), a slow and long-lasting secretory process previously described in normal and tumor pheochromocytes.
  • Morphometric analysis revealed that the frequency of all these microscopic parameters was found to be significantly increased in adrenal chromaffin cells from reserpinized rats in comparison to cells from control animals.
  • [MeSH-minor] Adrenal Medulla / cytology. Animals. Male. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16475147.001).
  • [ISSN] 1552-4884
  • [Journal-full-title] The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology
  • [ISO-abbreviation] Anat Rec A Discov Mol Cell Evol Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic Agents; 8B1QWR724A / Reserpine
  •  go-up   go-down


38. Nakamura M, Han B, Nunobiki O, Kakudo K: Adrenomedullin: a tumor progression factor via angiogenic control. Curr Cancer Drug Targets; 2006 Nov;6(7):635-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenomedullin: a tumor progression factor via angiogenic control.
  • ADM is synthesized and is secreted from many mammalian tissues, including the adrenal medulla, endothelial and vascular smooth muscle cells, as well as the myocardium and central nervous system.
  • ADM has been implicated as a mediator of several diseases such as cardiovascular and renal disorders, sepsis, inflammation, diabetes and cancer.
  • ADM is also expressed in a variety of tumors, including breast, endometrial and prostate cancer.
  • ADM has been shown to be a mitogenic factor capable of stimulating growth of several cancer cell types.
  • In addition, ADM is a survival factor for certain cancer cells and an indirect suppressor of the immune response.
  • The major focus of this review will be on the role of ADM in cancer, with emphasis on its utility in diagnostic and prognostic terms, along with its relevance as a therapeutic target.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100569.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Adrenomedullin; 0 / Receptors, Peptide; 148498-78-6 / Adrenomedullin
  • [Number-of-references] 111
  •  go-up   go-down


39. Fukuda T, Takahashi K, Suzuki T, Saruta M, Watanabe M, Nakata T, Sasano H: Urocortin 1, urocortin 3/stresscopin, and corticotropin-releasing factor receptors in human adrenal and its disorders. J Clin Endocrinol Metab; 2005 Aug;90(8):4671-8
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urocortin 1, urocortin 3/stresscopin, and corticotropin-releasing factor receptors in human adrenal and its disorders.
  • OBJECTIVE, DESIGN, AND SETTING: We examined in situ expression of Ucn and CRF receptors in nonpathological human adrenal gland and its disorders using immunohistochemistry and mRNA in situ hybridization.
  • RESULTS: Ucn immunoreactivity was localized in the cortex and medulla of nonpathological adrenal glands.
  • Ucn1 immunoreactivity was marked in the medulla, whereas Ucn3 was immunostained mostly in the cortex.
  • Both CRF type 1 and CRF2 were expressed in the cortex, particularly in the zonae fasciculata and reticularis but very weakly or undetectably in the medulla.
  • Ucn and CRF receptors were all expressed in the tumor cells of pheochromocytomas, adrenocortical adenomas, and carcinomas, but its positivity was less than that in nonpathological adrenal glands, suggesting that Ucn1, Ucn3, and CRF receptors were down-regulated in these adrenal neoplasms.
  • CONCLUSIONS: Ucn1, Ucn3, and CRF receptors are all expressed in human adrenal cortex and medulla and may play important roles in physiological adrenal functions.
  • [MeSH-major] Adrenal Cortex / physiology. Adrenal Cortex Neoplasms / physiopathology. Corticotropin-Releasing Hormone / genetics. Pheochromocytoma / physiopathology. Receptors, Corticotropin-Releasing Hormone / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15914529.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRF receptor type 1; 0 / CRF receptor type 2; 0 / RNA, Messenger; 0 / Receptors, Corticotropin-Releasing Hormone; 0 / UCN3 protein, human; 0 / Urocortins; 9015-71-8 / Corticotropin-Releasing Hormone
  •  go-up   go-down


40. Fukumitsu N, Ashida H, Ogi S, Uchiyama M, Mori Y, Ikemoto I, Sakamoto N, Tojo K, Kawakami M: A case of ganglioneuroma in which 131I-6beta-iodomethyl-19-norcholest-5(10)-en-3beta-ol scintigraphy showed high uptake in the adrenal gland leading to a misdiagnosis. Ann Nucl Med; 2006 Jan;20(1):69-73
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ganglioneuroma in which 131I-6beta-iodomethyl-19-norcholest-5(10)-en-3beta-ol scintigraphy showed high uptake in the adrenal gland leading to a misdiagnosis.
  • We experienced a case in which 131I-6beta-iodomethyl-19-norcholest-5(10)-en-3beta-ol (131I-adosterol) scintigraphy showed high uptake in the right adrenal gland.
  • Unexpectedly, pathological finding showed the right adrenal gland was occupied with a large ganglioneuroma.
  • This is an instructive case in which 131I-adosterol scintigraphy showed abnormal high uptake in the adrenal gland, in spite of the fact that the adrenal gland was occupied by a tumor derived from adrenal medulla.
  • [MeSH-major] 19-Iodocholesterol / analogs & derivatives. Adenoma / radionuclide imaging. Adrenal Gland Neoplasms / radionuclide imaging. Diagnostic Errors / prevention & control. Ganglioneuroma / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485578.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 30461-91-7 / 19-Iodocholesterol; 68232-36-0 / 6-iodomethylcholesterol
  •  go-up   go-down


41. Namour F, Ayav A, Lu X, Klein M, Muresan M, Bresler L, Tramoy D, Guéant JL, Brunaud L: Lack of association between microsatellite instability and benign adrenal tumors. World J Surg; 2006 Jul;30(7):1240-6
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of association between microsatellite instability and benign adrenal tumors.
  • BACKGROUND: The adrenal gland may give rise to pheochromocytomas, which are catecholamine-producing tumors originating from the adrenal medulla, or to adrenocortical tumors, which derive from the adrenocortical cortex and may be secreting or not.
  • AIM: The aim of this study was to investigate a third genetic mechanism by evaluating microsatellite instability using the reference markers (Bat25, Bat26, D2S123, D5S346, D17S250) validated by the National Cancer Institute.
  • No microsatellite instability was detected in any tumor.
  • A second patient with a MEN-2A syndrome and a two-sided pheochromocytoma exhibited a loss of heterozygosity for D2S123 in the right tumor only and a retention of heterozygosity for all markers in the left tumor.
  • CONCLUSIONS: These results suggest that microsatellite instability, evaluated by the five reference markers of the National Cancer Institute, is not a feature of benign adrenal tumors.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Microsatellite Repeats / genetics. Pheochromocytoma / genetics
  • [MeSH-minor] Adult. Aged. Alleles. DNA, Neoplasm / analysis. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Polymerase Chain Reaction. Proto-Oncogene Proteins / genetics

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 Jan 15;57(2):300-3 [9000572.001]
  • [Cites] Hum Pathol. 2004 Mar;35(3):335-42 [15017590.001]
  • [Cites] Int J Oncol. 2005 May;26(5):1385-91 [15809732.001]
  • [Cites] J Clin Pathol. 2005 Aug;58(8):805-10 [16049280.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4371-4 [11389062.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7048-51 [11156410.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Dec;47(6):707-12 [9497878.001]
  • [Cites] Horm Res. 1997;47(4-6):263-8 [9167962.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):1248-51 [12629114.001]
  • [Cites] Lab Invest. 2001 Oct;81(10):1453-6 [11598157.001]
  • [Cites] JAMA. 2004 Aug 25;292(8):943-51 [15328326.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):349-53 [10433928.001]
  • [Cites] Oncogene. 1997 Oct 2;15(14):1713-8 [9349505.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4739-43 [9354434.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4749-56 [9354436.001]
  • [Cites] Cancer Res. 2001 May 15;61(10 ):4112-21 [11358834.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4545-9 [11389088.001]
  • [Cites] Cancer Lett. 2001 Mar 10;164(1):61-8 [11166916.001]
  • [Cites] In Vivo. 2005 Mar-Apr;19(2):359-65 [15796198.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1804-11 [12454837.001]
  • [Cites] Exp Mol Pathol. 2006 Feb;80(1):67-71 [15963980.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):771-5 [15289882.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Dec;59(6):707-15 [14974911.001]
  • [Cites] ANZ J Surg. 2003 Sep;73(9):727-38 [12956790.001]
  • [Cites] Horm Metab Res. 2005 Jun;37(6):384-90 [16001332.001]
  • [Cites] Eur J Surg Oncol. 2003 Apr;29(3):201-12 [12657227.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Jul;5(4):599-611 [16013977.001]
  • [Cites] Surgery. 2003 Dec;134(6):932-9; discussion 939-40 [14668725.001]
  • [Cites] World J Surg. 2002 Aug;26(8):965-71 [12045857.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23 ):6796-802 [12460887.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):651-9 [10666394.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1484-93 [15619207.001]
  • [Cites] J Med Genet. 1995 Dec;32(12):934-7 [8825918.001]
  • (PMID = 16715450.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


42. Nomikos IN, Zizi-Serbetzoglou A, Matsakis G, Elemenoglou J, Vamvakopoulos NC: Association of an oversized adrenal cortical adenoma with expression of pheochromocytoma-like neurosecretory features. J BUON; 2008 Jul-Sep;13(3):425-8
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of an oversized adrenal cortical adenoma with expression of pheochromocytoma-like neurosecretory features.
  • Abnormal stimulation of adrenal function may be either direct, affecting similarly cortical and medullary secretion, or indirect affecting primarily the medulla.
  • Indirect activation of clinically detectable adrenomedullary function may develop as a physical consequence of a non-functional adrenal tumor exerting pressure on the medulla by its size, location and direction of growth.
  • Our case of an oversized and overweight adrenal tumor associated with expression of late-onset pheochromocytoma-like clinical symptoms may be explained by the physical indirect rather than the biological direct activation of adrenomedullary function like hyperplasia or cancer.
  • [MeSH-major] Adenoma / pathology. Adrenal Cortex Neoplasms / pathology. Adrenal Medulla / pathology. Pheochromocytoma / pathology

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18979561.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 57285-09-3 / Inhibins
  •  go-up   go-down


43. Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang X, Di Cristofano A, Pandolfi PP, Hay N: The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev; 2006 Jun 15;20(12):1569-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice.
  • The tumor suppressor PTEN is frequently inactivated in human cancers.
  • Here we showed that the deficiency of Akt1 is sufficient to dramatically inhibit tumor development in Pten+/- mice.
  • Akt1 deficiency had a profound effect on endometrium and prostate neoplasia, two types of human cancer, in which PTEN is frequently mutated, and also affected thyroid and adrenal medulla tumors and intestinal polyps.
  • Even haplodeficiency of Akt1 was sufficient to markedly attenuate the development of high-grade prostate intraepithelial neoplasia (PIN) and endometrial carcinoma.
  • These results have significant implications for cancer therapy.


44. Corti A: Chromogranin A and the tumor microenvironment. Cell Mol Neurobiol; 2010 Nov;30(8):1163-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromogranin A and the tumor microenvironment.
  • Chromogranin A (CgA) is an acidic glycoprotein belonging to a family of regulated secretory proteins stored in the dense core granules of the adrenal medulla and of many other neuroendocrine cells and neurons.
  • A growing body of evidence suggests that CgA is more than a diagnostic/prognostic marker for cancer patients.
  • Indeed, results of in vitro experiments and in vivo studies in animal models suggest that this protein and its fragments can affect several elements of the tumor microenvironment, including fibroblasts and endothelial cells.
  • In this article, recent findings implicating CgA as a modulator of the tumor microenvironment and suggesting that abnormal secretion of CgA could play important roles in tumor progression and response to therapy in cancer patients are reviewed and discussed.
  • [MeSH-major] Chromogranin A / metabolism. Neoplasms / metabolism. Tumor Microenvironment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2001 Jan;438(1):86-91 [11213840.001]
  • [Cites] Regul Pept. 2006 Jul 15;135(1-2):78-84 [16725215.001]
  • [Cites] Invasion Metastasis. 1994-1995;14(1-6):210-22 [7657514.001]
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20835-43 [9252409.001]
  • [Cites] FASEB J. 2007 Oct;21(12):3052-62 [17566084.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):1992-2000 [11391577.001]
  • [Cites] Kidney Int. 1990 May;37(5):1357-62 [2345431.001]
  • [Cites] Curr Opin Pharmacol. 2004 Aug;4(4):314-20 [15251122.001]
  • [Cites] Endocrinology. 1999 Sep;140(9):4104-12 [10465282.001]
  • [Cites] Pharmacol Rev. 2000 Jun;52(2):237-68 [10835101.001]
  • [Cites] Cell Mol Life Sci. 2007 Nov;64(22):2863-86 [17717629.001]
  • [Cites] Eur Heart J. 2002 Jun;23(12):967-74 [12069452.001]
  • [Cites] Regul Pept. 2010 Nov 30;165(1):12-20 [20211659.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Aug;3(8):586-99 [12154370.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):924-32 [8611427.001]
  • [Cites] J Endocrinol. 2000 Jun;165(3):703-14 [10828855.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):583-92 [16862189.001]
  • [Cites] Acta Physiol Scand. 1994 Sep;152(1):11-9 [7810329.001]
  • [Cites] Endocrinology. 1994 Jul;135(1):337-42 [8013369.001]
  • [Cites] Ann Oncol. 1997 Jul;8(7):685-90 [9296223.001]
  • [Cites] PLoS One. 2009;4(2):e4501 [19225567.001]
  • [Cites] Endocr Pathol. 2002 Summer;13(2):117-22 [12165659.001]
  • [Cites] J Biol Chem. 2001 Sep 21;276(38):35875-82 [11451958.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):845-53 [17599769.001]
  • [Cites] Eur J Endocrinol. 2004 Mar;150(3):299-303 [15012614.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):10745-53 [10753865.001]
  • [Cites] FASEB J. 2004 Mar;18(3):554-6 [14734634.001]
  • [Cites] J Leukoc Biol. 2009 Jan;85(1):81-7 [18832606.001]
  • [Cites] Diabetes Obes Metab. 2006 Nov;8(6):621-33 [17026486.001]
  • [Cites] J Biol Chem. 1998 Jun 5;273(23):14339-46 [9603942.001]
  • [Cites] J Biol Chem. 2000 Sep 22;275(38):29257-63 [10875933.001]
  • [Cites] N Engl J Med. 2003 Mar 20;348(12):1134-49 [12646671.001]
  • [Cites] Regul Pept. 2010 Jun 8;162(1-3):33-43 [20116404.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54 [17895480.001]
  • [Cites] N Engl J Med. 1986 May 1;314(18):1145-51 [3007986.001]
  • [Cites] Lancet Oncol. 2003 Sep;4(9):565-73 [12965278.001]
  • [Cites] Cytokine Growth Factor Rev. 1996 Oct;7(3):231-40 [8971478.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):45911-9 [12297497.001]
  • [Cites] Eur Heart J. 2007 May;28(9):1117-27 [17389654.001]
  • [Cites] Biochem J. 1989 Aug 15;262(1):1-13 [2684154.001]
  • [Cites] Regul Pept. 2006 Mar 15;134(1):30-7 [16445995.001]
  • [Cites] Curr Med Chem. 2008;15(14):1444-51 [18537621.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):941-6 [11830555.001]
  • [Cites] Adv Exp Med Biol. 2000;482:351-9 [11192595.001]
  • [Cites] J Biol Chem. 1994 Oct 28;269(43):26988-95 [7929439.001]
  • [Cites] Adv Exp Med Biol. 2000;482:167-78 [11192578.001]
  • [Cites] Cell Mol Life Sci. 2010 Jun;67(12):2107-18 [20217454.001]
  • [Cites] Endocr Rev. 1991 May;12(2):181-7 [2070778.001]
  • (PMID = 21080056.001).
  • [ISSN] 1573-6830
  • [Journal-full-title] Cellular and molecular neurobiology
  • [ISO-abbreviation] Cell. Mol. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Peptide Fragments; 126729-24-6 / vasostatin I
  •  go-up   go-down


45. Erem C, Kocak M, Cinel A, Erso HO, Reis A: Dopamine-secreting adrenal ganglioneuroma presenting with paroxysmal hypertension attacks. Saudi Med J; 2008 Jan;29(1):122-5
Hazardous Substances Data Bank. DOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dopamine-secreting adrenal ganglioneuroma presenting with paroxysmal hypertension attacks.
  • Adrenal ganglioneuromas are rare tumors originating from the neural crest tissue of the sympathetic nervous system.
  • We report a case of dopamine-secreting adrenal ganglioneuroma associated with paroxysmal hypertensive attacks in an adult patient.
  • Abdominal CT and MRI revealed a solid round tumor approximately 4 cm in diameter on the upper pole of the right kidney.
  • Histological diagnosis of the tumor was a ganglioneuroma originating from the adrenal medulla.
  • In conclusion, this is a case of dopamine-secreting adrenal ganglioneuroma associated with paroxysmal hypertensive attacks in an adult patient.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Dopamine / secretion. Ganglioneuroma / complications. Hypertension / etiology
  • [MeSH-minor] Adrenalectomy. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed


46. Rangaswamy M, Kumar SP, Asha M, Manjunath G: CT-guided fine needle aspiration cytology diagnosis of extra-adrenal pheochromocytoma. J Cytol; 2010 Jan;27(1):26-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT-guided fine needle aspiration cytology diagnosis of extra-adrenal pheochromocytoma.
  • Pheochromocytoma is a rare tumor, accounting for <0.1% of the hypertensive population.
  • Extra-adrenal pheochromocytomas (EAPs) are rarer still, accounting for 10% of all pheochromocytomas.
  • Pheochromocytomas are functional catecholamine-secreting tumors of the paraganglionic chromaffin cells found in the adrenal medulla and the extra-adrenal paraganglia cells.
  • The smears showed loosely cohesive tumor cells with prominent anisokaryosis and abundant eosinophilic, granular cytoplasm.
  • The diagnosis was later confirmed by histopathology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042531.001).
  • [ISSN] 0974-5165
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2964848
  • [Keywords] NOTNLM ; CT-guided FNAC / paraganglia / pheochromocytoma / retroperitoneal
  •  go-up   go-down


47. Cotesta D, Petramala L, Serra V, Giustini S, Divona L, Calvieri S, De Toma G, Ciardi A, Corsi A, Massa R, Reale MG, Letizia C: Pheochromocytoma associated with adrenocortical tumor in the same gland. Two case reports and literature review. Minerva Endocrinol; 2006 Jun;31(2):183-9
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pheochromocytoma associated with adrenocortical tumor in the same gland. Two case reports and literature review.
  • Pheochromocytomas are catecholamine-producing neuroendocrine tumours arising from chromaffin cells of the adrenal medulla or extra-adrenal paraganglionic system that show 2 distinctive features, rarity and clinical variability.
  • Pheochromocytoma occasionally is associated with pathological lesions of the adrenal cortex.
  • The diagnosis of pheochromocytoma was confirmed in both cases with laboratory analysis and the lesion was achieved by employing 3 imaging techniques: computed tomography (CT), magnetic resonance imaging (MRI) and scintigraphy with (123)I-metaiodobenzilguanidine (MIBG).
  • The patients underwent adrenalectomy and in the same adrenal gland we found a pheochromocytoma associated with a nonfunctioning cortical adenoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Gland Neoplasms / diagnosis. Adrenocortical Adenoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pheochromocytoma / diagnosis
  • [MeSH-minor] 3-Iodobenzylguanidine. Adrenalectomy. Adult. Humans. Male. Middle Aged. Neurofibromatosis 1 / diagnosis. Radiopharmaceuticals. Treatment Outcome

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16682942.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 35MRW7B4AD / 3-Iodobenzylguanidine
  • [Number-of-references] 41
  •  go-up   go-down


48. Paik KY: [Paraganglioma of the pancreas metastasized to the adrenal gland: a case report]. Korean J Gastroenterol; 2009 Dec;54(6):409-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paraganglioma of the pancreas metastasized to the adrenal gland: a case report].
  • Paraganglioma is a rare neuroendocrine tumor arising from the neural crest, which includes tissues such as the adrenal medulla, carotid and aortic body, organs of Zuckerkandl, and other unnamed paraganglia.
  • A well defined ovoid shape mass in left adrenal gland was suggested adenoma.
  • Microscopic examination with pancreas and adrenal gland revealed that the cells were arranged in a characteristic Zellballen pattern.
  • On the basis of these findings, we diagnosed the tumor as a paraganglioma of the pancreas and adrenal gland.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Paraganglioma / diagnosis
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / surgery. Aged. Chromogranin A / metabolism. Female. Humans. Phosphopyruvate Hydratase / metabolism. S100 Proteins / metabolism. Synaptophysin / metabolism. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026898.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / S100 Proteins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


49. Molatore S, Liyanarachchi S, Irmler M, Perren A, Mannelli M, Ercolino T, Beuschlein F, Jarzab B, Wloch J, Ziaja J, Zoubaa S, Neff F, Beckers J, Höfler H, Atkinson MJ, Pellegata NS: Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytoma. Proc Natl Acad Sci U S A; 2010 Oct 26;107(43):18493-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytoma.
  • Pheochromocytomas are rare neoplasias of neural crest origin arising from chromaffin cells of the adrenal medulla and sympathetic ganglia (extra-adrenal pheochromocytoma).
  • Pheochromocytoma that develop in rats homozygous for a loss-of-function mutation in p27Kip1 (MENX syndrome) show a clear progression from hyperplasia to tumor, offering the possibility to gain insight into tumor pathobiology.
  • We compared the gene-expression signatures of both adrenomedullary hyperplasia and pheochromocytoma with normal rat adrenal medulla.
  • Hyperplasia and tumor show very similar transcriptome profiles, indicating early determination of the tumorigenic signature.
  • Overexpression of these genes precedes histological changes in affected adrenal glands.
  • Adrenal and extra-adrenal pheochromocytoma development clearly follows diverged molecular pathways in MENX rats.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Multiple Endocrine Neoplasia / genetics. Pheochromocytoma / genetics
  • [MeSH-minor] Adrenal Medulla / metabolism. Adrenal Medulla / pathology. Animals. Base Sequence. Biomarkers, Tumor / genetics. Cyclin-Dependent Kinase Inhibitor p27 / genetics. DNA Primers / genetics. Disease Models, Animal. Gene Expression Profiling. Homeodomain Proteins / genetics. Humans. Hyperplasia. Neural Cell Adhesion Molecule L1 / genetics. PC12 Cells. Paraganglioma / genetics. Rats. Rats, Mutant Strains. Species Specificity

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 1998 Apr 1;196(1):119-27 [9527885.001]
  • [Cites] Diabetes. 2005 Dec;54(12):3402-9 [16306355.001]
  • [Cites] Exp Cell Res. 2005 Jun 10;306(2):343-8 [15925590.001]
  • [Cites] Curr Opin Oncol. 2006 Jan;18(1):1-8 [16357557.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3478-81 [16787982.001]
  • [Cites] Dev Biol. 2006 Oct 15;298(2):335-43 [16928368.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15558-63 [17030811.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:112-21 [17102078.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):160-5 [17427103.001]
  • [Cites] Genes Dev. 2007 Jul 15;21(14):1731-46 [17626791.001]
  • [Cites] Neuroscience. 2007 Jul 29;147(4):928-37 [17582688.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Aug;92(8):3321-5 [17519308.001]
  • [Cites] Virchows Arch. 2007 Jul;451(1):37-46 [17554557.001]
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3575-80 [17917782.001]
  • [Cites] Curr Opin Neurobiol. 2008 Jun;18(3):245-50 [18760361.001]
  • [Cites] J Clin Endocrinol Metab. 2009 May;94(5):1826-34 [19141585.001]
  • [Cites] Endocr Pathol. 2008 Spring;19(1):9-16 [18317952.001]
  • [Cites] Cancer Lett. 2009 Sep 18;282(2):137-45 [19144458.001]
  • [Cites] Int J Cancer. 2010 May 15;126(10):2362-72 [19876893.001]
  • [Cites] Cell Tissue Res. 1999 Nov;298(2):185-206 [10550645.001]
  • [Cites] Cell. 1999 Nov 24;99(5):499-510 [10589678.001]
  • [Cites] Eur J Nucl Med. 2001 Mar;28(3):359-68 [11315605.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):49-54 [11404820.001]
  • [Cites] Mech Dev. 2001 Oct;108(1-2):3-12 [11578857.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3048-51 [12036912.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:11-28 [12381538.001]
  • [Cites] BMC Bioinformatics. 2004 Feb 18;5:16 [14975175.001]
  • [Cites] Mol Neurobiol. 2004 Aug;30(1):35-47 [15247487.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Dec;63(6):1372-8 [2430990.001]
  • [Cites] Development. 1998 Feb;125(4):609-20 [9435282.001]
  • [Cites] Development. 1999 Feb;126(3):525-34 [9876181.001]
  • (PMID = 20937862.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE21006
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cdkn1b protein, rat; 0 / DNA Primers; 0 / Homeodomain Proteins; 0 / Neural Cell Adhesion Molecule L1; 0 / PHOX2A protein, human; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Other-IDs] NLM/ PMC2972990
  •  go-up   go-down


50. van Nederveen FH, Korpershoek E, deLeeuw RJ, Verhofstad AA, Lenders JW, Dinjens WN, Lam WL, de Krijger RR: Array-comparative genomic hybridization in sporadic benign pheochromocytomas. Endocr Relat Cancer; 2009 Jun;16(2):505-13
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pheochromocytomas (PCC) are catecholamine-producing tumors arising from the adrenal medulla that occur either sporadically or in the context of hereditary cancer syndromes, such as multiple endocrine neoplasia type 2 (MEN2), von Hippel-Lindau disease (VHL), neurofibromatosis type 1, and the PCC-paraganglioma syndrome.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Chromosome Aberrations. Comparative Genomic Hybridization. Oligonucleotide Array Sequence Analysis. Pheochromocytoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 3 / genetics. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Multiple Endocrine Neoplasia Type 2a / genetics. Mutation / genetics. Von Hippel-Lindau Tumor Suppressor Protein / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19153209.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


51. Korpershoek E, Van Nederveen FH, Dannenberg H, Petri BJ, Komminoth P, Perren A, Lenders JW, Verhofstad AA, De Herder WW, De Krijger RR, Dinjens WN: Genetic analyses of apparently sporadic pheochromocytomas: the Rotterdam experience. Ann N Y Acad Sci; 2006 Aug;1073:138-48
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are usually located in the adrenal medulla, although in about 10% the tumors arise from extra-adrenal chromaffin tissue.
  • The majority of PCCs arise sporadically, but PCCs occur also in the context of hereditary cancer syndromes.
  • Familial PCC is inherited as an autosomal dominant trait alone or as a component of the multiple endocrine neoplasia Type 2 (MEN2) syndrome (RET gene), Von Hippel-Lindau (VHL) disease (VHL gene), neurofibromatosis Type 1 (NF1 gene), or familial pheochromocytoma-paraganglioma (PCC-PGL) syndrome (SDHD/B and C genes).
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Pheochromocytoma / genetics
  • [MeSH-minor] Genetic Predisposition to Disease. Germ-Line Mutation. Humans. Polymerase Chain Reaction. Proto-Oncogene Proteins c-ret / genetics. Succinate Dehydrogenase / genetics. Von Hippel-Lindau Tumor Suppressor Protein / genetics

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17102080.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.3.99.1 / Succinate Dehydrogenase; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


52. Sveinbjörnsson B, Rasmuson A, Baryawno N, Wan M, Pettersen I, Ponthan F, Orrego A, Haeggström JZ, Johnsen JI, Kogner P: Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy. FASEB J; 2008 Oct;22(10):3525-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy.
  • The metabolism of arachidonic acid by the cyclooxygenase (COX) or lipoxygenase (LO) pathways generates eicosanoids that have been implicated in the pathogenesis of a variety of human diseases, including cancer.
  • In this study, we examined the expression and significance of components within the 5-LO pathway in human neuroblastoma, an embryonal tumor of the sympathetic nervous system.
  • Expression of 5-LO and FLAP was evident in tumor cells but not in nonmalignant adrenal medulla where neuroblastomas typically arise.
  • [MeSH-minor] 5-Lipoxygenase-Activating Proteins. Apoptosis. Arachidonate 5-Lipoxygenase / biosynthesis. Carrier Proteins / antagonists & inhibitors. Carrier Proteins / biosynthesis. Cell Cycle. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Enzyme Inhibitors / pharmacology. Epoxide Hydrolases / biosynthesis. Glutathione Transferase / biosynthesis. Humans. Leukotriene Antagonists / pharmacology. Lipoxygenase Inhibitors. Membrane Proteins / antagonists & inhibitors. Membrane Proteins / biosynthesis. Receptors, Leukotriene / biosynthesis. Receptors, Leukotriene / drug effects

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591367.001).
  • [ISSN] 1530-6860
  • [Journal-full-title] FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • [ISO-abbreviation] FASEB J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5-Lipoxygenase-Activating Proteins; 0 / ALOX5AP protein, human; 0 / Carrier Proteins; 0 / Enzyme Inhibitors; 0 / Leukotriene Antagonists; 0 / Leukotrienes; 0 / Lipoxygenase Inhibitors; 0 / Membrane Proteins; 0 / Receptors, Leukotriene; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; EC 2.5.1.18 / Glutathione Transferase; EC 3.3.2.- / Epoxide Hydrolases; EC 3.3.2.- / leukotriene A4 hydrolase; EC 4.4.1.20 / leukotriene-C4 synthase
  •  go-up   go-down


53. Kamoun M, Mnif MF, Rekik N, Belguith N, Charfi N, Mnif L, Elleuch M, Mnif F, Kamoun T, Mnif Z, Kamoun H, Sellami-Boudawara T, Hachicha M, Abid M: Ganglioneuroma of adrenal gland in a patient with Turner syndrome. Ann Diagn Pathol; 2010 Apr;14(2):133-6
MedlinePlus Health Information. consumer health - Turner Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ganglioneuroma of adrenal gland in a patient with Turner syndrome.
  • Computed tomography disclosed a well-defined solid lesion in the left adrenal measuring 6.5 x 5 cm with minimal contrast enhancement.
  • Histologic examination revealed an encapsulated mass originated from the left adrenal medulla.
  • Tumor tissue comprised abundant collagen fibers and spindloid cells admixed with mature ganglion cells.
  • The tumor was diagnosed as left adrenal ganglioneuroma.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / pathology. Ganglioneuroma / complications. Ganglioneuroma / pathology. Turner Syndrome / complications

  • Genetic Alliance. consumer health - Turner syndrome.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • (PMID = 20227019.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Kim J, Yamamoto F, Gondo S, Yanase T, Mukai T, Maeda M: 6-Deoxy-6-[131I]iodo-L-ascorbic acid for the in vivo study of ascorbate: autoradiography, biodistribution in normal and hypolipidemic rats, and in tumor-bearing nude mice. Biol Pharm Bull; 2009 Nov;32(11):1906-11
Hazardous Substances Data Bank. L-Ascorbic Acid .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 6-Deoxy-6-[131I]iodo-L-ascorbic acid for the in vivo study of ascorbate: autoradiography, biodistribution in normal and hypolipidemic rats, and in tumor-bearing nude mice.
  • Normal female rat distribution studies showed high and specific uptake of 6-deoxy-6-[(131)I]iodo-L-ascorbic acid (6-(131)IAsA) into the adrenal glands, known to highly express the ascorbate sodium-dependent vitamin C transporter-2 (SVCT-2), and the adrenal gland was clearly visualized by whole-body autoradiography.
  • Preinjection of sulfinpyrazone, a known blocker of ascorbate transport, with 6-(131)IAsA resulted in decreased uptake of radioactivity in rat adrenal glands compared to the control group, seemingly illustrating the participation of the SVCT transporter (probably the SVCT-2 subtype) in the uptake process in vivo.
  • 4-Aminopyrazolo[3,4-d]pyrimidine-induced hypolipidemic rats showed a 1.7-fold increase in adrenal uptake of radioactivity at 30 min postinjection of 6-(131)IAsA, compared to the control, with increased adrenal-to-liver and adrenal-to-kidney ratios.
  • To further characterize 6-(131)IAsA for its tumor uptake properties, biodistribution studies were also performed using male nude mice implanted with either Y-1 adrenocortical tumor cells or adrenal medulla-derived PC12 cells.
  • None of these tumors exhibited relevant uptake of 6-(131)IAsA while normal adrenal glands showed high uptake of radioactivity, suggesting that these tumors in this model have only a poor transport capacity for this agent.
  • The present study demonstrates that the use of radioiodinated 6-IAsA may help to obtain information about functional alterations in diseased adrenal glands, but it does not exhibit desirable properties as a tumor-seeking agent for ascorbic acid bioactivity.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Iodine Radioisotopes / pharmacokinetics. Lipids / blood. Neoplasms, Experimental / metabolism

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19881306.001).
  • [ISSN] 1347-5215
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / 6-deoxy-6-iodoascorbic acid; 0 / Iodine Radioisotopes; 0 / Lipids; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


55. Prontera P, Ferrando B, Giuliani V, Falcinelli F, Mencarelli A, Rogaia D, Pasini B, Donti E: A novel mutation in the SDHD gene responsible for familial paraganglioma. Medical and psychological implications. Genet Couns; 2008;19(4):413-8
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Familial paragangliomas/pheochromocytomas are dominantly inherited disorders characterized by the development of highly vascularized tumors of the head and neck, derived from non-chromaffin cells of the extra-adrenal paraganglia, and tumors with endocrine activity, derived from chromaffin cells, usually located in the adrenal medulla and pre- and para-vertebral thoracoabdominal regions.
  • [MeSH-minor] Carotid Body Tumor / blood supply. Carotid Body Tumor / genetics. Carotid Body Tumor / psychology. Cerebral Angiography. Chromosome Deletion. Chromosomes, Human, Pair 11 / genetics. Codon, Nonsense / genetics. Exons / genetics. Founder Effect. Gene Duplication. Heterozygote Detection. Humans. Male. Middle Aged. Mutation, Missense / genetics. Neoplasms, Multiple Primary / blood supply. Neoplasms, Multiple Primary / genetics. Neoplasms, Multiple Primary / psychology. Paraganglioma, Extra-Adrenal / blood supply. Paraganglioma, Extra-Adrenal / genetics. Paraganglioma, Extra-Adrenal / psychology. Pedigree. Point Mutation / genetics. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Genetic Counseling.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19239085.001).
  • [ISSN] 1015-8146
  • [Journal-full-title] Genetic counseling (Geneva, Switzerland)
  • [ISO-abbreviation] Genet. Couns.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / SDHD protein, human; EC 1.3.99.1 / Succinate Dehydrogenase
  •  go-up   go-down


56. Knape P, Reisch N, Dörr HG, Reincke M, Quinkler M: [Treatment of adult men with congenital adrenal hyperplasia syndrome due to 21-hydroxylase deficiency]. Dtsch Med Wochenschr; 2008 May;133(19):1025-9
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of adult men with congenital adrenal hyperplasia syndrome due to 21-hydroxylase deficiency].
  • Information about the treatment of males with congenital adrenal hyperplasia (CAH) is scarce and there are no therapeutical guidelines.
  • The aim in the treatment of adult male CAH patients is preservation of fertility, prevention of an addisonian crisis, blood pressure management, prevention of testicular adrenal rest tumors (TART), maintaining well-being and good quality of life, satisfactory sexual function and prevention of long-term side effects of gluco- and mineralocorticoid therapy.
  • [MeSH-major] Adrenal Hyperplasia, Congenital / therapy. Adrenogenital Syndrome / therapy. Glucocorticoids / therapeutic use. Mineralocorticoids / therapeutic use. Steroid 21-Hydroxylase / metabolism
  • [MeSH-minor] Addison Disease / etiology. Addison Disease / prevention & control. Adrenal Medulla / physiopathology. Adrenal Rest Tumor / etiology. Adrenal Rest Tumor / prevention & control. Adult. Continuity of Patient Care. Humans. Hypertension / etiology. Hypertension / prevention & control. Infertility, Male / etiology. Infertility, Male / prevention & control. Male. Testicular Neoplasms / etiology. Testicular Neoplasms / prevention & control


57. Zhou M, Shen D, Head JE, Chew EY, Chévez-Barrios P, Green WR, Chan CC: Ocular clusterin expression in von Hippel-Lindau disease. Mol Vis; 2007;13:2129-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its mRNA is ubiquitously expressed, with high levels in von Hippel-Lindau (VHL) target organs such as the brain, liver, kidney, and adrenal medulla.
  • RESULTS: All retinal hemangioblastoma were composed of typical VHL tumor cells admixed with small vascular channels as well as glial cells.
  • CONCLUSIONS: Clusterin shows possible important functions in tumor suppression by the VHL gene product (pVHL) and the potential to be a novel biomarker in retinal hemangioblastoma associated VHL disease.

  • MedlinePlus Health Information. consumer health - Eye Care.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Biochem Sci. 2000 Mar;25(3):95-8 [10694874.001]
  • [Cites] Neoplasma. 2007;54(1):46-50 [17203891.001]
  • [Cites] Nat Med. 2001 Mar;7(3):338-43 [11231633.001]
  • [Cites] Surv Ophthalmol. 2001 Sep-Oct;46(2):117-42 [11578646.001]
  • [Cites] Curr Eye Res. 2001 Sep;23(3):157-65 [11803476.001]
  • [Cites] Oncogene. 2002 Jan 31;21(6):929-36 [11840338.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):237-46 [12086860.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Nov;34(11):1430-48 [12200037.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38214-9 [12882985.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7076-80 [14612498.001]
  • [Cites] World J Gastroenterol. 2004 May 15;10(10):1387-91 [15133840.001]
  • [Cites] Glia. 2004 Jul;47(1):35-45 [15139011.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] Cancer. 1976 Nov;38(5):2042-56 [1033029.001]
  • [Cites] Am J Ophthalmol. 1980 Apr;89(4):540-5 [7369317.001]
  • [Cites] Medicine (Baltimore). 1989 Jan;68(1):1-29 [2642584.001]
  • [Cites] Q J Med. 1990 Nov;77(283):1151-63 [2274658.001]
  • [Cites] Ophthalmology. 1992 Jan;99(1):140-5 [1741127.001]
  • [Cites] J Neurochem. 1993 Oct;61(4):1498-505 [8377000.001]
  • [Cites] Am J Med. 1994 Aug;97(2):158-68 [8059782.001]
  • [Cites] JAMA. 1995 Feb 15;273(7):564-70 [7837390.001]
  • [Cites] Radiology. 1995 Mar;194(3):629-42 [7862955.001]
  • [Cites] Ophthalmic Genet. 1995 Sep;16(3):79-84 [8556282.001]
  • [Cites] J Med Genet. 1996 Feb;33(2):120-7 [8929948.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jan;93(1):74-83 [9062583.001]
  • [Cites] Am J Hum Genet. 1997 Apr;60(4):765-71 [9106522.001]
  • [Cites] Hum Pathol. 1997 May;28(5):540-3 [9158701.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):504-8 [9458097.001]
  • [Cites] J Invest Dermatol. 1999 Mar;112(3):290-6 [10084304.001]
  • [Cites] Arch Ophthalmol. 1999 Mar;117(3):371-8 [10088816.001]
  • [Cites] Arch Ophthalmol. 1999 May;117(5):625-30 [10326959.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1999 Jun;237(6):513-7 [10379614.001]
  • [Cites] Am J Ophthalmol. 1958 Oct;46(4):525-34 [13583072.001]
  • [Cites] Trans Am Ophthalmol Soc. 2004;102:75-9; discussion 79-81 [15747747.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(13):5675-86 [15964822.001]
  • [Cites] Mol Vis. 2005;11:697-704 [16163267.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 9;338(1):627-38 [16153592.001]
  • [Cites] Cell Death Differ. 2006 Jan;13(1):12-9 [16179938.001]
  • [Cites] Am J Pathol. 2006 Feb;168(2):574-84 [16436671.001]
  • [Cites] Postepy Hig Med Dosw (Online). 2006;60:45-51 [16474275.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 May;47(5):1982-90 [16639006.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9256-61 [16754848.001]
  • [Cites] Ophthalmology. 2007 Jan;114(1):147-56 [17070589.001]
  • [Cites] Mol Vis. 2000 Oct 27;6:184-91 [11054462.001]
  • (PMID = 18079682.001).
  • [ISSN] 1090-0535
  • [Journal-full-title] Molecular vision
  • [ISO-abbreviation] Mol. Vis.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 EY000222-22; United States / Intramural NIH HHS / / Z99 EY999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Clusterin; 0 / RNA, Messenger
  • [Other-IDs] NLM/ NIHMS36212; NLM/ PMC2173882
  •  go-up   go-down


58. Nofech-Mozes S, Mackenzie R, Kahn HJ, Ehrlich L, Raphael SJ: Breast metastasis by medullary thyroid carcinoma detected by FDG positron emission tomography. Ann Diagn Pathol; 2008 Feb;12(1):67-71
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medullary thyroid carcinoma (MTC) is an uncommon thyroid cancer comprising 5% to 8% of thyroid neoplasms.
  • In contrast to common thyroid tumors, this tumor originates from the calcitonin-producing C cells.
  • Common metastatic sites include the liver, bone, brain, and adrenal medulla.
  • (1) metastasis to the breast is an extremely rare occurrence and could be easily confused clinically and pathologically with a primary breast neoplasm and (2) this is the first reported case of detection of breast metastasis by an MTC using FDG ((18)F-fluoro-2-deoxy-D-glucose) positron emission tomography with an accompanying histologic description.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cisplatin / therapeutic use. Combined Modality Therapy. Doxorubicin / therapeutic use. Female. Humans. Immunohistochemistry. Middle Aged. Palliative Care

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164420.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


59. Plouin PF, Gimenez-Roqueplo AP: Pheochromocytomas and secreting paragangliomas. Orphanet J Rare Dis; 2006;1:49
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Catecholamine-producing tumors may arise in the adrenal medulla (pheochromocytomas) or in extraadrenal chromaffin cells (secreting paragangliomas).
  • Their prevalence is about 0.1% in patients with hypertension and 4% in patients with a fortuitously discovered adrenal mass.
  • These tumors may be sporadic or part of any of several genetic diseases: familial pheochromocytoma-paraganglioma syndromes, multiple endocrine neoplasia type 2, neurofibromatosis 1 and von Hippel-Lindau disease.
  • The most specific and sensitive diagnostic test for the tumor is the determination of plasma or urinary metanephrines.
  • The tumor can be located by computed tomography, magnetic resonance imaging and metaiodobenzylguanidine scintigraphy.
  • Treatment requires resection of the tumor, generally by laparoscopic surgery.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / therapy. Paraganglioma, Extra-Adrenal / diagnosis. Paraganglioma, Extra-Adrenal / secretion. Pheochromocytoma / diagnosis. Pheochromocytoma / therapy
  • [MeSH-minor] Adrenal Gland Diseases / diagnosis. Catecholamines / biosynthesis. Catecholamines / secretion. Diagnosis, Differential. Genetic Testing / methods. Humans. Hypertension / etiology. Prognosis. Proto-Oncogene Proteins c-ret / genetics

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 2003 Aug;24(4):539-53 [12920154.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5615-21 [14500403.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4533-9 [14557417.001]
  • [Cites] Trends Endocrinol Metab. 2003 Dec;14(10):453-9 [14643060.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):479-91 [14764749.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):197-211 [15013219.001]
  • [Cites] JAMA. 2004 Aug 25;292(8):943-51 [15328326.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):423-36 [15369446.001]
  • [Cites] Medicine (Baltimore). 1991 Jan;70(1):33-45 [1988765.001]
  • [Cites] J Clin Invest. 1995 Nov;96(5):2503-9 [7593641.001]
  • [Cites] Ann Intern Med. 1996 Aug 15;125(4):300-3 [8678394.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4771-4 [12364472.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4991-5004 [15611513.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):77-85 [15652751.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2110-6 [15644401.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8812-8 [16314641.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):827-36 [16317055.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Feb;2(2):60-1 [16932255.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1235-46 [12368197.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 [10690869.001]
  • [Cites] Ann Intern Med. 2001 Feb 20;134(4):315-29 [11182843.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1480-6 [11297571.001]
  • [Cites] Am J Hum Genet. 2001 Dec;69(6):1186-97 [11605159.001]
  • [Cites] JAMA. 2002 Mar 20;287(11):1427-34 [11903030.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Eur J Endocrinol. 2002 Jul;147(1):85-94 [12088924.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2656-66 [12788870.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:41-53 [12381540.001]
  • [Cites] Hypertension. 1997 May;29(5):1133-9 [9149678.001]
  • (PMID = 17156452.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Catecholamines; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human
  • [Number-of-references] 29
  • [Other-IDs] NLM/ PMC1702343
  • [General-notes] NLM/ Original DateCompleted: 20070718
  •  go-up   go-down


60. Kupka S, Haack B, Zdichavsky M, Mlinar T, Kienzle C, Bock T, Kandolf R, Kroeber SM, Königsrainer A: Large proportion of low frequency microsatellite-instability and loss of heterozygosity in pheochromocytoma and endocrine tumors detected with an extended marker panel. J Cancer Res Clin Oncol; 2008 Apr;134(4):463-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Pheochromocytoma (PCC) is a usually benign tumor originated in the majority of patients from the adrenal medulla.
  • Among the 23 patients with endocrine tumors, only three (one pancreatic endocrine tumor, one duodenal neuro-endocrine tumor, one hepatic metastasis of a primary tumor with unknown origin) demonstrated MSI.

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Teratog Carcinog Mutagen. 2003;Suppl 1:255-65 [12616616.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):241-9 [15944796.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):353-60 [11433399.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3444-9 [11705861.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):229-36 [15599934.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1564-7 [15619218.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):38-44 [8536886.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):285-92 [11196176.001]
  • [Cites] Hum Mol Genet. 2002 Oct 1;11(20):2347-54 [12351569.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):93-8 [17143284.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1114-5 [17021141.001]
  • [Cites] Hum Mol Genet. 1998 May;7(5):895-903 [9536095.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] In Vivo. 2005 Mar-Apr;19(2):359-65 [15796198.001]
  • [Cites] Hum Pathol. 2002 Mar;33(3):322-9 [11979373.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2536-40 [12171881.001]
  • [Cites] Int J Colorectal Dis. 2006 Oct;21(7):625-31 [16557375.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):10-1 [17192781.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):300-3 [9521327.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Apr 15;150(2):128-35 [15066320.001]
  • [Cites] World J Surg. 2006 Jul;30(7):1240-6 [16715450.001]
  • [Cites] Exp Mol Med. 2004 Apr 30;36(2):122-9 [15150440.001]
  • [Cites] Breast Cancer Res Treat. 2000 Mar;60(2):135-42 [10845276.001]
  • [Cites] Surgery. 2003 Dec;134(6):902-8; discussion 909 [14668721.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Cancer Treat Rev. 2006 Dec;32(8):607-18 [17055172.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):145-52 [16724208.001]
  • (PMID = 17828419.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang WC, Ostberg JR, Jensen MC: Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther; 2007 Apr;15(4):825-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously described a tumor L1-cell adhesion molecule-specific, single chain antibody-derived, chimeric antigen receptor designated CE7R for re-directing the antigen-specific effector functioning of cytolytic T lymphocytes.
  • No overt toxicities to tissues known to express L1-cell adhesion molecule (e.g., central nervous system, adrenal medulla, and sympathetic ganglia) were observed.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17299405.001).
  • [ISSN] 1525-0016
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000043; United States / NCI NIH HHS / CA / P30 CA35572-21; United States / NCI NIH HHS / CA / R21 CA105824
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Neural Cell Adhesion Molecule L1; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


62. Björklund P, Cupisti K, Fryknäs M, Isaksson A, Willenberg HS, Akerström G, Hellman P, Westin G: Stathmin as a marker for malignancy in pheochromocytomas. Exp Clin Endocrinol Diabetes; 2010 Jan;118(1):27-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pheochromocytomas of the adrenal medulla may be life-threatening catecholamine-producing tumors which are malignant in about 10% of cases.
  • Differential diagnosis between malignant and benign tumors is dependent on the development of metastasis or extensive local invasion.
  • We applied an expression microarray containing 7770 cDNA clones and analysed the expression profiles in eleven tumors compared to normal adrenal medulla.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Biomarkers, Tumor / metabolism. Pheochromocytoma / diagnosis. Stathmin / metabolism
  • [MeSH-minor] Adrenal Medulla / metabolism. Adrenal Medulla / pathology. Adult. Aged. Blotting, Western. Diagnosis, Differential. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart, New York.
  • (PMID = 19449284.001).
  • [ISSN] 1439-3646
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / STMN1 protein, human; 0 / Stathmin
  •  go-up   go-down


63. Gorsane I, Zouaghi K, Goucha R, Bacha MM, Hedri H, Khiari K, Abderrahim E, Abdallah TB, Abdallah NB, Moussa FB, Maiz HB, Kheder A: [Pheochromocytoma in end-stage renal disease patient treated by peritoneal dialysis]. Nephrol Ther; 2008 Dec;4(7):597-601
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pheochromocytoma is a rare tumor responsible for paroxysmal hypertension which is difficult to control.
  • Diagnosis is important because it represents a curable form of hypertension.
  • These cases are specially responsible for diagnosis and therapeutic problems.
  • Radiographic diagnosis tests were negative but MIBG scintigraphy was able to localise the tumor in the left suprarenal gland.
  • He had coelioscopic left adrenalectomy without complications, microscopic studies showed an hyperplasia of the adrenal medulla.
  • We conclude that refractory hypertension, as a possible diagnosis, is uncommon in peritoneal dialysis patients.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Kidney Failure, Chronic / complications. Kidney Failure, Chronic / therapy. Nephritis / complications. Pheochromocytoma / diagnosis


64. Puc J, Placha G, Wocial B, Podsypanina K, Parsons R, Gaciong Z: Analysis of PTEN mutation in non-familial pheochromocytoma. Ann N Y Acad Sci; 2006 Aug;1073:317-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PTEN, a tumor suppressor gene, is frequently mutated in a variety of human tumors.
  • In mice, monoallelic inactivation of this gene predisposes animals to neoplasia of multiple organs.
  • Interestingly, Pten heterozygous mice develop bilateral hyperplasia of the adrenal medulla.
  • Examination of protein expression by immunohistochemistry using 8 normal adrenals and 11 sporadic pheochromocytomas showed no decrease in the PTEN protein expression in the tumor tissue, but upregulation of insulin-like growth factor II, a peptide implicated in growth of adrenal tissue, was observed in four cases (36%).
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Mutation. PTEN Phosphohydrolase / genetics. Pheochromocytoma / genetics

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17102102.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 3.1.3.48 / Pten protein, mouse; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


65. Reisch N, Walz MK, Erlic Z, Neumann HP: [Pheochromocytoma - still a challenge]. Internist (Berl); 2009 Jan;50(1):27-35
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pheochromocytomas are rare, mostly benign catecholamine-producing tumors arising from the chromaffin cells of the adrenal medulla or in the paraganglia.
  • Computed tomography scan and magnetic resonance imaging of the adrenal glands and abdomen as well as functional imaging with (123)Iod-MIBG scintigraphy and (18)F-dopa positron emission tomography are used for tumor localization.
  • The therapy of choice is the endoscopic adrenal sparing surgery following preoperative alpha-blockade.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / therapy. Hypertension / diagnosis. Hypertension / prevention & control. Pheochromocytoma / diagnosis. Pheochromocytoma / therapy

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2006;36(11):961-5 [17072715.001]
  • [Cites] Eur J Endocrinol. 1999 Dec;141(6):619-24 [10601965.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):685-93 [11158032.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2729-31 [16790714.001]
  • [Cites] J Endocrinol Invest. 2007 Sep;30(8):647-52 [17923795.001]
  • [Cites] Am J Hum Genet. 2004 Jan;74(1):153-9 [14685938.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1323-9 [15517476.001]
  • [Cites] Nouv Presse Med. 1981 Mar 7;10(11):869-72 [7208288.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Aug;91(8):2851-8 [16735498.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1531-8 [8105382.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1005-12 [12045858.001]
  • [Cites] J Hypertens. 2006 Dec;24(12):2331-9 [17082709.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23 (34):8812-8 [16314641.001]
  • [Cites] World J Surg. 2001 Jun;25(6):728-34 [11376407.001]
  • [Cites] JAMA. 2002 Mar 20;287(11):1427-34 [11903030.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):897-911 [15613462.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):827-36 [16317055.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):423-36 [15369446.001]
  • [Cites] APMIS. 2004 Sep;112(9):551-9 [15601303.001]
  • [Cites] JAMA. 2004 Aug 25;292(8):943-51 [15328326.001]
  • [Cites] Curr Opin Oncol. 2005 Jan;17(1):13-8 [15608506.001]
  • [Cites] J Nucl Med. 2007 Oct;48(10 ):1599-606 [17873132.001]
  • [Cites] J Am Coll Surg. 2004 Apr;198(4):525-34; discussion 534-5 [15051000.001]
  • [Cites] J Intern Med. 2005 Jan;257(1):60-8 [15606377.001]
  • [Cites] Endocr Pathol. 2006 Winter;17(4):329-36 [17525481.001]
  • [Cites] N Engl J Med. 2007 Sep 6;357(10):1054-6 [17804857.001]
  • [Cites] Eur J Endocrinol. 2004 May;150(5):681-6 [15132724.001]
  • [Cites] Eur J Surg Oncol. 2004 Jun;30(5):556-9 [15135486.001]
  • [Cites] Fam Cancer. 2005;4(1):49-54 [15883710.001]
  • [Cites] Surgery. 2003 Dec;134(6):956-62; discussion 962-3 [14668728.001]
  • [Cites] J Clin Hypertens (Greenwich). 2002 Jan-Feb;4(1):62-72 [11821644.001]
  • [Cites] Curr Hypertens Rep. 2004 Dec;6(6):477-84 [15527694.001]
  • [Cites] Fam Cancer. 2005;4(1):13-6 [15883705.001]
  • [Cites] Horm Res. 1998;49(6):295-7 [9623522.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jun;83(6):2175-85 [9626157.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 May;30(5):689-94 [12618904.001]
  • [Cites] Clin Chem. 2005 Apr;51(4):735-44 [15718487.001]
  • [Cites] Ann Endocrinol (Paris). 2005 Jun;66(3):178-85 [15988378.001]
  • [Cites] Br J Anaesth. 2004 Apr;92(4):512-7 [14766711.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):479-91 [14764749.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):239-48 [12872341.001]
  • [Cites] Int J Urol. 1999 Mar;6(3):119-24 [10226821.001]
  • [Cites] Radiology. 2002 Feb;222(2):507-12 [11818620.001]
  • [Cites] N Engl J Med. 2007 Sep 27;357(13):1311-5 [17898100.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Ann Intern Med. 1988 Aug 15;109(4):267-73 [3395037.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Apr;92(4):1217-25 [17284633.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:465-90 [17102115.001]
  • (PMID = 19099277.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 49
  •  go-up   go-down


66. Yamaguchi K, Hara I, Takeda M, Tanaka K, Yamada Y, Fujisawa M, Kawabata G: Two cases of ganglioneuroma. Urology; 2006 Mar;67(3):622.e1-4
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although ganglioneuroma is a relatively rare tumor of the sympathetic nervous system, detection of this tumor has increased as imaging techniques such as computed tomography and ultrasonography have become prevalent.
  • Magnetic resonance imaging in 1 patient showed a homogeneous mass with a low signal intensity on T1-weighted imaging and a heterogeneous mass with a high signal intensity on T2-weighted imaging, both characteristic of neurogenic tumor.
  • Histopathologic examination demonstrated that one tumor was located on the adrenal medulla, with the other in the extra-adrenal retroperitoneal space.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Ganglioneuroma / diagnosis. Retroperitoneal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16504264.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Sandgren J, Andersson R, Rada-Iglesias A, Enroth S, Akerstrom G, Dumanski JP, Komorowski J, Westin G, Wadelius C: Integrative epigenomic and genomic analysis of malignant pheochromocytoma. Exp Mol Med; 2010 Jul 31;42(7):484-502
Hazardous Substances Data Bank. L-Lysine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epigenomic and genomic changes affect gene expression and contribute to tumor development.
  • The histone modifications trimethylated histone H3 lysine 4 (H3K4me3) and lysine 27 (H3K27me3) are epigenetic regulators associated to active and silenced genes, respectively and alterations of these modifications have been observed in cancer.
  • Pheochromocytoma is a rare endocrine tumor of the adrenal gland that mostly occurs sporadic with unknown epigenetic/genetic cause.
  • The integrated analysis of the tumor expression levels, in relation to normal adrenal medulla, indicated that either histone modifications or chromosomal alterations, or both, have great impact on the expression of a substantial fraction of the genes in the investigated sample.
  • Candidate tumor suppressor genes identified with decreased expression, a H3K27me3 mark and/or in regions of deletion were for instance TGIF1, DSC3, TNFRSF10B, RASSF2, HOXA9, PTPRE and CDH11.
  • Our approach to associate histone methylations and DNA copy number changes to gene expression revealed apparent impact on global gene transcription, and enabled the identification of candidate tumor genes for further exploration.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Adrenal Gland Neoplasms / pathology. Epigenesis, Genetic. Genome, Human / genetics. Genomics. Pheochromocytoma / genetics. Pheochromocytoma / pathology
  • [MeSH-minor] Female. Gene Dosage / genetics. Gene Expression Regulation, Neoplastic. Gene Regulatory Networks / genetics. Histones / metabolism. Humans. Lysine / metabolism. Methylation. Protein Processing, Post-Translational. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytokine Growth Factor Rev. 2008 Apr;19(2):111-20 [18308616.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):286-98 [18371363.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):299-312 [18371364.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2641-51 [18413731.001]
  • [Cites] BMB Rep. 2008 Apr 30;41(4):294-9 [18452649.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2551-9 [18451216.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):741-50 [18488029.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):897-903 [18552846.001]
  • [Cites] Nature. 2008 Aug 7;454(7205):766-70 [18600261.001]
  • [Cites] Carcinogenesis. 2008 Jul;29(7):1312-8 [18310659.001]
  • [Cites] Endocr Relat Cancer. 2008 Sep;15(3):777-86 [18499731.001]
  • [Cites] Mutat Res. 2008 Dec 1;647(1-2):21-9 [18723033.001]
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):333-7 [10888885.001]
  • [Cites] Mamm Genome. 2000 Sep;11(9):767-73 [10967136.001]
  • [Cites] Nature. 1993 Jun 3;363(6428):458-60 [8099202.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4169-71 [8364910.001]
  • [Cites] EMBO J. 1998 Jan 2;17(1):215-22 [9427755.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):897-911 [15613462.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Mar;42(3):260-8 [15609347.001]
  • [Cites] Cell. 2005 Jan 28;120(2):169-81 [15680324.001]
  • [Cites] J Surg Oncol. 2005 Mar 1;89(3):193-201 [15719371.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):161-72 [15788647.001]
  • [Cites] Oncogene. 2005 Jun 2;24(24):3987-94 [15806169.001]
  • [Cites] Sci Signal. 2008;1(46):pe49 [19018012.001]
  • [Cites] Science. 1993 May 28;260(5112):1317-20 [8493574.001]
  • [Cites] Immunity. 2009 Jan 16;30(1):155-67 [19144320.001]
  • [Cites] Oncogene. 2009 Feb 19;28(7):994-1004 [19079341.001]
  • [Cites] PLoS One. 2009;4(3):e4687 [19262738.001]
  • [Cites] Cancer Cell. 2009 Apr 7;15(4):328-40 [19345331.001]
  • [Cites] J Gastroenterol. 2009;44(4):305-12 [19267258.001]
  • [Cites] Epigenetics. 2009 Feb 16;4(2):107-13 [19276669.001]
  • [Cites] Endocr Relat Cancer. 2009 Jun;16(2):505-13 [19153209.001]
  • [Cites] Immunity. 2009 Jun 19;30(6):912-25 [19523850.001]
  • [Cites] Endocr Relat Cancer. 2010 Sep;17(3):561-79 [20410162.001]
  • [Cites] Nat Protoc. 2009;4(1):44-57 [19131956.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R669-80 [16168112.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3214-22 [16051735.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):83-93 [16215979.001]
  • [Cites] Hum Mol Genet. 2005 Nov 15;14(22):3435-47 [16221759.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1159-64 [16161042.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D632-6 [16381948.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1733-42 [16278676.001]
  • [Cites] Bioinformatics. 2006 Apr 15;22(8):1024-6 [16455749.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):656-67 [16575877.001]
  • [Cites] Genome Res. 2006 Jul;16(7):890-900 [16751344.001]
  • [Cites] J Urol. 2006 Sep;176(3):891-5 [16890646.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:541-56 [17102123.001]
  • [Cites] Nat Genet. 2006 Dec;38(12):1386-96 [17099711.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5527-32 [17369352.001]
  • [Cites] Endocr Relat Cancer. 2007 Mar;14(1):125-34 [17395981.001]
  • [Cites] Cell. 2007 May 18;129(4):823-37 [17512414.001]
  • [Cites] Br J Cancer. 2007 Jun 18;96(12):1783-7 [17519903.001]
  • [Cites] Cell. 2007 Jul 13;130(1):77-88 [17632057.001]
  • [Cites] Mol Endocrinol. 2007 Aug;21(8):1835-46 [17505060.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):553-60 [17603471.001]
  • [Cites] Oncol Rep. 2007 Sep;18(3):673-7 [17671718.001]
  • [Cites] Virchows Arch. 2007 Nov;451(5):959-66 [17846785.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10657-63 [18006806.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Dec;92(12):4865-72 [17878247.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D773-9 [18086701.001]
  • [Cites] Nat Genet. 2000 Nov;26(3):268-70 [11062460.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4568-74 [11134110.001]
  • [Cites] Lancet. 2001 Apr 14;357(9263):1181-2 [11323050.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):49-54 [11404820.001]
  • [Cites] J Cell Biol. 2001 Jul 23;154(2):345-54 [11470823.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):777-85 [12360280.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12963-8 [12297621.001]
  • [Cites] Hum Mol Genet. 2002 Dec 1;11(25):3221-9 [12444106.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):539-53 [12920154.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 20;95(16):1196-204 [12928344.001]
  • [Cites] Endocr Pathol. 2003 Winter;14(4):329-50 [14739490.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3487-94 [15007382.001]
  • [Cites] Genes Dev. 2004 Jul 1;18(13):1592-605 [15231737.001]
  • [Cites] Nat Cell Biol. 2004 Aug;6(8):731-40 [15235609.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1119-28 [15167935.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Mol Cancer Res. 2004 Sep;2(9):495-503 [15383628.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Cancer Res. 1992 Mar 1;52(5):1364-8 [1737399.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Jun;4(4):337-42 [1377942.001]
  • [Cites] J Biol Chem. 1992 Jul 25;267(21):15252-7 [1634555.001]
  • [Cites] Hum Mutat. 2008 Mar;29(3):398-408 [18058796.001]
  • [Cites] Bioinformatics. 2008 Mar 15;24(6):751-8 [18204059.001]
  • [Cites] Cancer Genomics Proteomics. 2008 Jan-Feb;5(1):37-42 [18359978.001]
  • (PMID = 20534969.001).
  • [ISSN] 2092-6413
  • [Journal-full-title] Experimental & molecular medicine
  • [ISO-abbreviation] Exp. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Histones; 0 / Tumor Suppressor Proteins; K3Z4F929H6 / Lysine
  • [Other-IDs] NLM/ PMC2912476
  •  go-up   go-down


68. Cole G, Suedmeyer WK, Johnson G: Pheochromocytoma in an African warthog (Phacochoerus aethiopicus). J Zoo Wildl Med; 2008 Dec;39(4):663-6
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A tumor of the right adrenal gland involving the medulla was found at gross necropsy.
  • Immunohistochemical staining of the tumor was positive for chromogranin and negative for neurofilament protein, which was diagnostic for pheochromocytoma.
  • [MeSH-major] Adrenal Gland Neoplasms / veterinary. Pheochromocytoma / veterinary. Swine Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110715.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Cadden IS, Atkinson AB, Johnston BT, Pogue K, Connolly R, McCance D, Ardill JE, Russell CF, McGinty A: Cyclooxygenase-2 expression correlates with phaeochromocytoma malignancy: evidence for a Bcl-2-dependent mechanism. Histopathology; 2007 Dec;51(6):743-51
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Phaeochromocytomas are rare but potentially life-threatening neuroendocrine tumours of the adrenal medulla or sympathetic nervous system ganglia.
  • METHODS AND RESULTS: COX-2 and Bcl-2 expression were examined immunohistochemically in tissue from 41 sporadic phaeochromocytoma patients followed up for a minimum of 5 years after diagnosis.
  • There was a statistically significant association between COX-2 histoscore (intensity x proportion) and the development of tumour recurrence or metastases (P = 0.006).
  • A significant relationship was observed between coexpression of COX-2 and Bcl-2 in the primary tumour and the presence of recurrent disease (P = 0.034).
  • A highly significant association was observed between (i) tumour-associated expression of these two oncoproteins (P = 0.001) and (ii) COX-2 histoscore and the presence of Bcl-2 expression (P = 0.002).
  • CONCLUSIONS: COX-2 and Bcl-2 may promote phaeochromocytoma malignancy, and these oncoproteins may be valuable surrogate markers of an aggressive tumour phenotype.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Biomarkers, Tumor / analysis. Cyclooxygenase 2 / biosynthesis. Pheochromocytoma / metabolism. Proto-Oncogene Proteins c-bcl-2 / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17916073.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


70. Powers JF, Evinger MJ, Zhi J, Picard KL, Tischler AS: Pheochromocytomas in Nf1 knockout mice express a neural progenitor gene expression profile. Neuroscience; 2007 Jul 29;147(4):928-37
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pheochromocytomas are adrenal medullary tumors that typically occur in adult patients, with increased frequency in multiple endocrine neoplasia type 2, von Hippel-Lindau disease, familial paraganglioma syndromes and neurofibromatosis type 1 (NF1).
  • We performed a microarray-based gene expression profiling study comparing mouse pheochromocytoma tissue to normal adult mouse adrenal medulla to develop a basis for studying the pathobiology of these tumors.
  • One of the most highly overexpressed genes is receptor tyrosine kinase Ret, which is known to be transiently expressed in the developing adrenal gland, down-regulated in adult adrenals and often overexpressed in human pheochromocytomas.
  • The findings are consistent with the recently proposed concept that persistent neural progenitors might give rise to pheochromocytomas in adult mouse adrenals and suggest that events predisposing to tumor development might occur before formation of the adrenal medulla or migration of cells from the neural crest.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Neurofibromin 1 / deficiency. Pheochromocytoma / genetics. Proto-Oncogene Proteins c-ret / metabolism

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582688.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM 46588; United States / NINDS NIH HHS / NS / NS 36785
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 1; 0 / RNA, Messenger; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / Ret protein, mouse
  •  go-up   go-down


71. Guillemot J, Compagnon P, Cartier D, Thouennon E, Bastard C, Lihrmann I, Pichon P, Thuillez C, Plouin PF, Bertherat J, Anouar Y, Kuhn JM, Yon L, Lefebvre H: Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptors. Endocr Relat Cancer; 2009 Mar;16(1):281-90
Hazardous Substances Data Bank. CISAPRIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tissue explants, obtained from 18 pheochromocytomas including the tumor removed from a 46-year-old female patient who experienced life-threatening hypertension crisis after metoclopramide administration and 17 additional pheochromocytomas (9 benign and 8 malignant) were studied.
  • RESULTS: Metoclopramide and the 5-HT(4) receptor agonist cisapride were found to activate catecholamine- and granin-derived peptide secretions by cultured tumor cells.
  • 5-HT(4) receptor mRNAs were detected in the patient's tumor and the series of 17 additional pheochromocytomas.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Dopamine Antagonists / pharmacology. Metoclopramide / pharmacology. Pheochromocytoma / drug therapy. Receptors, Serotonin, 5-HT4 / genetics
  • [MeSH-minor] Adrenal Medulla / cytology. Adrenal Medulla / drug effects. Catecholamines / secretion. Chromogranins / secretion. Cisapride / pharmacology. Domperidone / pharmacology. Female. Humans. Middle Aged. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Serotonin Receptor Agonists / pharmacology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • Hazardous Substances Data Bank. Metoclopramide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948374.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Catecholamines; 0 / Chromogranins; 0 / Dopamine Antagonists; 0 / RNA, Messenger; 0 / Serotonin Receptor Agonists; 158165-40-3 / Receptors, Serotonin, 5-HT4; 5587267Z69 / Domperidone; L4YEB44I46 / Metoclopramide; UVL329170W / Cisapride
  •  go-up   go-down


72. Cayo MA, Cayo AK, Jarjour SM, Chen H: Sodium butyrate activates Notch1 signaling, reduces tumor markers, and induces cell cycle arrest and apoptosis in pheochromocytoma. Am J Transl Res; 2009 Jan 31;1(2):178-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sodium butyrate activates Notch1 signaling, reduces tumor markers, and induces cell cycle arrest and apoptosis in pheochromocytoma.
  • BACKGROUND: Pheochromocytoma is a neuroendocrine (NE) tumor of the adrenal medulla for which surgical resection is the only therapy.
  • Our lab has demonstrated the importance of the Notch1 signaling pathway in NE neoplasia, indicating that this pathway could be a target for emergent treatments in pheochromocytoma.
  • We hypothesized that the HDAC inhibitor Sodium Butyrate (NaB) might activate Notch1 in pheochromocytoma resulting in altered tumor cell proliferation.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 Jun;229(6):755-64; discussion 764-6 [10363888.001]
  • [Cites] World J Urol. 1999 Feb;17(1):35-9 [10096149.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):5355-60 [9144241.001]
  • [Cites] Cell. 1996 Jul 12;86(1):147-57 [8689682.001]
  • [Cites] Surgery. 1995 Dec;118(6):988-94; discussion 994-5 [7491544.001]
  • [Cites] Cell. 1993 Nov 19;75(4):653-60 [8242741.001]
  • [Cites] Brain Res. 1987 Jan;428(1):151-5 [3815113.001]
  • [Cites] Endocrinol Metab Clin North Am. 1988 Jun;17(2):397-414 [3042392.001]
  • [Cites] Cell. 1978 May;14(1):115-21 [667928.001]
  • [Cites] Cardiol Rev. 2002 Jan-Feb;10(1):44-50 [11790269.001]
  • [Cites] Mol Cell Biol. 2002 May;22(9):3129-39 [11940670.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):423-36 [15369446.001]
  • [Cites] Ann Surg. 2008 Jun;247(6):1036-40 [18520232.001]
  • [Cites] Oncologist. 2008 Feb;13(2):98-104 [18305053.001]
  • [Cites] Curr Opin Oncol. 2008 Jan;20(1):34-46 [18043254.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1515-20; discussion 1520 [17874277.001]
  • [Cites] Oncologist. 2007 Aug;12(8):942-51 [17766653.001]
  • [Cites] Oncologist. 2007 May;12(5):535-42 [17522241.001]
  • [Cites] J Biol Chem. 2006 Dec 29;281(52):39819-30 [17090547.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Oct;289(4):G636-42 [16160079.001]
  • [Cites] Mol Cancer Ther. 2005 Jun;4(6):910-7 [15956248.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18030-5 [15596714.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • (PMID = 19956429.001).
  • [ISSN] 1943-8141
  • [Journal-full-title] American journal of translational research
  • [ISO-abbreviation] Am J Transl Res
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109053; United States / NCI NIH HHS / CA / R21 CA117117; United States / NIDDK NIH HHS / DK / T35 DK062709
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2776315
  • [Keywords] NOTNLM ; Butyrate / HDAC inhibitor / Notch1 / PC-12 / neuroendocrine / pheochromocytoma
  •  go-up   go-down


73. Handa U, Khullar U, Mohan H: Pigmented pheochromocytoma: report of a case with diagnosis by fine needle aspiration. Acta Cytol; 2005 Jul-Aug;49(4):421-3
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented pheochromocytoma: report of a case with diagnosis by fine needle aspiration.
  • BACKGROUND: Pheochromocytoma is a common tumor of the adrenal medulla, but its pigmented variant is rare.
  • Histopathologic findings and immunohistochemical stains confirmed the diagnosis.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Pheochromocytoma / diagnosis

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16124172.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipofuscin; 0 / Melanins; 9011-92-1 / Hemosiderin
  •  go-up   go-down


74. Elkahloun AG, Powers JF, Nyska A, Eisenhofer G, Tischler AS: Gene expression profiling of rat pheochromocytoma. Ann N Y Acad Sci; 2006 Aug;1073:290-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To compare the molecular profiles of rat and human pheochromocytomas and to identify pathways potentially involved in pathogenesis of rat pheochromocytomas, we conducted a gene expression profiling study comparing 31 pheochromocytomas obtained from the National Toxicology Program to normal adult rat adrenal medulla.
  • Downregulated genes included receptors and tumor-suppressor genes, including NF2 and Dmbt1.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Gene Expression Profiling. Pheochromocytoma / genetics

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17102098.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA48017; United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


75. Cascón A, Montero-Conde C, Ruiz-Llorente S, Mercadillo F, Letón R, Rodríguez-Antona C, Martínez-Delgado B, Delgado M, Díez A, Rovira A, Díaz JA, Robledo M: Gross SDHB deletions in patients with paraganglioma detected by multiplex PCR: a possible hot spot? Genes Chromosomes Cancer; 2006 Mar;45(3):213-9
SciCrunch. OMIM: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pheochromocytoma and paraganglioma are rare neuroendocrine tumors that arise in the adrenal medulla and the extra-adrenal paraganglia, respectively.
  • Although this is the first report describing the presence of gross deletions in patients with apparently sporadic paragangliomas, the extra-adrenal location of the tumor seems to constitute a determining factor for whether to include these patients in genetic testing for gross deletions in the SDHB gene.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Gene Deletion. Iron-Sulfur Proteins / genetics. Paraganglioma / genetics. Pheochromocytoma / genetics. Protein Subunits / genetics. Succinate Dehydrogenase / genetics


76. Daub KF: Pheochromocytoma: challenges in diagnosis and nursing care. Nurs Clin North Am; 2007 Mar;42(1):101-11, viii
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pheochromocytoma: challenges in diagnosis and nursing care.
  • Pheochromocytomas are catecholamine-secreting tumors arising from chromaffin cells of the sympathoadrenal system, which includes the adrenal medulla and sympathetic ganglionic tissue.
  • Challenges in diagnosis, tumor location, and treatment are considerable.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / nursing. Pheochromocytoma / diagnosis. Pheochromocytoma / nursing

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270594.001).
  • [ISSN] 0029-6465
  • [Journal-full-title] The Nursing clinics of North America
  • [ISO-abbreviation] Nurs. Clin. North Am.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


77. Shyla A, Hölzlwimmer G, Calzada-Wack J, Bink K, Tischenko O, Guilly MN, Chevillard S, Samson E, Graw J, Atkinson MJ, Pellegata NS: Allelic loss of chromosomes 8 and 19 in MENX-associated rat pheochromocytoma. Int J Cancer; 2010 May 15;126(10):2362-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pheochromocytomas are neoplasias of neural crest origin that arise from the chromaffin cells of the adrenal medulla.
  • We also analyzed additional candidate genes, that is, rat homologues of genes predisposing to human pheochromocytoma and known tumor-suppressor genes, but we found no AI.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Chromosomes, Human, Pair 19. Chromosomes, Human, Pair 8. Cyclin-Dependent Kinase Inhibitor p27 / genetics. Frameshift Mutation. Loss of Heterozygosity. Pheochromocytoma / genetics

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19876893.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn1b protein, rat; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


78. Lai EW, Joshi BH, Martiniova L, Dogra R, Fujisawa T, Leland P, de Krijger RR, Lubensky IA, Elkahloun AG, Morris JC, Puri RK, Pacak K: Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy. J Clin Endocrinol Metab; 2009 Aug;94(8):2952-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy.
  • CONTEXT: Pheochromocytomas and paragangliomas are rare catecholamine-secreting neuroendocrine tumors arising from the adrenal medulla and sympathetic tissues.
  • OBJECTIVE: The objective of the study was to identify and characterize overexpression of IL-13 receptor-alpha2 (IL-13Ralpha2) gene expression in human and murine tumors and verify xenograft mouse pheochromocytoma cell (MPC)-derived tumor's response to a selective cytotoxin.
  • INTERVENTION: The function of IL-13Ralpha2 in these tumor cells was examined by evaluating tumor sensitivity to a recombinant IL-13-Pseudomonas exotoxin (IL-13PE).
  • MAIN OUTCOME MEASURES: IC(50) and tumor size were measured.
  • Our results showed a statistically significant decrease in tumor size as early as 3 d after initial treatment and further suppressed growth of MPC tumors.

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Med. 2002 Aug;8(8):487-94 [12435859.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1948-56 [12060640.001]
  • [Cites] J Neurooncol. 2003 Oct;65(1):37-48 [14649884.001]
  • [Cites] Mol Cancer Ther. 2004 Feb;3(2):137-47 [14985454.001]
  • [Cites] J Immunol. 1997 Jan 15;158(2):756-64 [8992992.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 8;238(1):90-4 [9299458.001]
  • [Cites] Int Immunol. 1998 Aug;10(8):1103-10 [9723696.001]
  • [Cites] Protein Expr Purif. 2005 Feb;39(2):189-98 [15642470.001]
  • [Cites] J Immunother. 2005 May-Jun;28(3):193-202 [15838375.001]
  • [Cites] Nat Med. 2006 Jan;12(1):99-106 [16327802.001]
  • [Cites] Technol Cancer Res Treat. 2006 Jun;5(3):239-50 [16700620.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1407-18 [16902988.001]
  • [Cites] Vitam Horm. 2006;74:479-504 [17027527.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:1-20 [17102067.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:541-56 [17102123.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):837-44 [17327604.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Apr;92(4):1217-25 [17284633.001]
  • [Cites] Cell Cycle. 2007 Aug 1;6(15):1946-50 [17671425.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Dec;92(12):4865-72 [17878247.001]
  • [Cites] Horm Metab Res. 2008 May;40(5):329-37 [18491252.001]
  • [Cites] J Pathol. 2009 Mar;217(4):597-604 [19142977.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1168-72 [10728667.001]
  • [Cites] Cell Tissue Res. 2000 Dec;302(3):309-20 [11151443.001]
  • [Cites] Ann Intern Med. 2001 Feb 20;134(4):315-29 [11182843.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):168-75 [11291041.001]
  • [Cites] Gene Ther. 2003 Jul;10(13):1116-28 [12808442.001]
  • (PMID = 19491224.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Immunotoxins; 0 / Interleukin-13 Receptor alpha2 Subunit; 0 / pseudomonas exoprotein A protein, Pseudomonas aeruginosa
  • [Other-IDs] NLM/ PMC2730867
  •  go-up   go-down


79. Hofland J, van Nederveen FH, Timmerman MA, Korpershoek E, de Herder WW, Lenders JW, Verhofstad AA, de Krijger RR, de Jong FH: Expression of activin and inhibin subunits, receptors and binding proteins in human pheochromocytomas: a study based on mRNA analysis and immunohistochemistry. Clin Endocrinol (Oxf); 2007 Mar;66(3):335-40
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Pheochromocytomas are uncommon tumours arising from chromaffin cells of the adrenal medulla and related paraganglia.
  • [MeSH-major] Adrenal Gland Neoplasms / chemistry. Biomarkers, Tumor / analysis. Inhibin-beta Subunits / analysis. Pheochromocytoma / chemistry
  • [MeSH-minor] Activin Receptors, Type I / analysis. Activin Receptors, Type I / genetics. Activin Receptors, Type II / analysis. Activin Receptors, Type II / genetics. Adult. Blotting, Northern / methods. Chi-Square Distribution. Diagnosis, Differential. Female. Follistatin / analysis. Follistatin / genetics. Gene Expression. Humans. Immunohistochemistry. Inhibins / analysis. Inhibins / genetics. Male. Middle Aged. Proteoglycans / analysis. Proteoglycans / genetics. RNA, Messenger / analysis. Receptors, Transforming Growth Factor beta / analysis. Receptors, Transforming Growth Factor beta / genetics. Reverse Transcriptase Polymerase Chain Reaction. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17302865.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Follistatin; 0 / Proteoglycans; 0 / RNA, Messenger; 0 / Receptors, Transforming Growth Factor beta; 0 / inhibin beta A subunit; 0 / inhibin-alpha subunit; 145170-29-2 / betaglycan; 57285-09-3 / Inhibins; 93443-12-0 / Inhibin-beta Subunits; EC 2.7.11.30 / ACVR1B protein, human; EC 2.7.11.30 / Activin Receptors, Type I; EC 2.7.11.30 / Activin Receptors, Type II; EC 2.7.11.30 / activin receptor type II-A; EC 2.7.11.30 / activin receptor type II-B
  •  go-up   go-down


80. Ait-Ali D, Turquier V, Tanguy Y, Thouënnon E, Ghzili H, Mounien L, Derambure C, Jégou S, Salier JP, Vaudry H, Eiden LE, Anouar Y: Tumor necrosis factor (TNF)-alpha persistently activates nuclear factor-kappaB signaling through the type 2 TNF receptor in chromaffin cells: implications for long-term regulation of neuropeptide gene expression in inflammation. Endocrinology; 2008 Jun;149(6):2840-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor (TNF)-alpha persistently activates nuclear factor-kappaB signaling through the type 2 TNF receptor in chromaffin cells: implications for long-term regulation of neuropeptide gene expression in inflammation.
  • Chromaffin cells of the adrenal medulla elaborate and secrete catecholamines and neuropeptides for hormonal and paracrine signaling in stress and during inflammation.
  • TNF-alpha-dependent signaling in neuroendocrine cells thus leads to a unique, persistent mode of NF-kappaB activation that features long-lasting transcription of both IkappaB and MIG-6, which may play a role in the long-lasting effects of TNF-alpha in regulating neuropeptide output from the adrenal, a potentially important feedback station for modulating long-term cytokine effects in inflammation.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9077-81 [7568076.001]
  • [Cites] DNA Cell Biol. 1995 Apr;14(4):321-9 [7536007.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6025-30 [8650213.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15002-7 [8663145.001]
  • [Cites] J Biol Chem. 1996 Jul 26;271(30):18068-73 [8663499.001]
  • [Cites] FEBS Lett. 1996 Aug 26;392(2):129-36 [8772190.001]
  • [Cites] Brain Res Mol Brain Res. 1996 Jun;38(2):260-6 [8793114.001]
  • [Cites] Endocr Res. 1996 Nov;22(4):819-29 [8969945.001]
  • [Cites] Oncogene. 1998 Apr 23;16(16):2095-102 [9572490.001]
  • [Cites] J Biol Chem. 1998 Jun 26;273(26):16346-50 [9632697.001]
  • [Cites] J Immunol. 1999 May 1;162(9):5466-76 [10228026.001]
  • [Cites] Mol Pharmacol. 1999 Jul;56(1):162-9 [10385697.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):22923-31 [10438457.001]
  • [Cites] J Biochem Mol Biol. 2005 May 31;38(3):281-9 [15943902.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26825-37 [15923644.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Mar;290(3):L501-8 [16299051.001]
  • [Cites] J Neuroimmunol. 2006 Mar;172(1-2):38-58 [16375977.001]
  • [Cites] Nat Methods. 2007 Jan;4(1):35-7 [17115035.001]
  • [Cites] Int J Mol Med. 2007 Mar;19(3):511-5 [17273801.001]
  • [Cites] Trends Genet. 2007 Apr;23(4):200-7 [17313995.001]
  • [Cites] Cancer Lett. 2007 Jul 18;252(2):299-306 [17300864.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5183-91 [10553038.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5656-65 [10553096.001]
  • [Cites] J Clin Invest. 2000 Jan;105(1):79-92 [10619864.001]
  • [Cites] Am J Physiol Cell Physiol. 2000 Feb;278(2):C344-51 [10666030.001]
  • [Cites] J Comp Neurol. 2000 May 29;421(2):234-46 [10813784.001]
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17344-8 [10747961.001]
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17838-47 [10749885.001]
  • [Cites] Brain Res Mol Brain Res. 2000 Nov 10;83(1-2):1-8 [11072090.001]
  • [Cites] Biochem Pharmacol. 2001 Mar 15;61(6):749-59 [11266661.001]
  • [Cites] Mol Pharmacol. 2001 Jul;60(1):42-52 [11408599.001]
  • [Cites] Nat Immunol. 2001 Oct;2(10):907-16 [11577346.001]
  • [Cites] Psychoneuroendocrinology. 2001 Nov;26(8):761-88 [11585678.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5615-9 [11701743.001]
  • [Cites] Cell. 2002 Apr;109 Suppl:S81-96 [11983155.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] J Neurosci Res. 2002 Aug 1;69(3):327-40 [12125074.001]
  • [Cites] Nat Rev Immunol. 2002 Oct;2(10):725-34 [12360211.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5668-71 [12384522.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(8):2680-98 [12665571.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):23094-100 [12686541.001]
  • [Cites] Biochem J. 2004 Mar 15;378(Pt 3):1089-94 [14674885.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):7043-52 [15153526.001]
  • [Cites] Mol Endocrinol. 2004 Jul;18(7):1721-39 [15087472.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32869-81 [15155767.001]
  • [Cites] Biochem J. 2004 Sep 1;382(Pt 2):393-409 [15214841.001]
  • [Cites] Mol Cell Biol. 1991 Feb;11(2):1017-22 [1990263.001]
  • [Cites] J Exp Med. 1992 May 1;175(5):1181-94 [1314883.001]
  • [Cites] J Immunol. 1992 May 15;148(10):3152-7 [1315830.001]
  • [Cites] Science. 1992 Aug 14;257(5072):967-71 [1354393.001]
  • [Cites] Science. 1993 Mar 26;259(5103):1912-5 [8096091.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):28-32 [8278379.001]
  • [Cites] J Biol Chem. 1994 Mar 4;269(9):6823-31 [7509811.001]
  • [Cites] J Biol Chem. 1994 Mar 11;269(10):7785-91 [8126005.001]
  • [Cites] Nature. 1994 Sep 22;371(6495):355-8 [7522304.001]
  • [Cites] J Neurochem. 1995 Feb;64(2):608-13 [7830054.001]
  • [Cites] Nucleic Acids Res. 1994 Dec 25;22(25):5640-8 [7838717.001]
  • [Cites] J Immunol. 1995 Nov 15;155(10):4685-91 [7594468.001]
  • (PMID = 18292192.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / Z01 MH002386
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Neuropeptides; 0 / Recombinant Proteins; 0 / TNF Receptor-Associated Factor 2; 0 / Tumor Necrosis Factor-alpha; 63231-63-0 / RNA
  • [Other-IDs] NLM/ PMC2408812
  •  go-up   go-down


81. Adams MS, Bronner-Fraser M: Review: the role of neural crest cells in the endocrine system. Endocr Pathol; 2009;20(2):92-100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to current understanding, neural crest cells give rise to the chromaffin cells of the adrenal medulla, chief cells of the extra-adrenal paraganglia, and thyroid C cells.
  • The endocrine tumors that correspond to these cell types are pheochromocytomas, extra-adrenal paragangliomas, and medullary thyroid carcinomas.
  • Although controversies concerning embryological origin appear to have mostly been resolved, questions persist concerning the pathobiology of each tumor type and its basis in neural crest embryology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 1993 Jun;157(2):348-58 [8099044.001]
  • [Cites] Evol Dev. 2001 Mar-Apr;3(2):47-58 [11341674.001]
  • [Cites] Ann Diagn Pathol. 2006 Apr;10(2):67-71 [16546039.001]
  • [Cites] Cell. 1992 Dec 11;71(6):973-85 [1458542.001]
  • [Cites] Ann R Coll Surg Engl. 2006 Sep;88(5):433-8 [17002842.001]
  • [Cites] Trends Cell Biol. 2005 Sep;15(9):494-501 [16084092.001]
  • [Cites] Dev Dyn. 2003 Jul;227(3):367-78 [12815622.001]
  • [Cites] J Pathol. 1998 Oct;186(2):117-8 [9924424.001]
  • [Cites] J Neurochem. 2002 Sep;82(5):1239-51 [12358771.001]
  • [Cites] Cell Stem Cell. 2008 Apr 10;2(4):392-403 [18397758.001]
  • [Cites] PLoS One. 2008;3(10 ):e3544 [18958156.001]
  • [Cites] Development. 1993 Feb;117(2):409-29 [8330517.001]
  • [Cites] Development. 1991 Dec;113(4):1093-104 [1811929.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):311-21 [15803157.001]
  • [Cites] Dev Growth Differ. 1999 Feb;41(1):59-72 [10445503.001]
  • [Cites] J Embryol Exp Morphol. 1967 Dec;18(3):343-58 [5590717.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4495-500 [15070746.001]
  • [Cites] Science. 1989 Mar 24;243(4898):1608-11 [2564699.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):129-40 [18242513.001]
  • [Cites] J Pathol. 1989 Oct;159(2):135-41 [2809889.001]
  • [Cites] J Embryol Exp Morphol. 1977 Oct;41:209-22 [22577.001]
  • [Cites] Histochemie. 1971;27(2):96-102 [5092696.001]
  • [Cites] Development. 1990 Sep;110(1):197-209 [1706978.001]
  • [Cites] BJU Int. 2008 Jul;102(2):220-4; discussion 224 [18284412.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1272-84 [18684026.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):238-42 [10757334.001]
  • [Cites] Science. 1983 Apr 15;220(4594):268-73 [17732898.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jul;85(14):5325-9 [2455901.001]
  • [Cites] Kaohsiung J Med Sci. 2006 Jan;22(1):14-9 [16570563.001]
  • [Cites] Anat Embryol (Berl). 1980;160(2):203-11 [7457916.001]
  • [Cites] Development. 1991 May;112(1):301-5 [1769335.001]
  • [Cites] Dev Biol. 1989 May;133(1):44-57 [2707486.001]
  • [Cites] Nat Rev Neurosci. 2007 Jun;8(6):466-79 [17514199.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):155-67 [16098468.001]
  • [Cites] Nature. 1988 Sep 8;335(6186):161-4 [2457813.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):897-911 [15613462.001]
  • [Cites] Endocr Pathol. 1995 Winter;6(4):323-335 [12114814.001]
  • [Cites] Evol Dev. 2006 Jan-Feb;8(1):74-80 [16409384.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):423-36 [15369446.001]
  • [Cites] Dev Growth Differ. 2003 Aug;45(4):361-7 [12950277.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1117-23 [16680154.001]
  • [Cites] Development. 1992 Jan;114(1):1-15 [1576952.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:241-52 [17102092.001]
  • [Cites] Dev Biol. 1990 Oct;141(2):243-53 [2210034.001]
  • [Cites] Pathol Annu. 1993;28 Pt 1:205-29 [8416138.001]
  • [Cites] Hum Mol Genet. 2002 Oct 1;11(20):2347-54 [12351569.001]
  • [Cites] Pediatr Pathol. 1993 Jul-Aug;13(4):463-73 [8372031.001]
  • [Cites] Genesis. 2001 Nov;31(3):111-7 [11747201.001]
  • [Cites] Development. 2004 Oct;131(19):4637-50 [15358668.001]
  • [Cites] Dev Biol. 1998 Mar 1;195(1):1-15 [9520319.001]
  • [Cites] Pigment Cell Res. 1999 Apr;12(2):81-8 [10231195.001]
  • [Cites] Mech Dev. 2002 Sep;117(1-2):115-22 [12204252.001]
  • [Cites] Histochemistry. 1974 Mar 13;38(4):297-305 [4135055.001]
  • [Cites] Proc R Soc Lond B Biol Sci. 1966 Apr 19;164(996):478-87 [4379579.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Dev Biol. 1996 Aug 1;177(2):580-9 [8806833.001]
  • [Cites] Mol Cell Neurosci. 2003 Sep;24(1):160-70 [14550777.001]
  • [Cites] Endocr Rev. 2004 Oct;25(5):722-46 [15466939.001]
  • [Cites] Dev Biol. 1984 Aug;104(2):390-405 [6745490.001]
  • [Cites] Lancet. 1968 Jan 20;1(7534):108-10 [4169600.001]
  • [Cites] Expert Opin Biol Ther. 2007 Apr;7(4):431-8 [17373895.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 20;95(16):1196-204 [12928344.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):407-14 [18091383.001]
  • [Cites] Dev Biol. 2008 May 15;317(2):389-400 [18402934.001]
  • [Cites] Dev Growth Differ. 2008 Jun;50 Suppl 1:S189-94 [18430164.001]
  • [Cites] Stem Cell Rev. 2008 Dec;4(4):256-60 [18712509.001]
  • [Cites] Nat Biotechnol. 2007 Dec;25(12):1468-75 [18037878.001]
  • [Cites] Nature. 2006 May 11;441(7090):218-22 [16688176.001]
  • [Cites] Mol Cell Biol. 1990 Dec;10(12):6216-24 [2174102.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):395-8 [9697704.001]
  • [Cites] Genes Dev. 1996 Jan 1;10(1):60-9 [8557195.001]
  • [Cites] Stem Cells. 2006 Dec;24(12):2692-702 [16931771.001]
  • [Cites] J Craniofac Genet Dev Biol. 1991 Oct-Dec;11(4):192-213 [1812125.001]
  • [Cites] Dev Dyn. 2004 Oct;231(2):258-69 [15366003.001]
  • [Cites] Dev Biol. 1989 Jul;134(1):112-8 [2659408.001]
  • [Cites] Methods Cell Biol. 2008;87:237-56 [18485300.001]
  • [Cites] Neuron. 1989 Dec;3(6):755-66 [2484346.001]
  • [Cites] Mol Cell Biol. 1991 Oct;11(10):4927-33 [1922026.001]
  • [Cites] Mol Cell Neurosci. 2006 May-Jun;32(1-2):67-81 [16626970.001]
  • [Cites] Gen Comp Endocrinol. 1979 Jan;37(1):81-92 [437500.001]
  • [Cites] Can J Microbiol. 1994 Feb;40(2):90-8 [7912643.001]
  • [Cites] J Clin Pathol. 1966 Mar;19(2):114-8 [5948665.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):696-9 [15470430.001]
  • [Cites] Dev Dyn. 2006 May;235(5):1300-9 [16342117.001]
  • [Cites] Dev Biol. 1980 Nov;80(1):96-106 [7439536.001]
  • [Cites] Dev Biol. 1986 May;115(1):44-55 [3516760.001]
  • [Cites] J Embryol Exp Morphol. 1985 Dec;90:437-55 [3834038.001]
  • [Cites] Dev Biol. 1974 Nov;41(1):162-84 [4140118.001]
  • [Cites] Histochemistry. 1974;40(3):209-14 [4604566.001]
  • [Cites] Development. 1988;103 Suppl:155-69 [3250849.001]
  • [Cites] Neuron. 2002 Aug 15;35(4):657-69 [12194866.001]
  • [Cites] J Anat. 1993 Oct;183 ( Pt 2):207-21 [8300412.001]
  • [Cites] J Histochem Cytochem. 1969 May;17(5):303-13 [4143745.001]
  • [Cites] Kaohsiung J Med Sci. 2007 Jul;23(7):325-31 [17606426.001]
  • [Cites] Hum Mol Genet. 2002 Dec 1;11(25):3231-6 [12444107.001]
  • [Cites] J Embryol Exp Morphol. 1975 Aug;34(1):125-54 [1185098.001]
  • [Cites] Mech Dev. 1997 Dec;69(1-2):3-11 [9486527.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):25-36 [12746560.001]
  • [Cites] Endocr Pathol. 2006 Summer;17(2):97-106 [17159241.001]
  • [Cites] Cell. 2008 Oct 31;135(3):408-10 [18984150.001]
  • [Cites] Development. 1995 Feb;121(2):525-38 [7768190.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;66:307-56 [11051768.001]
  • [Cites] Nature. 1967 May 27;214(5091):929-30 [5299162.001]
  • [Cites] Dev Cell. 2007 Sep;13(3):405-20 [17765683.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:557-70 [17102124.001]
  • [Cites] Neurochem Res. 2005 Jun-Jul;30(6-7):921-5 [16187226.001]
  • [Cites] Dev Biol. 1997 Aug 1;188(1):34-42 [9245509.001]
  • [Cites] Development. 2002 Dec;129(24):5731-41 [12421712.001]
  • [Cites] Curr Opin Genet Dev. 2006 Aug;16(4):360-6 [16793256.001]
  • [Cites] Dev Biol. 1991 Nov;148(1):95-106 [1936578.001]
  • [Cites] J Endocrinol. 1967 Feb;37(2):205-9 [5334670.001]
  • [Cites] EMBO J. 1990 Nov;9(11):3631-9 [1976511.001]
  • [Cites] Dev Dyn. 2008 Apr;237(4):1021-33 [18351660.001]
  • [Cites] Dev Biol. 1993 Mar;156(1):191-200 [7680628.001]
  • [Cites] Evol Dev. 2007 May-Jun;9(3):267-77 [17501750.001]
  • [Cites] Development. 1995 Jul;121(7):2099-106 [7635055.001]
  • [Cites] Endocr Pathol. 2008 Fall;19(3):139-47 [18758692.001]
  • [Cites] Annu Rev Neurosci. 1993;16:129-58 [8460888.001]
  • [Cites] Biol Rev Camb Philos Soc. 1990 Aug;65(3):277-373 [2205303.001]
  • [Cites] Nat Genet. 1998 May;19(1):87-90 [9590297.001]
  • [Cites] J Exp Zool B Mol Dev Evol. 2005 Jul 15;304(4):298-303 [15880502.001]
  • [Cites] Anat Embryol (Berl). 1979;157(1):113-20 [517756.001]
  • [Cites] J Comp Neurol. 1980 Sep 15;193(2):423-34 [7440776.001]
  • [Cites] Nat Genet. 1994 Jul;7(3):353-61 [7920653.001]
  • [Cites] Dev Biol. 1963 Jun;6:279-310 [14000137.001]
  • [Cites] Dev Biol. 1991 Oct;147(2):451-9 [1680763.001]
  • [Cites] Dev Growth Differ. 2000 Jun;42(3):199-201 [10910124.001]
  • [Cites] Cell. 1999 Mar 5;96(5):737-49 [10089888.001]
  • [Cites] Am J Pathol. 1986 Oct;125(1):45-54 [3777139.001]
  • [Cites] Saudi Med J. 2008 Jul;29(7):957-61 [18626520.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Jul;9(7):557-68 [18523435.001]
  • [Cites] Neuroscience. 2007 Jul 29;147(4):928-37 [17582688.001]
  • [Cites] Proc R Soc Med. 1966 Jul;59(7):602-3 [5939499.001]
  • (PMID = 19377845.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 141
  •  go-up   go-down


82. Krishnan C, Higgins JP, West RB, Natkunam Y, Heerema-McKenney A, Arber DA: Microtubule-associated protein-2 is a sensitive marker of primary and metastatic neuroblastoma. Am J Surg Pathol; 2009 Nov;33(11):1695-704
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined the diagnostic utility of MAP-2 as a marker of neuroblastoma and attempted to characterize the expression of this protein in other tumors in the morphologic differential diagnosis of neuroblastoma.
  • In normal tissues, MAP-2 staining was essentially restricted to organs derived from the neural crest (adrenal medulla, endocrine organs).
  • Variant patterns of staining were seen in exocrine organs, monocyte/macrophages and solitary fibrous tumor/hemangiopericytoma family of tumors.
  • CONCLUSIONS: MAP-2 is a sensitive and specific marker of neuroblastoma, both in the primary tumor and bone marrow biopsy settings.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Microtubule-Associated Proteins / metabolism. Neuroblastoma / diagnosis
  • [MeSH-minor] Bone Marrow Neoplasms / diagnosis. Bone Marrow Neoplasms / metabolism. Bone Marrow Neoplasms / secondary. Cytoplasm / metabolism. Cytoplasm / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Predictive Value of Tests. Synaptophysin / metabolism. Tissue Array Analysis

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Neuroblastoma 2.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19701075.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MAP2 protein, human; 0 / Microtubule-Associated Proteins; 0 / Synaptophysin
  •  go-up   go-down


83. Longo L, Borghini S, Schena F, Parodi S, Albino D, Bachetti T, Da Prato L, Truini M, Gambini C, Tonini GP, Ceccherini I, Perri P: PHOX2A and PHOX2B genes are highly co-expressed in human neuroblastoma. Int J Oncol; 2008 Nov;33(5):985-91
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this light, we have carried out a quantitative expression analysis of PHOX2B and its paralogue PHOX2A on a panel of NB cell lines and NB tumour samples to identify a possible differential expression between NB cells and their normal counterpart (adrenal medulla cells).
  • Our results revealed that both PHOX2A and PHOX2B are over-expressed in tumour samples and NB cell lines.
  • [MeSH-minor] Adrenal Medulla / metabolism. Cell Line, Tumor. DNA Mutational Analysis. Humans. Pedigree. Up-Regulation

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949361.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / NBPhox protein; 0 / PHOX2A protein, human; 0 / Transcription Factors
  •  go-up   go-down


84. Luo Z, Li J, Qin Y, Ma Y, Liang X, Xian J, Lu D, Wei M, Yang JY, Yang MQ, He Z: Differential expression of human telomerase catalytic subunit mRNA by in situ hybridization in pheochromocytomas. Endocr Pathol; 2006;17(4):387-98
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While no statistical difference in p27kip1 expressions was observed among benign, malignant, and suspected malignant tumors, there was a statistical difference between the normal adrenal medulla samples and tumors (p < 0.001).
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Pheochromocytoma / genetics. RNA, Messenger / metabolism. Telomerase / genetics
  • [MeSH-minor] Adolescent. Adrenal Medulla / metabolism. Adrenal Medulla / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Female. Follow-Up Studies. Humans. In Situ Hybridization. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4280-6 [12970299.001]
  • [Cites] Endocr J. 2004 Feb;51(1):47-52 [15004408.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):246-55 [12640105.001]
  • [Cites] J Pathol. 2000 Jun;191(2):175-80 [10861578.001]
  • [Cites] Nat Med. 1995 Mar;1(3):249-55 [7585042.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4073-81 [11051259.001]
  • [Cites] Am J Gastroenterol. 2002 Apr;97(4):1022-30 [12003383.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5762-8 [15355904.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):401-7 [9033255.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):176-9 [9428495.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1743-52 [15014027.001]
  • [Cites] Nat Med. 1997 Feb;3(2):222-5 [9018243.001]
  • [Cites] Cancer. 1990 Mar 1;65(5):1180-4 [2406010.001]
  • [Cites] J Immunol. 2000 Oct 15;165(8):4346-52 [11035070.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):737-49 [15743786.001]
  • [Cites] BMC Cancer. 2005 Aug 08;5:98 [16086840.001]
  • [Cites] Carcinogenesis. 2003 Jul;24(7):1167-76 [12807729.001]
  • [Cites] Cell. 1998 Mar 6;92(5):587-90 [9506510.001]
  • [Cites] Science. 1997 Aug 15;277(5328):955-9 [9252327.001]
  • [Cites] Nat Med. 1997 Feb;3(2):227-30 [9018244.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 1999;107(4):272-5 [10433067.001]
  • [Cites] Toxicol Pathol. 2002 Jul-Aug;30(4):492-500 [12187940.001]
  • [Cites] Hum Pathol. 1990 Nov;21(11):1168-80 [2172151.001]
  • [Cites] Pathol Oncol Res. 2005;11(1):45-9 [15800682.001]
  • [Cites] Endocr Pathol. 2005 Spring;16(1):23-32 [16000843.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):911-4 [16126869.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):551-66 [11979086.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2626-34 [10893296.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 Sep;78(3):201-14 [11595501.001]
  • [Cites] J Clin Pathol. 1999 Aug;52(8):555-68 [10645224.001]
  • (PMID = 17525487.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


85. Babińska A, Gnacińska A, Swiatkowska-Stodulska R, Sworczak K: Myocardial infarction in a 30-year-old patient with pheochromocytoma and type 1 neurofibromatosis. Pol Arch Med Wewn; 2008 Sep;118(9):517-23
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chromaffinoma of the adrenal medulla (pheochromocytoma--PHEO) is a rare cause of arterial hypertension which is diagnosed incidentally or run in a family as a component of disease syndromes of the genetic origin.
  • A correct diagnosis of PHEO allows the right treatment to be administered.
  • The evaluation of the secondary arterial hypertension led to the detection of the adrenal tumor.
  • Based on the clinical presentation and the tumor characteristics, on computed tomography, PHEO was suspected.
  • The patient underwent laparoscopic, right-sided adrenalectomy, and the histopathological examination definitely concurred with the diagnosis of PHEO.
  • The diagnosis toward PHEO is recommended if the patient with NF1 shows arterial hypertension.
  • Proper diagnosis and treatment protects the patient against life-threatening cardiovascular complications.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Myocardial Infarction / diagnosis. Myocardial Infarction / etiology. Neurofibromatosis 1 / complications. Pheochromocytoma / complications


86. Kremens B: [Systemic therapy in children and adolescents]. Urologe A; 2007 Oct;46(10):1404-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • National and supranational treatment studies are the standard of care for pediatric cancer in Germany; they yield 5-year survival rates of almost 90% for nephroblastoma and germ cell tumors and 60% for neuroblastoma (all stages) and rhabdomyosarcoma.
  • The principles of antineoplastic therapy are the same as in adult cancer medicine; the drugs used depend upon the disease.
  • [MeSH-minor] Adolescent. Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / mortality. Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Adrenal Medulla. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Humans. Infant. Kidney Neoplasms / drug therapy. Kidney Neoplasms / mortality. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Neoplasm Staging. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / mortality. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / surgery. Neuroblastoma / drug therapy. Neuroblastoma / mortality. Neuroblastoma / pathology. Neuroblastoma / surgery. Prognosis. Radiotherapy, Adjuvant. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / mortality. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / surgery. Survival Rate. Wilms Tumor / drug therapy. Wilms Tumor / mortality. Wilms Tumor / pathology. Wilms Tumor / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17823786.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


87. Flores-Hernández SS, Ahumada Mendoza H, Santana-Montero BL, González Flores Mde L: [Early diagnosis of a newborn with a mediastinal mass]. Gac Med Mex; 2005 Nov-Dec;141(6):535-8
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early diagnosis of a newborn with a mediastinal mass].
  • Neuroblastoma is an embryonal tumour that evolves from the neural crest cell.
  • This neoplasm may arise at any site in the sympathetic nervous system, including the brain, the cervical region, the posterior mediastinum, the para-aortic sympathetic ganglia, the pelvis, and the adrenal medulla.
  • The clinical presentation in neonatal age is rare and the differential diagnosis includes congenital lung malformations, pneumoniae, atelectasia, etc.
  • This case illustrates how a patient with an X-ray image compatible with a thoracic tumor should be studied.
  • [MeSH-major] Mediastinal Neoplasms / diagnosis. Neuroblastoma / diagnosis
  • [MeSH-minor] Early Diagnosis. Female. Humans. Infant, Newborn

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381510.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


88. Al-Shammari NF, Redha E, Al Hajeri MH: Cervical neonatal neuroblastoma with recurrent SVT. Gulf J Oncolog; 2009 Jul;(6):45-57
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroblastoma is the most common extracranial solid tumor of childhood and the third most common paediatric malignancy after leukemia and central nervous system (CNS) tumors.
  • The median age at diagnosis is 22 months.
  • They occur most commonly in the adrenal medulla (35%).
  • Neuroblastomas also occur as primary tumors in the extra-adrenal retroperitoneum in 30% of cases, in the posterior mediastinum in 20% of cases , in the neck up to 5% of cases and in the pelvis in 5% of cases.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20194085.001).
  • [ISSN] 2078-2101
  • [Journal-full-title] The Gulf journal of oncology
  • [ISO-abbreviation] Gulf J Oncolog
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Kuwait
  •  go-up   go-down


89. Bach U, Hailey JR, Hill GD, Kaufmann W, Latimer KS, Malarkey DE, Maronpot RM, Miller RA, Moore RR, Morrison JP, Nolte T, Rinke M, Rittinghausen S, Suttie AW, Travlos GS, Vahle JL, Willson GA, Elmore SA: Proceedings of the 2009 National Toxicology Program Satellite Symposium. Toxicol Pathol; 2010 Jan;38(1):9-36
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The topic of the 2009 Symposium was "Tumor Pathology and INHAND (International Harmonization of Nomenclature and Diagnostic Criteria for Lesions in Rats and Mice) Nomenclature."
  • [MeSH-minor] Adrenal Medulla / pathology. Animals. Cell Proliferation. Cholangiocarcinoma / pathology. Immunohistochemistry. Liver Neoplasms / pathology. Meningioma / pathology. Mice. Rats. Terminology as Topic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IARC Sci Publ. 1994;(122 Pt I-7):1-80 [7989086.001]
  • [Cites] IARC Sci Publ. 1994;(111):223-69 [8082908.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):247-54 [9665485.001]
  • [Cites] Toxicol Pathol. 1998 Jul-Aug;26(4):461-73 [9715504.001]
  • [Cites] Toxicol Pathol. 1998 Jul-Aug;26(4):501-11 [9715509.001]
  • [Cites] Toxicol Pathol. 2009 Aug;37(5):694-7 [19638442.001]
  • [Cites] Vet Pathol. 1979 May;16(3):318-24 [442462.001]
  • [Cites] Toxicol Pathol. 2000 Jan-Feb;28(1):178-92 [10669006.001]
  • [Cites] Vet Pathol. 2000 Sep;37(5):439-48 [11055867.001]
  • [Cites] Toxicol Pathol. 2002 Sep-Oct;30(5):580-91 [12371667.001]
  • [Cites] Cancer Res. 1975 Nov;35(11 Pt 1):3214-23 [171067.001]
  • [Cites] J Natl Cancer Inst. 1980 Jan;64(1):177-206 [6986002.001]
  • [Cites] J Natl Cancer Inst. 1984 Jan;72(1):151-60 [6582295.001]
  • [Cites] Toxicol Pathol. 1986;14(2):263-73 [3764323.001]
  • [Cites] Environ Health Perspect. 1986 Sep;68:117-23 [3465532.001]
  • [Cites] Vet Pathol. 1987 Jan;24(1):50-8 [3824823.001]
  • [Cites] Toxicol Pathol. 1997 Mar-Apr;25(2):211-6 [9125780.001]
  • (PMID = 20008954.001).
  • [ISSN] 1533-1601
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 ES999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS623985; NLM/ PMC4195590
  •  go-up   go-down


90. Bayley JP, van Minderhout I, Hogendoorn PC, Cornelisse CJ, van der Wal A, Prins FA, Teppema L, Dahan A, Devilee P, Taschner PE: Sdhd and SDHD/H19 knockout mice do not develop paraganglioma or pheochromocytoma. PLoS One; 2009;4(11):e7987
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SDHD is remarkable in showing an 'imprinted' tumor suppressor phenotype.
  • We also crossed this mouse with a knockout of H19, a postulated imprinted modifier gene of Sdhd tumorigenesis, to evaluate if loss of these genes together would lead to the initiation or enhancement of tumor development.
  • No paraganglioma or other tumor development was seen in Sdhd KO mice followed for their entire lifespan, in sharp contrast to the highly penetrant phenotype in humans.
  • Heterozygous Sdhd KO mice did not show hyperplasia of paraganglioma-related tissues such as the carotid body or of the adrenal medulla, or any genotype-related pathology, with similar body and organ weights to wildtype mice.
  • [MeSH-minor] Animals. Female. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Genotype. Heterozygote. Male. Mice. Mice, Knockout. Phenotype. RNA, Long Noncoding

  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] Science. 2009 Aug 28;325(5944):1139-42 [19628817.001]
  • [Cites] Genomics. 2001 Apr 1;73(1):56-65 [11352566.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):49-54 [11404820.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Apr 15;150(2):128-35 [15066320.001]
  • [Cites] Oncogene. 2004 May 20;23(23):4076-83 [15064708.001]
  • [Cites] Nature. 1987 Mar 19-25;326(6110):292-5 [3821905.001]
  • [Cites] Lancet. 1989 Dec 2;2(8675):1291-4 [2574254.001]
  • [Cites] Nature. 1995 May 4;375(6526):34-9 [7536897.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1999 Jul;45(5):737-50 [10512203.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10933-40 [15572694.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):161-72 [15788647.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):827-36 [16317055.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12417-22 [18719115.001]
  • [Cites] Nat Genet. 2000 Nov;26(3):268-70 [11062460.001]
  • (PMID = 19956719.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / H19 long non-coding RNA; 0 / RNA, Long Noncoding; 0 / RNA, Untranslated; EC 1.3.99.1 / Succinate Dehydrogenase
  • [Other-IDs] NLM/ PMC2776493
  •  go-up   go-down


91. Pollard PJ, El-Bahrawy M, Poulsom R, Elia G, Killick P, Kelly G, Hunt T, Jeffery R, Seedhar P, Barwell J, Latif F, Gleeson MJ, Hodgson SV, Stamp GW, Tomlinson IP, Maher ER: Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab; 2006 Nov;91(11):4593-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These similarities between the downstream consequences of VHL inactivation and HIF dysregulation in renal cell carcinoma and PCC may explain how inactivation of the ubiquitously expressed VHL protein results in susceptibility to specific tumor types.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Head and Neck Neoplasms / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Paraganglioma / metabolism. Pheochromocytoma / metabolism. Succinate Dehydrogenase / genetics. Transcription Factors / metabolism. Von Hippel-Lindau Tumor Suppressor Protein / genetics
  • [MeSH-minor] Adrenal Medulla / metabolism. Basic Helix-Loop-Helix Transcription Factors. Gene Expression Regulation, Neoplastic. Germ-Line Mutation. Humans. Immunohistochemistry


92. Vezzalini M, Mombello A, Menestrina F, Mafficini A, Della Peruta M, van Niekerk C, Barbareschi M, Scarpa A, Sorio C: Expression of transmembrane protein tyrosine phosphatase gamma (PTPgamma) in normal and neoplastic human tissues. Histopathology; 2007 Apr;50(5):615-28

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: Membranous and/or cytoplasmic PTPgamma expression was detected in the majority of epithelial cell types and in endocrine cells, with the highest expression in adrenal medulla, endocrine cells of the gastrointestinal tract and pancreatic islets.
  • CONCLUSIONS: We have analysed PTPgamma expression in archival paraffin-embedded tissues for the first time, demonstrating particularly high expression in endocrine cells and both down- and up-regulation in neoplasia, the latter possibly reflecting the undifferentiated state of the neoplastic cells, suggesting a complex role for this phosphatase.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neoplasms / enzymology. Nerve Tissue Proteins / metabolism. Protein Tyrosine Phosphatases / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Down-Regulation. Endocrine System / cytology. Endocrine System / enzymology. Female. Fluorescent Antibody Technique, Indirect. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. In Situ Hybridization. Male. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Receptor-Like Protein Tyrosine Phosphatases, Class 5. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17394498.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Cell Surface; EC 3.1.3.48 / PTPRG protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 5
  •  go-up   go-down


93. Salanci BV, Ergün EL: Patterns of salivary gland uptake in I-131 MIBG scintigraphy. Rev Esp Med Nucl; 2006 May-Jun;25(3):198-201
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • I-131 MIBG scintigraphy is routinely used in the diagnosis of neuroendocrine tumours with high specificity.
  • The organs with dense sympathetic innervation such as salivary glands, heart, lachrymal glands, spleen and rarely adrenal medulla are normally visualized with I-131 MIBG.
  • Absence of radioactivity may be a result of sympathic denervation or tumor.
  • [MeSH-minor] Adult. Child. Diagnosis, Differential. Drug Storage. Female. Head and Neck Neoplasms / diagnosis. Humans. Iodides / administration & dosage. Male. Paraganglioma / diagnosis. Parotid Gland / radionuclide imaging. Salivary Gland Neoplasms / diagnosis. Sodium Pertechnetate Tc 99m / pharmacokinetics. Submandibular Gland / radionuclide imaging. Sympathectomy. Temperature. Tissue Distribution. Treatment Refusal

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16762276.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Iodides; 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 35MRW7B4AD / 3-Iodobenzylguanidine; A0730CX801 / Sodium Pertechnetate Tc 99m; T66M6Y3KSA / Lugol's solution
  •  go-up   go-down


94. Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr, Wang CY, Haas GP: Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg; 2006 Apr;30(4):628-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Prostate-specific membrane antigen (PSMA) is upregulated in androgen-dependent prostate carcinoma and it has been targeted for immunotherapy and diagnosis of this cancer.
  • RESULTS: Prostate-specific membrane antigen was detected in the epithelium of prostate, urinary bladder, proximal tubules of kidney, liver, esophagus, stomach, small intestine, colon, breast, fallopian tubes and testicular seminiferous tubules, hippocampal neurons and astrocytes, ependyma, cortex and medulla of the adrenal gland, and ovary stroma.
  • It was also detected in neoplasms of the prostate, kidney, urinary bladder, stomach, small intestine, colon, lung, adrenal gland, and testis.
  • The broad distribution of PSMA may make it suitable for the diagnosis and therapy of a wide variety of tumors.
  • [MeSH-major] Antigens, Surface / analysis. Biomarkers, Tumor / analysis. Glutamate Carboxypeptidase II / analysis. Neoplasms / pathology. Prostate / pathology. Prostatic Neoplasms / pathology. Tumor Cells, Cultured / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1987 Sep-Oct;7(5B):927-35 [2449118.001]
  • [Cites] Eur J Biochem. 1997 Nov 15;250(1):1-6 [9431984.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4049-54 [11051255.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23 (21):4591-601 [15837970.001]
  • [Cites] J Urol. 1994 Dec;152(6 Pt 1):1952-5 [7966649.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2005;8(4):359-63 [16172607.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Aug;286(2):1020-5 [9694964.001]
  • [Cites] Urology. 1998 May;51(5A Suppl):89-97 [9610563.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7995-8001 [15520207.001]
  • [Cites] J Biol Chem. 1999 Mar 26;274(13):8470-83 [10085079.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1807-11 [7511053.001]
  • [Cites] Eur Urol. 2000 Aug;38(2):208-17 [10895014.001]
  • [Cites] J Urol. 2004 Apr;171(4):1709-14 [15017271.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):81-5 [9815541.001]
  • [Cites] J Neurochem. 1997 Dec;69(6):2270-7 [9375657.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3192-8 [10397265.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):799-803 [10074909.001]
  • [Cites] Carcinogenesis. 1994 Apr;15(4):595-9 [8149467.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2321-4 [9192800.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):323-9 [12949815.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9554-9 [12876198.001]
  • [Cites] Urology. 1998 Oct;52(4):637-40 [9763084.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3215-20 [9501243.001]
  • [Cites] Cancer Res. 1998 Nov 1;58(21):4787-9 [9809977.001]
  • [Cites] Mamm Genome. 2001 Feb;12(2):117-23 [11210180.001]
  • [Cites] Cancer Res. 1993 Jan 15;53(2):227-30 [8417812.001]
  • [Cites] Int J Cancer. 1995 Sep 4;62(5):552-8 [7665226.001]
  • [Cites] Prostate. 2004 Feb 1;58(2):200-10 [14716746.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3782-9 [10919651.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1441-3 [7882349.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):749-53 [8570628.001]
  • [Cites] Prostate. 2002 Sep 15;53(1):9-23 [12210476.001]
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):528-39 [14755683.001]
  • [Cites] Prostate. 2000 May 1;43(2):150-7 [10754531.001]
  • [Cites] Int J Cancer. 2002 Nov 20;102(3):244-9 [12397643.001]
  • [Cites] J Urol. 1998 Dec;160(6 Pt 2):2396-401 [9817391.001]
  • (PMID = 16555021.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / 1R01AG21389-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Biomarkers, Tumor; EC 3.4.17.21 / Glutamate Carboxypeptidase II; EC 3.4.17.21 / glutamate carboxypeptidase II, human
  •  go-up   go-down


95. Jarbo C, Buckley PG, Piotrowski A, Mantripragada KK, Benetkiewicz M, Diaz de Ståhl T, Langford CF, Gregory SG, Dralle H, Gimm O, Bäckdahl M, Geli J, Larsson C, Westin G, Akerström G, Dumanski JP: Detailed assessment of chromosome 22 aberrations in sporadic pheochromocytoma using array-CGH. Int J Cancer; 2006 Mar 1;118(5):1159-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pheochromocytoma is a predominantly sporadic neuroendocrine tumor derived from the adrenal medulla.
  • Future analysis of this tumor type should preferably be performed in the context of the entire human genome using genome-wide array-CGH, which is a superior methodological approach.
  • Supplemental material for this article can be found on the International Journal of Cancer website at http://www.interscience.wiley.com/jpages/0020-7136/suppmat/index.html.

  • Genetic Alliance. consumer health - Chromosome 22.
  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16161042.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


96. Bonar CJ, Lewandowski AH, Arafah B, Capen CC: Pheochromocytoma in an aged female African elephant (Loxodonta africana). J Zoo Wildl Med; 2005 Dec;36(4):719-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Necropsy revealed an enlarged right adrenal medulla.
  • Special stains and electron microscopy demonstrated chromaffin granules, suggesting that the tumor was derived from catecholamine secreting cells of the adrenal medulla, and may have been functionally secretory.
  • Serum levels of both norepinephrine and epinephrine were elevated at time of death, supporting the functional nature of the tumor.
  • Pheochromocytoma should be considered as a differential diagnosis in cases of suspected hypertension and acute death in elephants.
  • [MeSH-major] Adrenal Gland Neoplasms / veterinary. Elephants. Pheochromocytoma / veterinary
  • [MeSH-minor] Animals. Death, Sudden / veterinary. Diagnosis, Differential. Fatal Outcome. Female. Immunohistochemistry / veterinary

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17312735.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Waldmann J, Fendrich V, Holler J, Buchholz M, Heinmöller E, Langer P, Ramaswamy A, Samans B, Walz MK, Rothmund M, Bartsch DK, Slater EP: Microarray analysis reveals differential expression of benign and malignant pheochromocytoma. Endocr Relat Cancer; 2010 Sep;17(3):743-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis of a malignant pheochromocytoma (PC) can only be established by the presence of distant metastases, but a subset of apparently benign PCs develop metastases.
  • The reference consisted of laser microdissected tissue from normal adrenal medulla.
  • Comparative analysis by microarray of all ten PCs (benign/malignant) versus normal adrenal medulla revealed a more than twofold expression difference in 455/539 and 491/671 genes respectively.
  • Several of these genes are known to participate on adrenal tumorigenesis, potential tumor suppressor genes, and oncogenes.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Adrenal Medulla / metabolism. Biomarkers, Tumor / metabolism. Gene Expression Profiling. Pheochromocytoma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Metastasis. Oligonucleotide Array Sequence Analysis. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Young Adult


98. Barron J: Phaeochromocytoma: diagnostic challenges for biochemical screening and diagnosis. J Clin Pathol; 2010 Aug;63(8):669-74
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phaeochromocytoma: diagnostic challenges for biochemical screening and diagnosis.
  • In the adrenal medulla and a phaeochromocytoma, catecholamines continuously leak from chromaffin granules into the cytoplasm and are converted to metadrenalines.
  • In conclusion, in screening for a possible phaeochromocytoma, biochemical investigations should be completed first to exclude or establish the diagnosis.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Biomarkers, Tumor / metabolism. Pheochromocytoma / diagnosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20547690.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Catecholamines
  •  go-up   go-down


99. Yanagisawa M, Kachi T: Inhibitory effects of adrenomedullary hormone on the induction and growth of fibrosarcoma by methylcholanthrene. Neuro Endocrinol Lett; 2005 Apr;26(2):113-20
Hazardous Substances Data Bank. 3-Methylcholanthrene .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The incidence of tumor at 90 days after the MC injection was 8 per 35 cases (22.9%) in the control group, 12 per 36 cases (33.3%) in the AMX + AMT group, 8 per 28 cases (28.6%) in the Bil.
  • DISCUSSION: The mechanisms of effects of AMX, AMT and/or epinephrine on the tumor incidence have been discussed with reference to tumor promotion, vascular neoplasia, etc.
  • [MeSH-major] Adrenal Medulla / physiology. Epinephrine / physiology. Fibrosarcoma / pathology. Fibrosarcoma / physiopathology
  • [MeSH-minor] Adrenalectomy. Animals. Hormones / physiology. Hormones / secretion. Hormones / therapeutic use. Male. Methylcholanthrene. Rats. Rats, Wistar. Transplantation, Autologous. Tumor Burden / physiology

  • Hazardous Substances Data Bank. EPINEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15855881.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Hormones; 56-49-5 / Methylcholanthrene; YKH834O4BH / Epinephrine
  •  go-up   go-down


100. Miller AD, Masek-Hammerman K, Dalecki K, Mansfield KG, Westmoreland SV: Histologic and immunohistochemical characterization of pheochromocytoma in 6 cotton-top tamarins (Saguinus oedipus). Vet Pathol; 2009 Nov;46(6):1221-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pheochromocytomas are uncommon neoplasms of the adrenal medulla that are most frequently reported in rats and select mouse strains.
  • In many cases, especially those in man, pheochromocytoma is associated with familial tumor syndromes, because of inherited mutations in a variety of proto-oncogenes and tumor suppressor genes.
  • The tumors in this population illustrate comparable histologic and immunohistochemical staining patterns with cases in other laboratory animals and humans, and, therefore, may indicate common underlying genetic alterations that precipitate tumor development.

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropeptides. 1999 Apr;33(2):159-63 [10657486.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1272-84 [18684026.001]
  • [Cites] Semin Diagn Pathol. 2000 May;17(2):120-6 [10839612.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):194-203 [10968705.001]
  • [Cites] Endocr Pathol. 2002 Spring;13(1):17-27 [12114747.001]
  • [Cites] Endocr Pathol. 2002 Summer;13(2):99-110 [12165657.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):3-23 [12746559.001]
  • [Cites] Vet Pathol. 2003 Jul;40(4):468-73 [12824520.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):883-95 [15168351.001]
  • [Cites] J Anat. 1989 Oct;166:213-25 [2533591.001]
  • [Cites] Histopathology. 1991 May;18(5):453-8 [1679411.001]
  • [Cites] J Med Primatol. 1996 Jan;25(1):34-41 [8740950.001]
  • [Cites] Vet Pathol. 1996 Sep;33(5):512-20 [8885177.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:557-70 [17102124.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Dec;65(6):699-705 [17121518.001]
  • [Cites] Vet Pathol. 2007 Jan;44(1):74-9 [17197626.001]
  • [Cites] Endocr Pathol. 2006 Winter;17(4):329-36 [17525481.001]
  • [Cites] Acta Physiol (Oxf). 2008 Feb;192(2):325-35 [18021328.001]
  • [Cites] Lab Anim. 2000 Jan;34(1):106-10 [10759374.001]
  • (PMID = 19605896.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR000168-47; United States / NCRR NIH HHS / RR / T32 RR007000; United States / NCRR NIH HHS / RR / RR00168; United States / NCRR NIH HHS / RR / P51 RR000168; United States / NCRR NIH HHS / RR / K26 RR000168; United States / NCRR NIH HHS / RR / T32 RR007000-32; United States / NCRR NIH HHS / RR / RR007000-32; United States / NCRR NIH HHS / RR / P51 RR000168-47; United States / NCRR NIH HHS / RR / RR07000
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS173473; NLM/ PMC2825153
  •  go-up   go-down






Advertisement